CD40l-specific tn3-derived scaffolds and methods of use thereof

Abstract

To provide Tn3 scaffolds comprising a CD40L-specific monomer subunit.SOLUTION: The present invention provides a Tn3 scaffold with a monomer subunit comprising seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, wherein the Tn3 scaffold specifically binds to CD40L. In some embodiments, the Tn3 scaffold comprises two CD40L-specific monomer subunits connected in tandem, and the two CD40L-specific monomer subunits are connected directly or via linkers.SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is related in part to U.S. Provisional Patent Application No. 61 / 546,028, filed October 11, 2011, U.S. Provisional Patent Application No. 61 / 323,708, filed April 13, 2010; International Application No. PCT / US2011 / 032184, filed April 12, 2011; International Application No. PCT / US2011 / 032188, filed April 12, 2011; and PCT Application No. PCT / US2008 / 012398, filed October 10, 2008, which contains subject matter published as WO 2009 / 058379A2. Each of the above referenced applications is incorporated herein by reference in its entirety.

[0002] Sequence Listing Reference This application incorporates by reference a sequence listing submitted via application via EFS-Web as a test filed entitled "CD40L-101WO1_SL.txt", created on October 3, 2012, and having a size of 232 kilobytes.

[0003] The present invention relates generally to the field of antibody mimetics, and specifically to scaffolds derived from the third fibronectin type III domain of human tenascin-C, useful, for example, for the generation of products with novel binding properties. In particular, the present invention relates to CD40L-specific Tn3 scaffolds, methods for making such scaffolds, and methods of use in the diagnosis and treatment of systemic lupus erythematosus and other autoimmune and / or inflammatory disorders. [Background technology]

[0004] The present invention relates to CD40L-specific protein scaffolds that bind to CD40L, useful, for example, in the treatment of autoimmune and / or inflammatory disorders.

[0005] Biomolecules that can specifically bind to desired target epitopes are of great importance as therapeutic, research, and medical diagnostic tools. A well-known example of this class of molecules is the antibody. Antibodies can be selected that bind with specific affinity to almost any structural epitope. However, classical antibodies are structurally complex heterotetrameric molecules that are difficult to express in simple eukaryotic systems. As a result, most antibodies are produced using complex and expensive mammalian cell expression systems.

[0006] Proteins that have relatively defined three-dimensional structures and are generally referred to as protein scaffolds can be used as reagents for the design of genetically engineered products.One particular area where such scaffolds are useful is the field of antibody mimic design.Antibody mimics, i.e., small molecule non-antibody protein therapeutics, take advantage of the advantages of antibodies and antibody fragments, such as high affinity binding of targets and low immunogenicity and toxicity, while avoiding some of their shortcomings, such as the tendency of antibody fragments to aggregate and be less stable than full-length IgG.

[0007] These shortcomings can be addressed by using antibody fragments that are created by removing part of the antibody native fold. However, this often leads to aggregation when amino acid residues that are normally buried in hydrophobic environments, such as the interface between variable and constant domains, are exposed to solvent. One example of a scaffold-based antibody mimic is based on the structure of the fibronectin type III domain (FnIII), a domain that is widely found across phyla and protein classes, for example, in mammalian blood and structural proteins. The design and use of the FnIII scaffold derived from the third FnIII domain of human tenascin-C is described in PCT applications PCT / US2011 / 032184 and PCT / US2011 / 032188, both of which are incorporated herein by reference in their entirety.

[0008] CD40L is a member of the TNF family of molecules expressed primarily on activated T cells (e.g., Th0, Th1, and Th2 subtypes) and forms similar homotrimers with other members of this family. In addition, CD40L has also been found expressed on mast cells, and activated basophils and eosinophils. CD40L binds to the CD40 receptor (CD40R) on antigen-presenting cells (APCs) and has a number of effects depending on the target cell type. In general, CD40L acts as a costimulatory molecule, inducing activation in APCs following T cell receptor stimulation by MHC molecules on APCs.

[0009] Signaling through the CD40 receptor by CD40L initiates a cascade of events that result in activation of CD40 receptor-bearing cells and optimal CD4+ T cell priming. More specifically, the cognate interaction of CD40L with the CD40 receptor promotes the differentiation of B cells into antibody-secreting and memory B cells (Burkly, In Adv. Exp. Med. Bio., Vol. 489., DM Monroe, U. Hedner, MRHoffman, C. Negrier, GF Savidge, and GCI White, eds. Klower Academic / Plenum Publishers, 2001, p. 135). Furthermore, the interaction of CD40L with the CD40 receptor promotes cell-mediated immunity through activation of macrophages and dendritic cells and the generation of natural killer cells and cytotoxic T lymphocytes (Burkly, supra).

[0010] The interaction of CD40L with the CD40 receptor has been shown to be important in several experimentally induced autoimmune diseases, such as collagen-induced arthritis, experimental allergic encephalomyelitis, oophoritis, colitis, and drug-induced lupus nephritis.Specifically, it has been shown that disease induction in all of these models can be blocked by CD40L antagonists at the time of antigen administration.Disease blocking using anti-CD40L antagonists has also been confirmed in animal models of spontaneous autoimmune diseases, such as insulin-dependent diabetes mellitus and lupus nephritis, as well as in graft-versus-host disease, transplantation, pulmonary fibrosis, and atherosclerosis disease models.

[0011] Disruption of the CD40L / CD40R pathway via CD40L blockade has been shown to be beneficial in many autoimmune-mediated diseases, including but not limited to, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD) and allograft rejection. For example, treatment with anti-CD40L antibodies prevented or ameliorated nephritis in a collagen-induced arthritis mouse model (Mohan et al. J. Immuno. 154:1470). Furthermore, anti-CD40L antibodies preserved renal function in SNF1 mice with established nephritis (Kalled et al. J. Immuno. 160:2158). CD40L levels correlate closely with clinical disease severity (i.e., reduced inflammation) and target tissue damage in both non-human and human.

[0012] SLE is a progressive and potentially fatal autoimmune disease. The diverse symptoms of lupus range from rashes and arthritis to anemia and thrombocytopenia to even psychiatric illness. There is clear evidence that many arms of the immune system are involved in the inflammatory process that leads to kidney, skin, brain disease and thrombosis. One characteristic feature of SLE is the loss of B-cell tolerance, and autoantibodies are prominent in patients with this disease. In lupus renal disease, anti-double-stranded DNA autoantibodies can form antibody-nucleosome complexes and precipitate in the renal glomerular basement membrane. These immune complexes can then activate complement, resulting in glomerulonephritis.

[0013] Expression of CD40R and CD40L has been found to be elevated in patients with SLE. Increased costimulatory signals likely contribute to the pathological inflammatory response found in SLE. SLE T cells have spontaneously increased activation with a reduced threshold of activation to self-antigens. Furthermore, these cells are hyporesponsive to further antigenic stimulation, resistant to apoptosis, have increased survival after activation, and have many altered intracellular signaling pathways. After CD40R activation on APCs by T cell CD40L, both APCs and T cells are activated and produce cytokines, contributing to the production of pathogenic autoantibodies and tissue damage (lupus nephritis) in SLE. Blockade of the CD40R / CD40L pathway is effective alone or in combination in blocking disease in lupus model mice. In patients with SLE, humanized CD40L antibodies reduced anti-dsDNA and B cells, proteinuria, and improved SLE disease severity.

[0014] However, targeting CD40L with conventional antibodies has raised significant safety concerns. For example, a study with anti-CD40L antibody 5c8 (BIOGEN®) in patients with chronic refractory idiopathic thrombocytopenic purpura (ITP) was put on hold due to reported thrombotic occlusive complications (Davidson et al. Arth Rheu, 43:S271). Furthermore, additional studies with surrogate antibodies directed against CD40L have resulted in other thrombotic-related complications (Davis et al. Arth Rheu, 43:S281; Schuler, Transplantation, 77:717). Due to the complications caused by antibody-directed antagonism of CD40L, there is an unmet need to target and antagonize CD40L with non-antibody alternatives. Therefore, targeting CD40L with a Tn3-based scaffold represents an attractive alternative by avoiding Fab2- and / or Fc-mediated platelet aggregation and downstream side effects.

[0015] Citation or discussion of a reference herein shall not be construed as an admission that it is prior art to the present invention. [Prior art documents] [Patent documents]

[0016] [Patent Document 1] PCT Application No. PCT / US2011 / 032184 [Patent Document 2] PCT / US2011 / 032188 specification [Non-patent literature]

[0017] [Non-Patent Document 1] Burkly,In Adv.Exp.Med.Bio.,Vol.489.,DMMonroe,U.Hedner,MRHoffman,C.Negrier,GFSavidge,and GCIWhite,eds.Klower Academic / Plenum Publishers,2001,p.135 [Non-Patent Document 2] Mohan et al. J. Immuno. 154:1470 [Non-Patent Document 3] Kalled et al.J.Immuno.160:2158 [Non-Patent Document 4] Davidson et al.Arth Rheu,43:S271 [Non-Patent Document 5] Davis et al.Arth Rheu,43:S281;Schuler,Transplantation,77:717 Summary of the Invention [Means for solving the problem]

[0018] The present invention provides a Tn3 scaffold comprising a CD40L-specific monomeric subunit, the monomeric subunit comprising seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, which specifically binds to CD40L. In some embodiments, the Tn3 scaffold comprises a single CD40L-specific monomeric subunit. In other embodiments, the Tn3 scaffold comprises two CD40L-specific monomeric subunits linked in tandem. In some specific embodiments, the Tn3 scaffold comprises two CD40L-specific monomeric subunits linked directly.

[0019] In some embodiments, the two CD40L-specific monomeric subunits are linked by a linker. In other embodiments, the linker comprises a peptide linker, which may be a flexible peptide linker. In some embodiments, the peptide linker is m X) n wherein X is serine (S), alanine (A), glycine (G), Leu (L), isoleucine (I), or valine (V); m and n are integer values; m is 1, 2, 3, or 4; and n is 1, 2, 3, 4, 5, 6, or 7. In some embodiments, the peptide linker comprises SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:142, or SEQ ID NO:143.

[0020] In some embodiments, the binding of the Tn3 scaffold comprising two CD40L-specific monomer subunits to CD40L is improved compared to that of the Tn3 scaffold comprising a single CD40L-specific monomer subunit. In other embodiments, the binding of the Tn3 scaffold comprising two CD40L-specific monomer subunits to CD40L improves the action on the target compared to that of the Tn3 scaffold comprising a single CD40L-specific monomer subunit. In other embodiments, the improvement in the binding of the Tn3 scaffold to CD40L is an improvement in binding affinity, an improvement in binding avidity, or both. In some embodiments, the binding affinity of the Tn3 scaffold comprising two CD40L-specific monomer subunits to CD40L and the Tn3 scaffold protein stability are improved compared to those of the Tn3 scaffold comprising a single CD40L-specific monomer subunit. In some embodiments, the binding avidity for CD40L and the Tn3 scaffold protein stability of a Tn3 scaffold comprising two CD40L-specific monomeric subunits are improved compared to those of a Tn3 scaffold comprising a single CD40L-specific monomeric subunit.

[0021] In some embodiments, at least one CD40L-specific monomer subunit in the Tn3 scaffold is linked to a linker or to a heterologous moiety. In other embodiments, the linker or heterologous moiety in the Tn3 scaffold is conjugated to the N-terminus or C-terminus of the CD40L-specific monomer subunit. In certain embodiments, the linker linked to the CD40L-specific monomer subunit in the Tn3 scaffold comprises a peptide linker, which in some embodiments may be a flexible peptide linker. The peptide linker may, in certain embodiments, be a peptide linker having a structure such as (G m X) n where X is serine (S), alanine (A), glycine (G), leucine (L), isoleucine (I), or valine (V); m and n are integers; m is 1, 2, 3, or 4; n is 1, 2, 3, 4, 5, 6, or 7. In some embodiments, the peptide linker attached to the CD40L-specific monomeric subunit in the Tn3 scaffold comprises SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:142, or SEQ ID NO:143.

[0022] In some embodiments, the Tn3 scaffold comprises a linker that comprises a functional moiety. In some embodiments, the functional moiety is an immunoglobulin or a fragment thereof. In some embodiments, the immunoglobulin or a fragment thereof comprises an Fc domain. In some embodiments, the Fc domain is not capable of inducing at least one FcγR-mediated effector function. In some embodiments, the at least one FcγR-mediated effector function is ADCC.

[0023] In some embodiments, the Tn3 scaffold comprises at least one CD40L-specific monomeric subunit linked to a heterologous moiety, which in some embodiments comprises a composition selected from the group consisting of a protein, a peptide, a protein domain, a linker, a drug, a toxin, a cytotoxic agent, an imaging agent, a radionuclide, a radioactive compound, an organic polymer, an inorganic polymer, polyethylene glycol (PEG), biotin, albumin, human serum albumin (HSA), an HSA FcRn binding moiety, an antibody, a domain of an antibody, an antibody fragment, a single chain antibody, a domain antibody, an albumin binding domain, an enzyme, a ligand, a receptor, a binding peptide, a non-FnIII scaffold, an epitope tag, a recombinant polypeptide polymer, a cytokine, and a combination of two or more of the foregoing moieties.

[0024] In some embodiments, the Tn3 scaffold comprises at least one CD40L-specific monomer subunit conjugated to PEG. In some embodiments, the Tn3 scaffold comprises at least one CD40L-specific monomer subunit conjugated to albumin. In some embodiments, the albumin is human serum albumin (HSA). In other embodiments, the HSA is a variant HSA. In some specific embodiments, the amino acid sequence of the variant HSA is SEQ ID NO: 133. In other embodiments, the variant HSA has at least one improved property compared to native HSA or a native HSA fragment. In some embodiments, the improved property is an altered plasma half-life compared to the plasma half-life of native HSA or a native HSA fragment. In some embodiments, the altered plasma half-life is a longer plasma half-life compared to the plasma half-life of native HSA or a native HSA fragment. In other embodiments, the altered plasma half-life is a shorter plasma half-life compared to the plasma half-life of native HSA or a native HSA fragment.

[0025] In some embodiments, the Tn3 scaffold is fused to the HSA variant that comprises at least one amino acid substitution in HSA domain III.In other embodiments, the Tn3 scaffold is fused to the HSA variant that comprises the sequence of full-length mature HSA (SEQ ID NO: 133 or 138) or a fragment thereof, except for at least one amino acid substitution numbered relative to the position in full-length mature HSA at the position selected from the group consisting of 407, 415, 463, 500, 506, 508, 509, 511, 512, 515, 516, 521, 523, 524, 526, 535, 550, 557, 573, 574 and 580; at least one amino acid substitution does not comprise the substitution of lysine (K) to glutamic acid (E) at position 573, and the Tn3 scaffold has a plasma half-life longer than the plasma half-life of the Tn3 scaffold that is not conjugated to such HSA variant.

[0026] In some embodiments, a Tn3 scaffold is fused to an HSA variant, and at least one amino acid substitution, numbered relative to positions in full-length mature HSA, is at a position selected from the group consisting of 463, 508, 523, and 524, and said Tn3 scaffold has a plasma half-life greater than the plasma half-life of a Tn3 scaffold that is not conjugated to said HSA variant.In some embodiments, the HSA variant comprises the sequence of full-length mature HSA (SEQ ID NO: 133 or 138), or a fragment thereof, except that: (a) a substitution of leucine (L) with asparagine (N) or tyrosine (Y) at position 407; (b) a substitution of valine (V) with threonine (T) at position 415; (c) a substitution of leucine (L) with asparagine (N) at position 463; (d) a substitution of lysine (K) with arginine (R) at position 500; (e) a substitution of threonine (T) with tyrosine (Y) at position 506; (f) a substitution of threonine (T) with tyrosine (Y) at position 508; (g) substitution of phenylalanine (F) with methionine (M) or tryptophan (W) at position 509; (h) substitution of alanine (A) with phenylalanine (F) at position 511; (i) substitution of aspartic acid (D) with tyrosine (Y) at position 512; (j) substitution of threonine (T) with glutamine (Q) at position 515; (k) substitution of leucine (L) with threonine (T) or tryptophan (W) at position 516; (l) substitution of arginine (R) with tryptophan (W) at position 521; (m ) substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (n) substitution of lysine (K) at position 524 with leucine (L); (o) substitution of glutamine (Q) at position 526 with methionine (M); (p) substitution of histidine (H) at position 535 with proline (P); (q) substitution of aspartic acid (D) at position 550 with glutamic acid (E); (r) substitution of lysine (K) at position 557 with glycine (G); (s) substitution of lysine (K) at position 573 with glycine (G); The Tn3 scaffold has a plasma half-life that is greater than the plasma half-life of a Tn3 scaffold that is not conjugated to the HSA variant, except for at least one amino acid substitution numbered relative to its position in full-length mature HSA selected from the group consisting of: (i) a substitution of at least one amino acid at position 574 with phenylalanine (F), histidine (H), proline (P), tryptophan (W), or tyrosine (Y); (ii) a substitution of at least one amino acid at position 574 with lysine (K) for asparagine (N); (iii) a substitution of at least one amino acid at position 580 with glutamine (Q) for lysine (K); and (iv) a combination of two or more of the foregoing substitutions.

[0027] In some embodiments, the Tn3 scaffold is fused to an HSA variant comprising the sequence of full-length mature HSA (SEQ ID NO: 133 or 138) or a fragment thereof, except for at least one amino acid substitution numbered relative to the position in full-length mature HSA selected from the group consisting of: (a) a substitution of leucine (L) at position 463 with asparagine (N); (b) a substitution of threonine (T) at position 508 with arginine (R); (c) a substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (d) a substitution of lysine (K) at position 524 with leucine (L); and (e) a combination of two or more of the foregoing substitutions, wherein the Tn3 scaffold has a plasma half-life greater than the plasma half-life of a Tn3 scaffold not conjugated to the HSA variant.

[0028] In some embodiments, the Tn3 scaffold comprises at least two identical CD40L-specific monomer subunits. In other embodiments, the Tn3 scaffold comprises at least two different CD40L-specific monomer subunits. In some embodiments, the Tn3 scaffold is a CD40 receptor agonist. In other embodiments, the Tn3 scaffold is a CD40 receptor antagonist.

[0029] In some embodiments, the Tn3 scaffold comprises at least two CD40L-specific monomer subunits that specifically bind to the same CD40L epitope. In other embodiments, the Tn3 scaffold comprises at least two CD40L-specific monomer subunits that specifically bind to different CD40L epitopes. In some embodiments, these different CD40L epitopes are non-overlapping epitopes. In other embodiments, these different CD40L epitopes are overlapping epitopes.

[0030] In some embodiments, the Tn3 scaffold binds at least two CD40L molecules, hi other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit that binds at least two CD40L molecules.

[0031] In some embodiments, the beta chain of at least one CD40L-specific monomer subunit of the Tn3 scaffold has at least 90% sequence identity with the beta chain of SEQ ID NO: 3. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising an A beta chain comprising SEQ ID NO: 11, or comprising an A beta chain comprising SEQ ID NO: 11 except for at least one mutation. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising a B beta chain comprising SEQ ID NO: 12, or comprising a B beta chain comprising SEQ ID NO: 12 except for at least one mutation. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising a C beta chain comprising SEQ ID NO: 13 or 14, or comprising a C beta chain comprising SEQ ID NO: 13 or 14 except for at least one mutation, where neither the cysteine ​​of SEQ ID NO: 13 nor the cysteine ​​of SEQ ID NO: 14 is substituted. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising a D beta chain comprising SEQ ID NO: 15, or comprising a D beta chain comprising SEQ ID NO: 15 except for at least one mutation.

[0032] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising an E beta chain comprising SEQ ID NO: 16, or comprising an E beta chain comprising SEQ ID NO: 16 except for at least one mutation. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising an F beta chain comprising SEQ ID NO: 17, or comprising an F beta chain comprising SEQ ID NO: 17 except for at least one mutation, wherein the cysteines in SEQ ID NO: 17 are not substituted. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising a G beta chain comprising SEQ ID NO: 18, or comprising a G beta chain comprising SEQ ID NO: 18 except for at least one mutation.

[0033] In some embodiments, the Tn3 scaffold has the amino acid sequence: IEV(X AB ) n ALITW(X BC ) n CELX 1 YGI(X CD ) n TTIDL(X DE ) n YSI(X EF ) n YEVSLIC(X FG ) n KETFTT (In the formula, X AB , X BC , X CD , X DE , X EF , and X FG represent the amino acid residues present in the sequences of the AB, BC, CD, DE, EF, and FG loops, respectively; X 1 represents amino acid residue A or T; the length of the loop, n, is an integer from 2 to 26. The CD40L-specific monomeric subunit comprises:

[0034] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the AB loop comprises SEQ ID NO: 4 or SEQ ID NO: 136, the sequence of the CD loop comprises SEQ ID NO: 6, and the sequence of the EF loop comprises SEQ ID NO: 8 or SEQ ID NO: 137. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, and 168. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 94, 95, 96, 97, 98, and 169. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 99, 139, and 170.

[0035] In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, and 174. In certain embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, and 175. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 129, 130, and 177. In one embodiment, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the AB loop comprises a sequence selected from the group consisting of SEQ ID NOs: 4 and 136.

[0036] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 99. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 84, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139.

[0037] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 85, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 86, the sequence of the DE loop comprises SEQ ID NO: 96, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 87, the sequence of the DE loop comprises SEQ ID NO: 97, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139.

[0038] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 88, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 89, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 90, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139.

[0039] In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the BC loop comprises SEQ ID NO: 91, the sequence of the DE loop comprises SEQ ID NO: 95, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the BC loop comprises SEQ ID NO: 92, the sequence of the DE loop comprises SEQ ID NO: 98, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, and the sequence of the BC loop comprises SEQ ID NO: 93, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139.

[0040] In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 100, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 101, the sequence of the DE loop comprises SEQ ID NO: 119, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 102, the sequence of the DE loop comprises SEQ ID NO: 120, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 103, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the AB loop comprises SEQ ID NO:136.

[0041] In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 104, the sequence of the DE loop comprises SEQ ID NO: 122, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 105, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 106, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the AB loop comprises SEQ ID NO: 136.

[0042] In certain embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 107, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 108, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the BC loop comprises SEQ ID NO: 109, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 110, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit, the sequence of the AB loop comprises SEQ ID NO: 136.

[0043] In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 111, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 130. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 108, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 112, the sequence of the DE loop comprises SEQ ID NO: 124, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 113, the sequence of the DE loop comprises SEQ ID NO: 125, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the AB loop comprises SEQ ID NO:136.

[0044] In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 114, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 115, the sequence of the DE loop comprises SEQ ID NO: 126, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 116, the sequence of the DE loop comprises SEQ ID NO: 127, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises CD40L-specific monomeric subunits, the sequence of the BC loop comprises SEQ ID NO: 117, the sequence of the DE loop comprises SEQ ID NO: 128, and the sequence of the FG loop comprises SEQ ID NO: 129. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit and the sequence of the AB loop comprises SEQ ID NO:136.

[0045] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit comprising a sequence selected from the group consisting of SEQ ID NOs: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 146. In some embodiments, the Tn3 scaffold comprises the amino acid sequence: IEVKDVTDTTALITWX 1 DX 2 X 3 X 4 X 5 X 6 X 7 X 8 CELTYGIKDVPGDRTTIDLWX 9 HX 10 AX 11 YSIGNLKPDTEYEVSLICRX 12 GDMSSNPAKETFTT (SEQ ID NO: 167) (In the formula, (a)X 1 represents the amino acid residue serine (S) or leucine (L); (b) X 2 represents the amino acid residue aspartic acid (D) or glutamic acid (E); (c) X 3 represents the amino acid residue histidine (H), isoleucine (I), valine (V), phenylalanine (F), or tryptophan (W); (d) X 4 represents the amino acid residue alanine (A), glycine (G), glutamic acid (E), or aspartic acid (D); (e) X 5 represents the amino acid residue glutamic acid (E), leucine (L), glutamine (Q), serine (S), aspartic acid (D), or asparagine (N); (f) X 6 represents the amino acid residue phenylalanine (F) or tyrosine (Y); (g) X 7 represents the amino acid residue isoleucine (I), valine (V), histidine (H), glutamic acid (E) or aspartic acid (D); (h) X 8 represents the amino acid residue glycine (G), tryptophan (W) or valine (V); (i) X 9represents the amino acid residue tryptophan (W), phenylalanine (F) or tyrosine (Y); (j) X 10 represents the amino acid residue serine (S), glutamine (Q), methionine (M) or histidine (H); (k) X 11 represents the amino acid residue tryptophan (W) or histidine (H); (l) X 12 represents the amino acid residue arginine (R) or serine (S) The CD40L-specific monomeric subunit comprises:

[0046] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomeric subunit comprising a sequence selected from the group consisting of SEQ ID NOs: 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, and 82.

[0047] In some embodiments, the Tn3 scaffold has the amino acid sequence: IEVX 1 DVTDTTALITWX 2 X 3 RSX 4 X 5 X 6 X 7 X 8 X 9 X 10 CELX 11 YGIKDVPGDRTTIDLX 12 X 13 X 14 X 15 YVHYSIGNLKPDTX 16 YEVSLICLTTDGTYX 17 NPAKETFTT (SEQ ID NO: 171) (In the formula, (a)X 1 represents the amino acid residues lysine (K) or glutamic acid (E); (b)X 2 represents the amino acid residues threonine (T) or isoleucine (I); (c)X 3 represents the amino acid residues asparagine (N) or alanine (A); (d)X 4 represents the amino acid residues serine (S), leucine (L), alanine (A), phenylalanine (F) or tyrosine (Y); (e)X 5 represents the amino acid residue tyrosine (Y), alanine (A), glycine (G), valine (V), isoleucine (I) or serine (S); (f)X 6 represents the amino acid residue tyrosine (Y), serine (S), alanine (A) or histidine (H); (g)X 7 represents the amino acid residues asparagine (N), aspartic acid (D), histidine (H) or tyrosine (Y); (h)X 8 represents the amino acid residue leucine (L), phenylalanine (F), histidine (H) or tyrosine (Y); (i)X 9 represents the amino acid residues histidine (H), proline (P), serine (S), leucine (L) or aspartic acid (D); (j)X 10 represents the amino acid residue glycine (G), phenylalanine (F), histidine (H) or tyrosine (Y); (k)X 11 represents the amino acid residues alanine (A) or threonine (T); (l)X 12 represents the amino acid residues serine (S), asparagine (N), glutamic acid (E), asparagine (R) or aspartic acid (D); (m)X 13 represents the amino acid residue serine (S), glutamine (Q), threonine (T), asparagine (N) or alanine (A); (n)X 14 represents the amino acid residues proline (P), valine (V), isoleucine (I) or alanine (A) or no amino acid; (o)X 15 represents the amino acid residue isoleucine (I) or no amino acid; (p)X 16represents the amino acid residue glutamic acid (E) or lysine (K); (q)X 17 represents the amino acid residue serine (S) or asparagine (N) The CD40L-specific monomeric subunit comprises:

[0048] In some embodiments, the Tn3 scaffold comprises a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 205, 206, 207 and 208. In other embodiments, the Tn3 scaffold consists of a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 205, 206, 207 and 208.

[0049] In some embodiments, the Tn3 scaffold comprises a sequence selected from the group consisting of SEQ ID NOs: 201, 202, 203, and 204. In some embodiments, the Tn3 scaffold consists of a sequence selected from the group consisting of SEQ ID NOs: 201, 202, 203, and 204. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit, said CD40L specificity being directed to human CD40L. In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit, said CD40L specificity being directed to membrane-bound CD40L (SEQ ID NO: 1), soluble CD40L (SEQ ID NO: 2), or a fragment thereof. In some specific embodiments, the Tn3 scaffold binds to CD40L and prevents binding of CD40L to CD40.

[0050] The invention also provides a method of altering the activity of a CD40L-expressing cell comprising contacting the CD40L-expressing cell with a Tn3 scaffold, where the Tn3 scaffold binds to CD40L and disrupts binding of CD40L to CD40. In some embodiments, the Tn3 scaffold has an affinity (K) of about 1 μM or less, or about 500 nM or less, or about 100 nM or less, or about 50 nM or less, or about 25 nM or less, or about 10 nM or less, or about 5 nM or less, or about 2 nM or less. d ) which binds to CD40L.

[0051] In some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit that specifically binds to a CD40L epitope that comprises amino acids located at positions 142 to 155, 200 to 230, or 247 to 251 of SEQ ID NO:2, and in some embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit that interacts with CD40L amino acids E142, Y146, M148, N151, L155, R200, R203, and E230. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit that interacts with CD40L amino acids R203, I204, V247, H249, and T251. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit that interacts with CD40L amino acids E142, Y146, M148, N151, L155 located in a first CD40L molecule and with CD40L amino acids R200, R203, and E230 located in a second CD40L molecule. In other embodiments, the Tn3 scaffold comprises a CD40L-specific monomer subunit that interacts with CD40L amino acids R203 and I204 located in a first CD40L molecule and with CD40L amino acids V247, H249, and T251 located in a second CD40L molecule.

[0052] The present invention also provides polypeptides comprising one or more CD40L-specific monomers, including, but not limited to, serum albumin fusions as described herein.

[0053] The invention also provides isolated nucleic acid molecules encoding a CD40L-specific Tn3 scaffold, expression vectors comprising the encoding nucleic acid molecules comprising a CD40L-specific Tn3 scaffold, and host cells comprising such vectors. The invention also provides a method of producing a Tn3 scaffold comprising culturing a host cell under conditions in which the CD40L-specific Tn3 scaffold encoded by the nucleic acid molecule is expressed.

[0054] The invention also provides a pharmaceutical composition comprising a CD40L-specific Tn3 scaffold and a pharma- ceutically acceptable excipient.The invention also provides a method of preventing, treating, ameliorating, or managing an autoimmune disease in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition comprising a CD40L-specific Tn3 scaffold.

[0055] The present invention also provides a method of reducing the frequency and amount of corticosteroids administered to a patient with autoimmunity comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a CD40L-specific Tn3 scaffold.

[0056] Autoimmune diseases that may be treated by administration of the CD40L-specific Tn3 scaffold include alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune disease of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, Sjogren's syndrome, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasia (including Graves' disease), corneal and other tissue transplants, as well as chronic inflammation, sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis (e.g., psoriatic arthritis), anaphylactic shock, organ ischemia, reperfusion injury, spinal cord injury, and allograft rejection. Autoimmune thrombocytopenia, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis The primary disease may be rheumatoid arthritis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis such as dermatitis herpetiformis vasculitis, vitiligo and Wegener's granulomatosis.

[0057] In some specific embodiments, the autoimmune disease treated by administration of a CD40L-specific Tn3 scaffold is systemic lupus erythematosus (SLE).

[0058] The method of treating with a CD40L-specific Tn3 scaffold may further include additional therapy, for example, immunotherapy, biotherapy, chemotherapy, radiation therapy, or small molecule drug therapy.

[0059] The present invention also relates to a protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:20 in complex with soluble CD40L (SEQ ID NO:2), 1 2 1 2 1 Provided is a protein crystal having an orthorhombic space group and unit cell dimensions of a=85.69 Å, b=90.64 Å, c=95.56 Å, crystal lattice at + / -0.1%. In some embodiments, the asymmetric unit of the crystal comprises a trimer of CD40L and three molecules of the Tn3 scaffold. In other embodiments, the crystal diffracts X-rays for determination of structural coordinates to a resolution of 3.2 Å or less.

[0060] The present invention also relates to a protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:68 in complex with soluble CD40L (SEQ ID NO:2), 1 Provided is a protein crystal having a 3 cubic space group and unit cell dimensions of a=b=c=97.62 Å, crystal lattice at + / -0.1%. In some embodiments, the asymmetric unit of the crystal contains one CD40L molecule and one Tn3 scaffold molecule. In other embodiments, the crystal diffracts X-rays for determining structural coordinates to a resolution of 2.7 Å or less.

[0061] The present invention also provides protein crystals comprising a Tn3 scaffold consisting of SEQ ID NO:28 or 146 in complex with soluble CD40L (SEQ ID NO:2), the crystal having a P321 space group and unit cell dimensions of a=95.53 Å, b=93.53 Å, c=66.69 Å, + / - 0.1%. In some embodiments, the asymmetric unit of the crystal comprises one CD40L molecule and one Tn3 scaffold molecule. In other embodiments, the crystal diffracts X-rays for determining structural coordinates to a resolution of 2.8 Å or less.

[0062] The present invention also relates to a protein crystal comprising two different Tn3 scaffolds consisting of SEQ ID NO:68 and SEQ ID NO:28 or 146 in complex with soluble CD40L (SEQ ID NO:2), 1 Provided is a protein crystal having a cubic space group and unit cell dimensions of a=80.32 Å, b=143.48 Å, c=111.27 Å, β=98.22 Å, crystal lattice at + / -0.1%. In some embodiments, the asymmetric unit of the crystal comprises two CD40L trimers and six respective Tn3 scaffold molecules. In other embodiments, the crystal diffracts X-rays for determining structural coordinates to a resolution of 1.9 Å or less.

[0063] In some embodiments, protein crystals are produced by using sitting drop vapor diffusion.The present invention also provides a method for making protein crystals, comprising: (a) mixing a volume of liquid comprising a Tn3 scaffold comprising CD40L-specific monomer subunits in complex with CD40L with a volume of reservoir solution comprising a precipitant; and (b) incubating the mixture obtained in step (a) in a closed vessel under suitable conditions for crystallization until protein crystals form.In some embodiments, the method for producing protein crystals comprises using sitting drop vapor diffusion.

[0064] In some embodiments, the methods of making protein crystals are used to produce crystals comprising the CD40L-specific Tn3 monomer subunit of SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:68, or SEQ ID NO:146.

[0065] The invention also provides a machine-readable data storage medium comprising a data storage material encoded with machine-readable instructions for (a) converting data into a graphical three-dimensional representation of the structure of a portion of a protein crystal of a Tn3 scaffold comprising a CD40L-specific monomeric subunit complexed with CD40L; and (b) causing display of said graphical three-dimensional representation. In some embodiments, such a Tn3 scaffold comprises SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:68, or SEQ ID NO:146. In other embodiments, such a protein crystal comprises (a) A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:20 in complex with soluble CD40L (SEQ ID NO:2), 1 2 1 2 1 Protein crystals with orthorhombic space group and unit cell dimensions of a=85.69 Å, b=90.64 Å, c=95.56 Å, crystal lattice at + / - 0.1%; (b) A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:68 in complex with soluble CD40L (SEQ ID NO:2), 1 A protein crystal having a crystal lattice with a cubic space group of 3 and unit cell dimensions of a=b=c=97.62 Å, + / - 0.1%; or (c) A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:20 and a Tn3 scaffold consisting of SEQ ID NO:68, both Tn3 scaffolds being in complex with soluble CD40L (SEQ ID NO:2). (d) Protein crystals comprising a Tn3 scaffold consisting of SEQ ID NO: 28 or 146 in complex with soluble CD40L (SEQ ID NO: 2), said protein crystals having a P321 space group and unit cell dimensions of a=95.53 Å, b=93.53 Å, c=66.69 Å, + / - 0.1% crystal lattice. (e) A protein crystal comprising two different Tn3 scaffolds consisting of SEQ ID NO: 68 and SEQ ID NO: 28 or 146 in complex with soluble CD40L (SEQ ID NO: 2), 1 Protein crystal with cubic space group and unit cell dimensions of a=80.32 Å, b=143.48 Å, c=111.27 Å, β=98.22 Å, crystal lattice at + / - 0.1% It is.

[0066] For the purpose of illustrating the invention, there is shown in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. [Brief description of the drawings]

[0067] [Figure 1A] Figure 1 shows inhibition of murine CD40L (MuCD40L)-induced CD86 expression measured using a D10G4.1 / PBMC (peripheral blood mononuclear cell) assay. The M13 murine CD40L-specific Tn3 scaffold, its M31 affinity-optimized variant (approximately 20-fold affinity improvement), anti-CD40L MR1 monoclonal antibody, and a negative control were assayed. IC50 values ​​are also shown. [Figure 1B] Figure 1 shows CD40L inhibition in a murine NfkB assay. The assay uses NIHT3T cells expressing murine CD40R and containing an NfkB-luciferase reporter construct. Addition of CD40L results in signaling (as measured by luciferase activity) that is inhibited by both the MR1 anti-CD40L antibody and the M31 CD40L-specific Tn3 scaffold. [Figure 2A] 1 shows the design of CD40L-specific tandem bivalent Tn3 scaffold and serum albumin (SA) fusion constructs. [Figure 2B] SDS-PAGE analysis of purified monovalent M13 constructs (CD40L-specific Tn3 constructs) or tandem bivalent scaffolds with linkers containing 1, 3, 5 or 7 Gly4Ser units (denoted GS) linking two M13Tn3 monomer subunits. Monovalent M13 constructs were run in lane 2, dimeric constructs with one GS unit (C1) were run in lanes 3 and 7, dimeric constructs with three GS units (C2) were run in lanes 4 and 8, dimeric constructs with five GS units (C3) were run in lanes 5 and 9, and dimeric constructs with seven GS units (C4) were run in lanes 6 and 10. Samples were run under either non-reducing (lanes 2-6) or reducing (lanes 7-10) conditions. [Figure 2C] Figure 1 shows competitive inhibition of murine CD40L binding to murine CD40 receptor immobilized on a biosensor chip by murine CD40L-specific monovalent (M13) or bivalent tandem scaffolds (M13-xGS-M13, where x is 1, 3, 5, or 7, corresponding to bivalent scaffolds with linkers containing 1, 3, 5, or 7 Gly4Ser units). The half-maximal inhibitory concentrations (IC50) for the various constructs are also shown. [Figure 2D] 1 shows the inhibitory effect of murine CD40L-specific Tn3 monovalent (M13) and bivalent tandem scaffolds on murine CD40L-induced CD86 expression on B cells. IC50 values ​​are provided for all Tn3 constructs and for the MR1 anti-murine CD40L antibody. [Figure 3A] We show high expression levels of murine CD40L-specific tandem bivalent Tn3 scaffolds fused to mouse serum albumin (MSA) in HEK293 cells. These constructs have one (G4S) repeat in the linker between the Tn3 scaffold units and three (G4S) repeats in the linker between the Tn3 scaffold and MSA. In addition, the constructs contain the N49Q mutation in each of the M13 and M31 scaffolds to remove potential N-linked glycosylation sites. 10 μl of culture supernatant harvested 3 or 6 days after transfection was run on an SDS-PAGE gel along with known amounts of purified protein. Expression levels were estimated to be 200 mg / l 6 days after transfection. Purification was performed by IMAC via the C-terminal His tag. [Figure 3B] Figure 1 shows inhibition of murine CD40L (MuCD40L)-induced CD86 expression measured using a D10G4.1 / PBMC cell assay. A CD40L-specific tandem bivalent Tn3 scaffold (M13-1GS-M13), an identical construct fused to mouse serum albumin (MSA) (M13-1GS-M13-MSA), and the MR1 anti-murine CD40L monoclonal antibody were assayed. IC50 values ​​for all constructs are provided. [Figure 3C]1 shows inhibition of murine CD40L (MuCD40L)-induced CD86 expression measured using a D10G4.1 / PBMC cell assay. A CD40L-specific tandem bivalent Tn3 scaffold (M13-1GS-M13) fused to mouse serum albumin (MSA) (M13-1GS-M13-MSA), an affinity matured variant of the M13 scaffold conjugated to MSA (M31Mono-MSA), a tandem bivalent scaffold comprising an M31 affinity optimized variant conjugated to MSA (M31-1GS-M31-MSA), a negative control tandem bivalent scaffold that does not bind murine CD40L (D1-1GS-D1-MSA), and the MR1 monoclonal antibody were assayed. IC50 values ​​are provided. [Figure 4A] Figure 1 shows the pharmacokinetics of several murine CD40L-specific constructs in mice as measured by ELISA. Plasma half-life (t1 / 2) values ​​for each construct are shown. [Figure 4B] FIG. 1 shows the pharmacokinetics of human CD40L-specific 342-HSA and a 342-HSA variant containing a Leu by Asn substitution at position 463 (L463N) and a Lys by Leu substitution at position 524 (K524L) in cynomolgus monkeys as measured by ELISA. [Figure 5A] Figure 1 shows B cell maturation in germinal centers (GCs) from a sheep red blood cell (SRBC) immunization assay. MR1 monoclonal anti-murine CD40L antibody was assayed. [Figure 5B] Figure 1 shows B cell maturation in germinal centers (GCs) from a sheep red blood cell (SRBC) immunization assay. M31-derived monovalent and bivalent constructs fused to MSA were assayed. A D1-D1 bivalent construct conjugated to MSA was used as a negative control. [Figure 5C] Figure 1 shows peripheral (non-GC) B cell maturation from a sheep red blood cell (SRBC) immunization assay. M31-derived monovalent and bivalent constructs fused to MSA were assayed. A D1-D1 bivalent construct conjugated to MSA was used as a negative control. [Figure 5D]The percentage (%CD4) and number (#CD4) of CD4 positive cells from a sheep red blood cell (SRBC) immunization assay are shown. M31-derived monovalent and bivalent constructs fused to MSA and the MR1 anti-CD40L monoclonal antibody were assayed. The D1-D1 bivalent construct conjugated to MSA was used as a negative control. [Figure 5E] The percentage (%CD44hi) and number (#CD44hi) of CD44hi positive cells from sheep red blood cell (SRBC) immunization assays are shown. M31-derived monovalent and bivalent constructs fused to MSA and MR1 anti-CD40L monoclonal antibody were assayed. D1-D1 bivalent construct conjugated to MSA was used as a negative control. [Figure 5F] Quantity of anti-SRBC IgG from a sheep red blood cell (SRBC) immunization assay is shown. M31-derived monovalent and bivalent constructs fused to MSA were assayed. A D1-D1 bivalent construct conjugated to MSA was used as a negative control. [Figure 5G] Anti-KLH IgM titers from a KLH-specific T cell-dependent antibody response (TDAR) model are shown. 342-derived monovalent and bivalent constructs fused to HSA were assayed. [Figure 5H] Anti-KLH IgG titers from a KLH-specific T cell-dependent antibody response (TDAR) model are shown. 342-derived monovalent and bivalent constructs fused to HSA were assayed. [Figure 6A] FIG. 1 shows the inhibitory effect of human CD40L-specific monovalent Tn3 monomer scaffolds 309 and 311 on human CD40L-induced CD86 expression on CD19-positive human PBMCs stimulated with Jurkat D1.1 cells. [Figure 6B] 1 shows the inhibitory effect of human CD40L-specific monovalent Tn3 monomer scaffolds 309 and 311 on human CD40L-stimulated B cell proliferation. [Figure 6C]Figure 1 shows the inhibitory effect of human CD40L-specific monovalent Tn3 monomer scaffolds 309 and 311 on plasma cell numbers in T / B cell co-cultures. Tn3 scaffold 309 was also shown to bind to activated primary T cells by FACS (data not shown). D1 scaffold ("Neg Tn3") was used as a control. Two monoclonal antibodies against CD40L, named aCD40L(RE) and aCD40L(Bio) (5c8 anti-human CD40L monoclonal antibody from Biogen), were also used as controls. [Figure 7A] Figure 1 shows that human CD40L-specific monovalent Tn3 scaffolds 309 and 311 have similar biophysical properties. Both scaffolds are monodisperse as measured by SEC. [Figure 7B] Figure 2 shows that human CD40L-specific monovalent Tn3 scaffolds 309 and 311 have similar biophysical properties. Both scaffolds have similar thermal stability as the parent Tn3 scaffold (designated Tn3 (wild type) in the graph) as measured by differential scanning calorimetry (DSC). [Figure 8A] Figure 1 shows inhibition of human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells. Monovalent (311) and bivalent (311_3GS and 311_7GS) human CD40L-specific Tn3 scaffolds were assayed. IC50 values ​​for each construct are shown. [Figure 8B] Figure 1 shows inhibition of human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells. Monovalent (309) and bivalent (309_3GS and 309_7GS) human CD40L-specific Tn3 scaffolds and Biogen's 5c8 anti-human CD40L monoclonal antibody were assayed. IC50 values ​​for each construct and antibody are shown. [Figure 9A] 1 shows a representative human CD40L-specific tandem bivalent Tn3 scaffold design fused to human serum albumin (HSA). "GGGGG" (SEQ ID NO: 148) and "GGGGA" (SEQ ID NO: 149) are alternative linkers to the "GGGGS" linker (SEQ ID NO: 147). [Figure 9B]Test purification from 293F cells on an IEX column. The shoulder fraction (<10% of the major peak) contains O-glycosylated protein attached to a serine residue present in the linker. [Figure 9C] Figure 1 shows inhibition of human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells. A bivalent (309) human CD40L-specific Tn3 scaffold, the same scaffold fused to HSA, and the 5c8 anti-human CD40L monoclonal antibody from Biogen were assayed. [Figure 9D] Figure 1 shows inhibition of human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells. Three bivalent (309) human CD40L-specific Tn3 scaffolds were tested. Three (G4S) repeats were present in the linker between the human CD40L-specific subunits (309 in this example), while the linker between the 309 subunit and HSA varied from one to three (G4S) repeats. 5c8 anti-human CD40L monoclonal antibody from Biogen was also assayed. [Figure 10A] The effect of mutations in the loop sequences of 309 (left panel) and 311 (right panel) on CD40L binding is shown. Binding indicates the signal intensity in the binding assay. WT is the variant with the original lead sequence (parental Tn3 sequence), while BC, DE and FG indicate variants in which the BC, DE or FG loop sequence was changed to the parental Tn3 sequence present in human tenascin-C. [Figure 10B] Figure 1 shows the inhibition profile of a panel of affinity-optimized scaffolds measured by human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells. Human CD40L-specific Tn3 clone 309 monomers were affinity-optimized. The affinity-optimized monomers are designed as clone 340 to clone 349. The clone 309wtFG construct had the entire FG loop replaced by the FG loop of the parent Tn3 scaffold. The 5c8 anti-CD40L monoclonal antibody was also assayed. [Figure 10C]Figure 1 shows the inhibition profile measured by human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells.Profiles of human CD40L-specific Tn3 311 monomer, its K4E variant, and a negative control are shown. [Figure 10D] Figure 1 shows the inhibition profile measured by human CD40L-induced CD86 expression on CD19-positive human PBMC stimulated by Jurkat D1.1 cells. Profiles of human CD40L-specific Tn3 311K4E monomer, affinity-optimized 311K4E_12 monomer, and 5c8 anti-CD40L monoclonal antibody are shown. IC50 for the two constructs and antibodies are also presented. [Figure 11A] 1 shows a multiple sequence alignment of the parent CD40L-specific Tn3 scaffold 309, the 309FGwt variant, and the affinity-optimized variants 340 to 349. Amino acid residues 1 to 42 are shown in FIG. 11A, and amino acid residues 43 to 83 are shown in FIG. 11B. Variant loops are indicated by shading. The consensus amino acid sequence is presented below the multiple sequence alignment. The aligned sequences correspond to the amino acid sequences of Tn3 scaffold clones 309 (SEQ ID NO:20), 309FGwt (SEQ ID NO:22), 340 (SEQ ID NO:24), 341 (SEQ ID NO:26), 342 (SEQ ID NO:28), 343 (SEQ ID NO:30), 344 (SEQ ID NO:32), 345 (SEQ ID NO:34), 346 (SEQ ID NO:36), 347 (SEQ ID NO:38), 348 (SEQ ID NO:40), and 349 (SEQ ID NO:42). [Figure 11B]1 shows a multiple sequence alignment of the parent CD40L-specific Tn3 scaffold 309, the 309FGwt variant, and the affinity-optimized variants 340 to 349. Amino acid residues 1 to 42 are shown in FIG. 11A, and amino acid residues 43 to 83 are shown in FIG. 11B. Variant loops are indicated by shading. The consensus amino acid sequence is presented below the multiple sequence alignment. The aligned sequences correspond to the amino acid sequences of Tn3 scaffold clones 309 (SEQ ID NO:20), 309FGwt (SEQ ID NO:22), 340 (SEQ ID NO:24), 341 (SEQ ID NO:26), 342 (SEQ ID NO:28), 343 (SEQ ID NO:30), 344 (SEQ ID NO:32), 345 (SEQ ID NO:34), 346 (SEQ ID NO:36), 347 (SEQ ID NO:38), 348 (SEQ ID NO:40), and 349 (SEQ ID NO:42). [Figure 12A] Figure 12 shows a multiple sequence alignment of the parent CD40L-specific Tn3 scaffold 311, the 311K4E variant, and the affinity-optimized variants 311K4E_1 to 311K4E_21. Amino acid residues 1 to 44 are shown in Figure 12A, and amino acid residues 45 to 87 are shown in Figure 12B. Variant loops are shown by shading. Amino acid variations outside the shaded loops are boxed. The consensus sequence is presented below the multiple sequence alignment. The aligned sequences were Tn3 scaffold clones 311 (SEQ ID NO: 44), 311K4E (SEQ ID NO: 46), 311K4E_1 (SEQ ID NO: 48), 311K4E_2 (SEQ ID NO: 50), 311K4E_2 (SEQ ID NO: 52), 311K4E_3 (SEQ ID NO: 54), 311K4E_4 (SEQ ID NO: 56), 311K4E_5 (SEQ ID NO: 58), 311K4E_7 (SEQ ID NO: 60), 311K4E_8 (SEQ ID NO: 62), 311K4E_9 (SEQ ID NO: 63), 311K4E_10 (SEQ ID NO: 104), 311K4E_11 (SEQ ID NO: 106), 311K4E_12 (SEQ ID NO: 108), 311K4E_13 (SEQ ID NO: 109), 311K4E_14 (SEQ ID NO: 110), 311K4E_15 (SEQ ID NO: 111), 311K4E_16 (SEQ ID NO: 122), 311K4E_17 (SEQ ID NO: 123), 311K4E_18 (SEQ ID NO: 124), 311K4E_19 (SEQ ID NO: 125), 311K4E_20 (SEQ ID NO: 126), 311K4E_21 (SEQ ID NO: 127), 311K4E_22 (SEQ ID NO: 128), 311K4E_23 (SEQ ID NO: 129), 31 4), 311K4E_10 (SEQ ID NO: 66), 311K4E_11 (SEQ ID NO: 68), 311K4E_12 (SEQ ID NO: 70), 311K4E_13 (SEQ ID NO: 72), 311K4E_14 (SEQ ID NO: 74), 311K4E_15 (SEQ ID NO: 76), 311K4E_16 (SEQ ID NO: 78), 311K4E_19 (SEQ ID NO: 80), 311K4E_20 (SEQ ID NO: 82), and 311K4E_21 (SEQ ID NO: 84). [Figure 12B]Figure 12 shows a multiple sequence alignment of the parent CD40L-specific Tn3 scaffold 311, the 311K4E variant, and the affinity-optimized variants 311K4E_1 to 311K4E_21. Amino acid residues 1 to 44 are shown in Figure 12A, and amino acid residues 45 to 87 are shown in Figure 12B. Variant loops are shown by shading. Amino acid variations outside the shaded loops are boxed. The consensus sequence is presented below the multiple sequence alignment. The aligned sequences were Tn3 scaffold clones 311 (SEQ ID NO: 44), 311K4E (SEQ ID NO: 46), 311K4E_1 (SEQ ID NO: 48), 311K4E_2 (SEQ ID NO: 50), 311K4E_2 (SEQ ID NO: 52), 311K4E_3 (SEQ ID NO: 54), 311K4E_4 (SEQ ID NO: 56), 311K4E_5 (SEQ ID NO: 58), 311K4E_7 (SEQ ID NO: 60), 311K4E_8 (SEQ ID NO: 62), 311K4E_9 (SEQ ID NO: 63), 311K4E_10 (SEQ ID NO: 104), 311K4E_11 (SEQ ID NO: 106), 311K4E_12 (SEQ ID NO: 108), 311K4E_13 (SEQ ID NO: 109), 311K4E_14 (SEQ ID NO: 110), 311K4E_15 (SEQ ID NO: 111), 311K4E_16 (SEQ ID NO: 122), 311K4E_17 (SEQ ID NO: 123), 311K4E_18 (SEQ ID NO: 124), 311K4E_19 (SEQ ID NO: 125), 311K4E_20 (SEQ ID NO: 126), 311K4E_21 (SEQ ID NO: 127), 311K4E_22 (SEQ ID NO: 128), 311K4E_23 (SEQ ID NO: 129), 31 4), 311K4E_10 (SEQ ID NO: 66), 311K4E_11 (SEQ ID NO: 68), 311K4E_12 (SEQ ID NO: 70), 311K4E_13 (SEQ ID NO: 72), 311K4E_14 (SEQ ID NO: 74), 311K4E_15 (SEQ ID NO: 76), 311K4E_16 (SEQ ID NO: 78), 311K4E_19 (SEQ ID NO: 80), 311K4E_20 (SEQ ID NO: 82), and 311K4E_21 (SEQ ID NO: 84). [Figure 13] Figure 1 shows a human NfkB inhibition assay using HEK293 cells expressing the human CD40 receptor and containing an NfkB-luciferase reporter construct. Addition of human CD40L results in signaling (measured by luciferase activity) that can be inhibited by CD40L binding molecules. CD40L-specific Tn3 scaffolds 340 and 342, as well as the 5c8 anti-CD40L monoclonal antibody, were assayed. [Figure 14] Binding of human CD40-specific Tn3 scaffolds to 24-hour anti-CD3 / 28-activated human CD4+ T cells. A monovalent 342 scaffold fused to HSA (designated 342-HSA) and a bivalent 342 scaffold fused to HSA (designated 342-342-HSA) were assayed. [Figure 15]Figure 3 shows inhibition of primary human T / B cell proliferation at day 3. Monovalent 340 scaffold fused to HSA (340-HSA), monovalent 342 scaffold fused to HSA (342-HSA), and bivalent 342 scaffold fused to HSA (342-342-HSA) were assayed. IC50 values ​​for each construct are shown. [Figure 16A] Aggregation assay on washed platelets. The graph shows representative ADP-induced aggregation positive controls for donors (top three traces, ADP: 0.5 μM, 1 μM, and 2 μM, respectively) along with immune complexes (IC) of 5c8 monoclonal antibody (600 nM) and soluble human CD40L (200 nM). [Figure 16B] Figure 1 shows an aggregation assay on washed platelets. The graph shows the lack of aggregation when using an immune complex of preformed 309-309 bivalent scaffold (not fused to HSA) and soluble CD40L. The concentration of human CD40L (soluble form) was held constant at 600 nM and the concentration of the scaffold construct was varied from 200 nM to 800 nM. [Figure 16C] Figure 1 shows an aggregation assay on washed platelets. The graph shows the lack of aggregation when using an immune complex of 342 monovalent scaffold and soluble human CD40L fused to preformed HSA. The concentration of human CD40L (soluble form) was kept constant at 600 nM, and the concentration of the scaffold construct was varied from 100 nM to 400 nM. The graph also shows the rapid aggregation induced by the immune complex of Biogen 5c8 monoclonal antibody and soluble human CD40L. [Figure 17A] Figure 1 shows a ribbon representation of the crystal structure of soluble CD40L in complex with the CD40L-specific Tn3 309 monomer scaffold. CD40L forms a trimer (polypeptides A, B and C). Each 309 scaffold (polypeptides D, E and F, circled) contacts two CD40L polypeptides. The specific contacts between each 309 scaffold and the first and second CD40L polypeptides are listed. This is a "top-down" view of the structure. [Figure 17B]1 shows a ribbon representation of the crystal structure of soluble CD40L in complex with the CD40L-specific Tn3 311K4E_12 monomer scaffold. CD40L forms a trimer (polypeptides A, B and C). Each 311K4E_12 monomer scaffold (polypeptides D, E and F, circled) contacts two CD40L polypeptides. The specific contacts between each 311K4E_12 monomer scaffold and the first and second CD40L polypeptides are listed. This is a "top-down" view of the structure. [Figure 17C] A ribbon representation illustrating that the 311K4E_12 and 309 scaffolds (circles) bind to different epitopes located in different parts of the CD40L trimer complex. Both scaffolds bind in the same groove that interacts with the CD40 receptor. This is a "side" view of the structure. [Figure 17D] 1 shows a ribbon representation of the crystal structure of soluble CD40L in complex with the CD40L-specific Tn3 342 monomer scaffold. Only one CD40L and one 342 monomer scaffold are shown. The specific contacts between the 342 monomer scaffold and the first CD40L polypeptide are listed. [Figure 17E] Figure 1 shows a ribbon representation illustrating that the 342 and 311K4E_12 scaffolds can simultaneously bind different epitopes located in different parts of the CD40L trimer complex. Both scaffolds bind in the same groove that interacts with the CD40 receptor. This is a "side" view of the structure. [Figure 18A] 17A shows the localization of contacts between amino acids in the trimer formed by the CD40L-specific Tn3 311K4E_12 monomer scaffold (SEQ ID NO:68) and the soluble CD40L (SEQ ID NO:2) molecule shown in FIG. Each scaffold contacts two CD40L molecules. The CD40L sequence (SEQ ID NO:2) is shown. Dotted underline = cytoplasmic domain; solid underline = signal anchor type II membrane protein; double underline = portion co-crystallized with the Tn3 scaffold; dark shading = residues on the first CD40L that contact Tn3; light shading = residues on the second CD40L that contact Tn3. [Figure 18B]17B shows the localization of contacts between amino acids in the CD40L-specific Tn3 309 monomer scaffold and the CD40L trimer shown in FIG. Each scaffold contacts two CD40L molecules. The CD40L sequence (SEQ ID NO:2) is shown. Dotted underline = cytoplasmic domain; solid underline = signal anchor type II membrane protein; double underline = portion co-crystallized with the Tn3 scaffold; dark shading = residues on the first CD40L that contact Tn3; light shading = residues on the second CD40L that contact Tn3; doubly enclosed residues contact the FG loop of the 309 scaffold that are likely not conserved in clones with the wild-type FG loop. [Figure 19] Panel A shows an exemplary chromatogram of the elution of Tn3 scaffold (309 or 311K4E_12), CD40L and the complex between them from a size-exclusion Superdex200 10 / 300GL column. Panel B shows crystals of the 309-CD40L complex. The crystals shown grew to dimensions of up to 0.15×0.15×0.1 mm. Panel C shows crystals of the 311K4E_12-CD40L complex. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0068] definition Before describing the invention in detail, it should be understood that the invention is not limited to specific compositions or process steps, as they may vary. It should be noted that the singular forms "a", "an" and "the" used in this specification and the appended claims include plural referents unless the context dictates otherwise. The terms "a" (also "an"), as well as "one or more" and "at least one" can be used interchangeably herein.

[0069] Furthermore, "and / or" as used herein should be interpreted as a specific disclosure of each of the two specified properties or components, with or without the other. Thus, the term "and / or" as used in phrases herein, such as "A and / or B", is intended to include "A and B", "A or B", "A" (single), and "B" (single). Similarly, the term "and / or" as used in phrases, such as "A, B, and / or C", is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).

[0070] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in the present invention.

[0071] Units, prefixes, and symbols are shown in their International System of Units (SI) accepted form. Numerical ranges are inclusive of the numbers defining the range. Unless otherwise noted, amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not intended to be limiting of the various aspects or embodiments of the invention, which may be had by reference to the specification in its entirety. Thus, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0072] Whenever an embodiment is described herein using the term "comprising," it is understood that otherwise similar embodiments described using the terms "consisting of" and / or "consisting essentially of" are also provided.

[0073] Amino acids are referred to herein by either their commonly known three letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Similarly, nucleotides are referred to by their commonly accepted one-letter codes.

[0074] The term "epitope" as used herein refers to a protein determinant that can bind to the scaffold of the present invention. Epitopes usually consist of chemically active surface molecular groups, such as amino acids or sugar side chains, and usually have specific three-dimensional structural characteristics and specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to conformational epitopes is lost in the presence of denaturing solvents, whereas the binding to non-conformational epitopes is not lost.

[0075] The terms "fibronectin type III (FnIII) ​​domain", "FnIII domain" and "FnIII scaffold" refer to a polypeptide homologous to human fibronectin type III domain, which has at least seven beta strands distributed between two beta sheets and which assemble with each other to form the core of the protein, and further contains solvent-exposed loops that connect the beta strands to each other. At least three such loops are present at each end of the beta sheet sandwich, which is the boundary of the protein perpendicular to the direction of the beta strands. In certain embodiments, the FnIII domain comprises seven beta strands designated A, B, C, D, E, F, and G that are connected to six loop regions designated AB, BC, CD, DE, EF, and FG, which connect each beta strand.

[0076] The term "Tn3 scaffold" as used herein refers to a molecule comprising at least one FnIII scaffold, the A beta chain comprising SEQ ID NO: 11, the B beta chain comprising SEQ ID NO: 12, the C beta chain comprising SEQ ID NO: 13 or 14, the D beta chain comprising SEQ ID NO: 15, the E beta chain comprising SEQ ID NO: 16, the F beta chain comprising SEQ ID NO: 17, and the beta chain G comprising SEQ ID NO: 18, and at least one loop is a non-natural variant of a loop in the "parent Tn3 scaffold". In an embodiment, one or more of the beta chains of the Tn3 molecule comprises at least one amino acid substitution, except that the cysteine ​​residues of the C beta chain (e.g., neither the cysteine ​​of SEQ ID NO: 13 nor the cysteine ​​of SEQ ID NO: 14) and the F beta chain (SEQ ID NO: 17) are not substituted.

[0077] The term "parent Tn3" as used herein refers to an FnIII scaffold comprising SEQ ID NO:3, ie, a thermostabilized cysteine ​​engineered FnIII scaffold derived from the third FnIII domain of human tenascin-C.

[0078] The term "multimer" or "multimeric scaffold" refers to a molecule comprising at least two associated FnIII scaffolds. The scaffolds forming the multimeric scaffold may be linked via a linker that allows each scaffold to function independently.

[0079] The terms "monomer," "monomer subunit," or "monomer scaffold" refer to a molecule that contains only one FnIII scaffold.

[0080] As used herein, the term "CD40L-specific monomeric subunit" refers to a Tn3 monomer derived from the "parent Tn3" that specifically binds to CD40L or a fragment thereof, such as a soluble form of CD40L.

[0081] The term "DNA" refers to a sequence of two or more covalently linked natural or modified deoxyribonucleotides.

[0082] The term "fusion protein" refers to a protein comprising (i) one or more scaffolds of the invention linked to (ii) a second, different protein (i.e., a "heterologous" protein). [Table 1]

[0083] In the present invention, the term "heterologous moiety" is used to indicate the addition of a composition to the scaffold of the present invention, which composition is not a normal part of the FnIII domain.Exemplary heterologous moieties include proteins, peptides, protein domains, linkers, drugs, toxins, contrast agents, radioactive compounds, organic and inorganic polymers, and any other composition that can provide activity that is not inherent to the FnIII domain itself, such as, but not limited to, polyethylene glycol (PEG), cytotoxic agents, radionuclides, contrast agents, biotin, dimerization domains (e.g., leucine zipper domains), human serum albumin (HSA) or its FcRn binding portion, antibody domains or fragments (e.g., antibody variable domains, CH1 domains, Ckappa domains, Clamda domains, CH2 or CH3 domains), single-chain antibodies, domain antibodies, albumin binding domains, IgG molecules, enzymes, ligands, receptors, binding peptides, non-FnIII scaffolds, epitope tags, recombinant polypeptide polymers, cytokines, etc.

[0084] The term "linker" as used herein refers to any molecular assembly that connects or links two or more scaffolds. A linker can be a molecule whose function is to act as a "spacer" between modules in a scaffold, or it can be a molecule with additional functions (i.e., "functional moiety"). Molecules included in the definition of "heterologous moiety" can also function as linkers.

[0085] The terms "linked" and "fused" are used interchangeably. These terms refer to the joining together of two or more scaffolds, heterologous moieties, or linkers by any means, including chemical conjugation or recombinant means.

[0086] The term "domain" or "protein domain" refers to a region of a protein that can fold into a stable three-dimensional structure independent of the rest of the protein and can confer a specific function. This structure maintains a defined function related to the function of the domain in the original protein, such as enzymatic activity, creating a recognition motif for another molecule, or providing the structural components necessary for the protein to exist in the protein's specific environment. Within both protein families and related protein superfamilies, protein domains can be evolutionarily conserved regions. When describing components of a multimeric scaffold, the terms "domain", "monomer scaffold", "monomer subunit" and "module" can be used interchangeably. "Native FnIII domain" refers to any non-recombinant FnIII domain encoded by an organism.

[0087] "Protein sequence" or "amino acid sequence" means a linear representation of the amino acid components in a polypeptide from amino-terminus to carboxyl-terminus in which residues that are adjacent to each other are contiguous in the primary structure of the polypeptide.

[0088] The term "nucleic acid" refers to any two or more covalently linked nucleotides or nucleotide analogs or derivatives. As used herein, this term includes, but is not limited to, DNA, RNA, and PNA. "Nucleic acid" and "polynucleotide" are used interchangeably herein.

[0089] The term "polynucleotide" is intended to encompass single and multiple nucleic acids and refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA) or plasmid DNA (pDNA). The term "isolated" nucleic acid or polynucleotide refers to a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. A recombinant polynucleotide, such as one encoding a scaffold of the invention, contained in a vector, is considered isolated for the purposes of the present invention. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the polynucleotides of the invention. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. Additionally, a polynucleotide or nucleic acid may be or may include regulatory elements, such as a promoter, a ribosome binding site, or a transcription terminator.

[0090] The term "pharmacologically acceptable" refers to a compound or protein that can be administered to an animal (eg, a mammal) without significant adverse medical effects.

[0091] The term "physiologically acceptable carrier" refers to a carrier that does not have significant deleterious effects on the host being treated and that retains the therapeutic properties of the compound with which it is administered. One exemplary physiologically acceptable carrier is physiological saline. Other physiologically acceptable carriers and their formulations are known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences, (18 th edition, ed. A. Gennaro, 1990, Mack Publishing Company, Easton, Pa.

[0092] "Polypeptide" means any sequence of two or more amino acids linked in a linear chain by amide bonds (peptide bonds), regardless of length, post-translational modification, or function. "Polypeptide", "peptide", and "protein" are used interchangeably herein. Thus, a peptide, dipeptide, tripeptide, or oligopeptide is included within the definition of "polypeptide", and the term "polypeptide" can be used in place of or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the product of post-expression modifications of a polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-natural amino acids. Polypeptides can be derived from natural biological sources or produced by recombinant technology, but need not necessarily be translated from a specified nucleic acid sequence. Polypeptides can be generated in any manner, including, but not limited to, by chemical synthesis.

[0093] The polypeptide of the present invention also includes fragments, derivatives, analogs, or variants of the above polypeptides, and any combination thereof.Variants can be natural or non-natural.Non-natural variants can be produced using mutagenesis techniques known in the art.Variant polypeptides can include conservative or non-conservative amino acid substitutions, deletions, or additions."Derivatives" also include peptides that contain one or more natural amino acid derivatives of the 20 standard amino acids.

[0094] "Randomized" or "mutated" means to include one or more amino acid changes, such as deletions, substitutions or additions, relative to a template sequence. "Randomize" or "mutate" means the process of introducing such amino acid changes into a sequence. Randomization or mutation can generally be achieved through deliberate, blind, or spontaneous sequence changes of a nucleic acid coding sequence, and can be performed by any technique, such as PCR, error-prone PCR, or chemical DNA synthesis. The terms "randomize", "randomized", "mutate", "mutated", and the like are used interchangeably herein.

[0095] "Cognate" or "cognate non-mutated protein" means a protein that is identical in sequence to a variant protein, except for amino acid mutations introduced into the variant protein when the variant protein is randomized or mutagenized.

[0096] "RNA" means a sequence of two or more covalently linked natural or modified ribonucleotides. An example of a modified RNA included in this term is phosphorothioate RNA.

[0097] The term "scaffold of the invention" or "scaffolds of the invention" as used herein refers to multimeric and monomeric Tn3 scaffolds. The term "target" refers to the compound recognized by the specific scaffold of the invention. The terms "target" and "antigen" are used interchangeably herein. For example, the term "specific" in the term "specifically binds" or "specific binding" as used herein refers to the relative affinity with which the Tn3 scaffold of the invention binds to one or more antigens via one or more antigen-binding domains, and the binding requires some complementarity between one or more antigen-binding domains and one or more antigens. According to this definition, the Tn3 scaffold of the invention is said to "specifically bind" to an epitope if it binds to that epitope more readily than it binds to a random, unrelated epitope.

[0098] An "affinity matured" scaffold is one that has one or more alterations, generally in the loops, that result in an improvement in the affinity of the Tn3 scaffold for an epitope compared to a parent Tn3 scaffold that does not have the alterations.

[0099] The term "affinity" as used herein refers to a measure of the strength of binding of a given Tn3 scaffold of the invention to an individual epitope.

[0100] The term "avidity" as used herein refers to the overall stability of the complex between the Tn3 scaffold population of the present invention and an epitope, i.e., the binding strength of multiple functionally combined Tn3 scaffolds with an antigen. Avidity relates to both the affinity of individual antigen-binding domains with a specific epitope, and also to the valency of the scaffold of the present invention.

[0101] The term "target effect" refers to the binding of the Tn3 scaffold of the present invention to one or more targets and the biological effect resulting from such binding. In this regard, the multiple antigen binding units in the Tn3 scaffold may interact with various targets and / or epitopes, for example, bringing two targets closer together physically, triggering metabolic cascades through interactions with distinct targets, etc. With respect to CD40L, "target effect" refers to an effect achieved, for example, by enhancing, stimulating or activating one or more biological activities of CD40L.

[0102] The term "valency" as used herein refers to the number of potential antigen binding modules, for example, the number of FnIII modules in many scaffolds of the present invention.When the Tn3 scaffold of the present invention comprises two or more antigen binding modules, each binding module can specifically bind, for example, to the same epitope or different epitopes in the same target or different targets.

[0103] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond or crosslink with a second thiol group.

[0104] The terms "immunoglobulin" and "antibody" include various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will recognize that heavy chains are classified as gamma, mu, alpha, delta, or epsilon. It is the nature of this chain that determines the "class" of an antibody as IgG, IgM, IgA, IgG, or IgE, respectively. Modified forms of each of these classes are readily identifiable to those skilled in the art. The term "antibody" as used herein includes, but is not limited to, intact antibodies, modified antibodies, antibody VL or VL domains, CH1 domains, Ckappa domains, Clamda domains, Fc domains (see below), CH2, or CH3 domains.

[0105] The term "Fc domain" as used herein refers to a portion of an antibody constant region. Conventionally, the term Fc domain refers to a protease (e.g., papain) cleavage product that includes the paired CH2, CH3 and hinge regions of an antibody. In the context of this disclosure, the term Fc domain or Fc refers to any polypeptide (or nucleic acid encoding such a polypeptide) that includes all or part of the CH2, CH3 and hinge regions of an immunoglobulin polypeptide, regardless of the means of production.

[0106] The term "modified antibody" as used herein includes synthetic forms of antibodies that are modified to be non-natural, e.g., to include at least two heavy chain portions, but not two complete heavy chains (e.g., domain deleted antibodies or minibodies); multispecific forms of antibodies that are modified to bind to two or more antigens or different epitopes of a single antigen (e.g., bispecific, trispecific, etc.). In addition, the term "modified antibody" includes multivalent forms of antibodies (e.g., trivalent, tetravalent, etc., antibodies against three or more copies of the same antigen) (see, e.g., Antibody Engineering, Kontermann & Dubel, eds., 2010, Springer Protocols, Springer).

[0107] The term "in vivo half-life" is used in its usual sense, i.e., the time when 50% of the biological activity of a polypeptide is still present in the body / target organ, or the time when the activity of the polypeptide is 50% of its initial value. As an alternative to measuring functional in vivo half-life, one can measure the "serum half-life", i.e., the time when 50% of the polypeptide molecules circulate in the plasma or bloodstream before being cleared. Measuring serum half-life is often easier than measuring functional in vivo half-life, and the magnitude of serum half-life is usually a good indicator of the magnitude of functional in vivo half-life. Alternative terms for serum half-life include "plasma half-life", circulating half-life, circulatory half-life, serum clearance, plasma clearance, and clearance half-life. The function to be retained is usually selected from procoagulant, proteolytic, cofactor binding, receptor binding activity, or other types of biological activity associated with a particular protein.

[0108] The term "increased" with respect to functional in vivo half-life or plasma half-life is used to indicate that the relevant half-life of a polypeptide is statistically significantly increased compared to that of a reference molecule (e.g., an unmodified polypeptide) as measured under comparable conditions.

[0109] The term "reduced" with respect to functional in vivo half-life or plasma half-life is used to indicate that the relevant half-life of a polypeptide is statistically significantly reduced compared to that of a reference molecule (e.g., an unmodified polypeptide) as measured under comparable conditions.

[0110] The term "expression" as used herein refers to the process by which a gene produces a biochemical, such as the scaffold of the present invention or a fragment thereof. This process includes any manifestation of the functional presence of a gene in a cell, including, but not limited to, gene knockdown and both transient and stable expression. It includes, but is not limited to, the transcription of a gene into one or more mRNAs, and the translation of such mRNAs into one or more polypeptides. If the final desired product is a biochemical, expression includes the production of that biochemical and any precursors.

[0111] An "expression product" can be either a nucleic acid, e.g., messenger RNA produced by transcription of a gene, or a polypeptide. Expression products as described herein further include nucleic acids that have undergone post-transcriptional modifications, e.g., polyadenylation, or polypeptides that have undergone post-transcriptional modifications, e.g., methylation, glycosylation, lipid addition, association with other protein subunits, proteolytic cleavage, etc.

[0112] As used herein, the term "vector" or "expression vector" is used to mean a vector that is introduced into a host cell according to the present invention and used as a vehicle to express a desired expression product. As known to those skilled in the art, such vectors can be easily selected from the group consisting of plasmids, phages, viruses and retroviruses. In general, vectors compatible with the present invention include a selection marker, a suitable restriction enzyme site for facilitating cloning of the desired nucleic acid, and the ability to enter and / or replicate in eukaryotic or prokaryotic cells.

[0113] The term "host cell" refers to a cell that harbors a vector constructed using recombinant DNA technology and that encodes at least one expression product. In describing the process of isolating an expression product from a recombinant host, unless otherwise specified, the terms "cell" and "cell culture" are used interchangeably to indicate the source of the expression product, i.e., recovery of the expression product from a "cell" means either recovery from spun down whole cells or recovery from a cell culture containing both the medium and the suspended cells.

[0114] The term "treat" or "treatment" as used herein refers to both therapeutic treatment and preventative or prophylactic measures, the purpose of which is to prevent or slow down (attenuate) the progression of an undesirable physiological change or disorder in a subject, such as an inflammatory disease or condition. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization of disease state (i.e., not worsening), slowing or delaying disease progression, improvement or alleviation of disease state, and remission (whether partial or complete), whether detectable or undetectable.

[0115] The term "treatment" also means prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with a condition or disorder as well as those prone to having the condition or disorder or those in which the condition or disorder is to be prevented.

[0116] The terms "subject," "individual," "animal," "patient," or "mammal" refer to any individual, patient or animal for whom diagnosis, prognosis, or treatment is desired, particularly mammalian subjects. Mammalian subjects include humans, domestic animals, farm animals, and zoo animals, sport animals, or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, cows, and the like.

[0117] The term "CD40L" as used herein refers to, but is not limited to, CD40L expressed on the surface of T cells, recombinantly expressed CD40L, CD40L expressed and purified from E. coli or other suitable recombinant protein expression systems, non-glycosylated CD40L, and soluble fragments of CD40L. As used herein, "CD40L" also refers to MegaCD40L. MegaCD40L™ is a highly active construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30 / adiponectin. This construct simulates the natural membrane-assisted aggregation of CD40L in vivo very efficiently. It provides a simple and equally potent alternative to the [CD40L+enhancer] combination (Alexis biochemicals). The term "CD40L" refers to monomeric and oligomeric forms of CD40L, e.g., trimeric CD40L.

[0118] The term "CD40L" refers to both full-length CD40L and soluble fragments, e.g., extracellular domain forms of CD40L obtained by proteolysis. The amino acid sequences of the membrane-bound and soluble forms of human CD40L (Swissprot: P29965) are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

[0119] The term "CD40L antagonist" or "antagonist" is used in the broadest sense and includes any molecule that partially or completely inhibits, reduces or inactivates one or more biological activities of CD40L in vitro, in situ, or in vivo, and biologically active variants thereof. For example, a CD40L antagonist may function, as a result of its binding to CD40L, to partially or completely inhibit, reduce or inactivate one or more biological activities of one or more CD40L molecules in vivo, in vitro, or in situ, or one or more CD40L molecules bound to CD40 or other targets.

[0120] The term "CD40L agonist" or "agonist" is used in the broadest sense and includes any molecule that partially or fully enhances, stimulates, or activates one or more biological activities of CD40L in vitro, in situ, or in vivo, and biologically active variants thereof. For example, a CD40L agonist may function, as a result of its binding to CD40L, to partially or fully enhance, stimulate, or activate one or more biological activities of one or more CD40L molecules in vivo, in vitro, or in situ, or one or more CD40L molecules bound to CD40R or other targets.

[0121] As used herein, the term "crystal" refers to a solid-state form of matter in which atoms are arranged in a periodically repeating pattern in three dimensions, typically forming a lattice.

[0122] The term "space group symmetry" as used herein refers to the total symmetry of a crystal that combines the translational symmetry of the crystal lattice with point group symmetry. A "space group" is designated by a capital letter (P, A, F, etc.) that identifies the lattice group followed by a point group symbol where the rotation and reflection elements are expanded to include the helical axes and glide planes. It should be noted that the point group symmetry for a given space group can be determined by removing the lattice center symbol of the space group, replacing all helical axes with the similar rotation axes, and replacing all glide planes with mirror planes. The point group symmetry for a space group describes the true symmetry of its reciprocal lattice.

[0123] The term "unit cell" as used herein means atoms in a crystal arranged in a regular repeating pattern, where the smallest repeating unit is called a unit cell. The entire structure can be reconstructed from the information of the unit cell, which is characterized by three lengths (a, b, and c) and three angles (α, β, and γ). The quantities a and b are the lengths of the base of the cell, and γ is the angle between these two sides. The quantity c is the height of the unit cell. The angles α and β describe the angles between the base and the vertical side of the unit cell.

[0124] As used herein, the term "machine-readable data storage medium" refers to a data storage material having machine-readable data encoded therein, such that a machine can be programmed with instructions for using such data and display the data in a desired format, such as a graphical three-dimensional representation of a molecule or molecular complex.

[0125] The term "X-ray diffraction pattern" refers to the pattern obtained from X-ray scattering of a periodic collection of molecules or atoms in a crystal. X-ray crystallography is a technique that exploits the fact that X-rays are diffracted by crystals. X-rays are of the right wavelength (in the angstrom range, approximately 10 -8 The electron density can be reconstructed based on the diffraction pattern obtained from X-ray scattering of a periodic collection of molecules or atoms in a crystal. Additional phase information can be extracted from the diffraction data or from supplementary diffraction experiments to complete the reconstruction (the phase problem of crystallography). The model is progressively incorporated into the experimental electron density and refined against the data to obtain an accurate molecular structure. The X-ray structure coordinates define a unique configuration of points in space. Those skilled in the art will appreciate that a set of structure coordinates for a protein or protein-ligand complex, or a portion thereof, defines a relative set of points, which in turn defines a configuration in three dimensions. Similar or identical configurations can be defined by sets of entirely different coordinates, provided that the distances and angles between the coordinates remain essentially the same. Additionally, a configuration of points can be defined by increasing or decreasing the distances between the coordinates by a scalar factor while keeping the angles essentially the same.

[0126] The term "crystal structure" as used herein refers to the three-dimensional or lattice spacing arrangement of repeating atomic or molecular units in crystalline material.The crystal structure of crystalline material can be determined by X-ray crystallography, see, for example, "Principles of Protein X-Ray Crystallography" by Jan Drenth, Springer Advanced Texts in Chemistry, Springer Verlag, 2nd ed., February 199, ISBN: 0387985875, and "Introduction to Macromolecular Crystallography" by Alexander McPherson, Wiley-Liss, October 18, 2002, ISBN: 0471251224.

[0127] The term "effector function" refers to those biological activities of an antibody or an antibody fragment attributable to the Fc region of the antibody (native Fc region or amino acid sequence variant Fc region) and vary with antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

[0128] The term "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) enables these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill the target cells with cytotoxins.

[0129] The term "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The FcR may be a native sequence human FcR. The FcR may bind to an IgG antibody (gamma receptor), including receptors of the FcγRI, FcγRII and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of these receptors. The term also includes the neonatal receptor FcRn.

[0130] The term "consensus sequence" refers to a protein sequence that shows the most common amino acid at a particular position after multiple sequences are aligned. A consensus sequence is a way of expressing the results of a multiple sequence alignment in which related sequences are compared to each other. The consensus sequence shows which residues are most abundant in the alignment at each position and the degree of variability at each position.

[0131] Introduction CD40L (also known as CD154, CD40 ligand, gp39 or TBAM) is a 33 kDa type II membrane glycoprotein (Swiss-Prot accession number P29965). In addition, shorter 18 kDa soluble forms of CD40L exist (also known as sCD40L or soluble CD40L). These soluble forms of CD40L are generated by proteolytic processing of the membrane-bound protein, but the cellular activity of the soluble species is weak except for higher oligomerization (e.g., trimerization).

[0132] The present invention provides a family of recombinant non-natural protein scaffolds (Tn3 scaffolds) capable of binding to CD40L. In particular, the proteins described herein can be used to display defined loops analogous to the complementarity determining regions ("CDRs") of antibody variable regions. These loops can be subjected to randomization or restricted evolution to generate diversity capable of binding to multiple target compounds. The Tn3 scaffolds can be used as monomers or can be assembled into multimeric scaffolds capable of binding to CD40L.

[0133] In a specific embodiment, the present invention provides CD40L-specific binding agents useful for preventing, improving, detecting, diagnosing, or monitoring diseases, including, but not limited to, autoimmune diseases. In other specific embodiments, the CD40L-specific Tn3 scaffolds of the present invention are useful for treating autoimmune diseases and conditions. In some embodiments, autoimmune diseases can include, but are not limited to, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allograft rejection.

[0134] The Tn3 scaffold of the present invention comprises a CD40L-specific monomer subunit derived from the third FnIII domain of human tenascin-C engineered with at least one non-natural intramolecular disulfide bond. The monomer subunits that make up the Tn3 scaffold of the present invention fold correctly and independently of each other, retaining their binding specificity and affinity, and each of the monomer scaffolds retains its functional properties. When the monomer subunits are assembled into a high valency multimeric Tn3 scaffold, the monomer subunits fold correctly and independently of each other, retaining their binding specificity and affinity, and each of the monomers retains its functional properties.

[0135] Tn3 scaffolds of the invention that contain two or more monomeric subunits can bind to multiple epitopes, for example (i) to multiple epitopes in a single target, (ii) to a single epitope in multiple targets, (iii) to multiple epitopes located on different subunits of a target, or (iv) to multiple epitopes on multiple targets, thus increasing avidity.

[0136] Furthermore, due to the possibility of varying the distance between multiple monomers via linkers, multimeric Tn3 scaffolds can bind multiple target molecules on a surface (on the same cell / surface or in different cells / surfaces). As a result of their spontaneous binding ability to two or more targets, the Tn3 multimeric scaffolds of the present invention can be used to modulate multiple pathways, crosslink receptors on cell surfaces, bind cell surface receptors on separate cells, and / or attach target molecules or cells to substrates.

[0137] Furthermore, the present invention provides affinity-matured scaffolds in which the affinity of the scaffold for a defined target is modulated via mutation.Furthermore, the present invention provides methods for producing the scaffolds of the present invention and for engineering the scaffolds to have desired physicochemical, pharmacological, or immunological properties.Furthermore, the present invention provides the use of such scaffolds and methods for therapeutic, preventive, and diagnostic uses.

[0138] FnIII structural motif The Tn3 scaffold of the present invention is based on the structure of fibronectin type III module (FnIII), which is a domain that is widely found in all three regions of organisms and viruses, and many protein classes.In a specific embodiment, the scaffold of the present invention is derived from the third FnIII domain of human tenascin-C (International Application No. PCT / US2008 / 012398, published as WO2009 / 058379; PCT / US2011 / 032184, published as WO2011 / 130324; and International Application No. PCT / US2011 / 032188, published as WO2011130328).

[0139] In one specific embodiment, the Tn3 scaffold of the invention comprises a CD40L-specific monomer subunit derived from the parent Tn3 scaffold. The overall three-dimensional fold of the monomer is closely related to that of the variable region of the heavy chain (VH) of the smallest functional antibody fragment that comprises the entire antigen recognition unit in single domain antibodies of camelids and camelids (e.g., llamas).

[0140] The native FnIII domains from the Tn3 monomer subunit and tenascin-C of the present invention are characterized by the same three-dimensional structure, i.e., a beta sandwich structure with three beta strands (A, B, and E) on one side and four beta strands (C, D, F, and G) on the other side, connected by six loop regions. These loop regions are named according to the beta strands connected to the N- and C-termini of each loop. Thus, the AB loop is located between beta strands AB, the BC loop is located between strands BC, the CD loop is located between beta strands CD, the DE loop is located between beta strands DE, the EF loop is located between beta strands EF, and the FG loop is located between beta strands FG. The FnIII domains have solvent-exposed loops that are tolerant to randomization, facilitating the generation of a diverse pool of protein scaffolds that can bind to specific targets with high affinity.

[0141] In one embodiment of the invention, Tn3 monomer subunits are subjected to directed evolution designed to randomize one or more of the loops that are similar to the complementarity determining regions (CDRs) of antibody variable regions. Such a directed evolution approach results in the production of antibody-like molecules with high affinity for a target of interest, e.g., CD40L.

[0142] Furthermore, in some embodiments, the Tn3 scaffold described in the present invention can be used to display defined exposed loops (e.g., loops that have already been randomized and selected based on target binding) to direct the evolution of molecules that bind to such introduced loops. This type of selection can be performed to identify recognition molecules for any individual CDR-like loop, or for recognition of two or all three CDR-like loops combined into a non-linear epitope binding moiety. The set of three loops (designated BC, DE, and FG) that can confer specific target binding spans the BC interstrand; the DE interstrand, and the FG beta-strand, respectively. The BC, DE, and FG loops of the third FnIII domain of human tenascin-C are 9, 6, and 10 amino acid residues long, respectively. The lengths of these loops fall within the narrow range of the cognate antigen recognition loops found in antibody heavy chains, i.e., 7-10, 4-8, and 4-28 amino acids long, respectively. Similarly, the second set of loops, the AB, CD, and EF loops (7, 7, and 8 amino acids long, respectively), span between the AB beta strands; the CD beta strands; and the EF beta strands, respectively.

[0143] Loops in the Tn3 monomer scaffold can be randomized and selected for high affinity binding to a target, and can make contacts with the target equivalent to the contacts of cognate CDR loops in an antibody.Thus, in some embodiments, AB, CD and EF loops are randomized and selected for high affinity binding to one or more targets, such as CD40L.In some embodiments, this randomization and selection process can be performed in parallel with the randomization of BC, DE and FG loops, while in other embodiments, this randomization and selection process is performed sequentially.

[0144] CD40L-specific monomeric subunit The present invention provides a CD40L-specific recombinant non-natural Tn3 scaffold comprising multiple beta strand domains linked to multiple loop regions, one or more of which vary by the deletion, substitution or addition of at least one amino acid from its cognate loop in wild-type Tn3 (SEQ ID NO:3) (see Table 1).

[0145] To generate improved CD40L-specific Tn3 monomer subunits with novel binding properties, the parent Tn3 is subjected to amino acid additions, deletions or substitutions. When comparing the sequence of a CD40L-specific Tn3 monomer subunit with the sequence of the parent Tn3, it is understood that the same definitions of beta strands and loops are utilized. In some embodiments, the CD40L-specific Tn3 monomer subunits of the present invention have the amino acid sequence: IEV(X AB ) n ALITW(X BC ) n CELX 1 YGI(X CD ) n TTIDL(X DE ) n YSI(X EF ) n YEVSLIC(X FG ) n KETFTT (In the formula, (a)X AB , X BC , X CD , X DE , X EF , and X FG represent the amino acid residues present in the sequences of the AB, BC, CD, DE, EF, and FG loops, respectively; (b)X 1 represents the amino acid residues alanine (A) or threonine (T); (c) the length of the loop, n, is an integer between 2 and 26. Includes. [Table 2]

[0146] In some embodiments, the CD40L-specific Tn3 monomer subunit of the present invention has the amino acid sequence: IEV(X AB ) n ALITW(X BC ) n CELX 1 YGI(X CD ) n TTIDL(X DE ) n YSI(X EF ) n YEVSLIC(X FG ) n KETFTT (In the formula, (a)X AB , X BC , X CD , X DE , X EF , and X FG represent the amino acid residues present in the sequences of the AB, BC, CD, DE, EF, and FG loops, respectively; (b)X 1 represents the amino acid residues alanine (A) or threonine (T); (c) the length of the loop, n, is an integer between 2 and 26. It consists of:

[0147] In one embodiment, the beta chain of the CD40L-specific Tn3 monomer scaffold has at least 90% sequence identity with the beta chain of the parent Tn3 scaffold (SEQ ID NO: 3). To calculate such percentage of sequence identity, methods known in the art are applied to align the amino acid sequences. The percentage of sequence identity is defined as the ratio of (a) the number of amino acids located in the beta chains that are identical in the sequence alignment to (b) the total number of amino acids located in the beta chains.

[0148] In one embodiment, the sequence of the AB loop comprises SEQ ID NO:4 or SEQ ID NO:136. In another embodiment, the sequence of the CD loop comprises SEQ ID NO:6. In another embodiment, the sequence of the EF loop comprises SEQ ID NO:8 or SEQ ID NO:137. In one embodiment, the sequence of the AB loop consists of SEQ ID NO:4 or SEQ ID NO:136. In another embodiment, the sequence of the CD loop consists of SEQ ID NO:6. In another embodiment, the sequence of the EF loop consists of SEQ ID NO:8 or SEQ ID NO:137.

[0149] In one embodiment, the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93. In another embodiment, the sequence of the BC loop consists of a sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93.

[0150] In one embodiment, the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 94, 95, 96, 97, and 98. In another embodiment, the sequence of the DE loop consists of a sequence selected from the group consisting of SEQ ID NOs: 94, 95, 96, 97, and 98.

[0151] In one embodiment, the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 99, and 139. In another embodiment, the sequence of the FG loop consists of a sequence selected from the group consisting of SEQ ID NOs: 9, 99, and 139.

[0152] In one embodiment, the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, and 117. In another embodiment, the sequence of the BC loop consists of a sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, and 117.

[0153] In some embodiments, the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, and 128. In other embodiments, the sequence of the DE loop consists of a sequence selected from the group consisting of SEQ ID NOs: 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, and 128.

[0154] In some embodiments, the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 129 and 130. In other embodiments, the sequence of the FG loop consists of a sequence selected from the group consisting of SEQ ID NOs: 129 and 130.

[0155] In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139. In some embodiments, the sequence of the BC loop consists of SEQ ID NO: 83, the sequence of the DE loop consists of SEQ ID NO: 94, and the sequence of the FG loop consists of SEQ ID NO: 9 or 139.

[0156] In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 83, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 99. In other embodiments, the sequence of the BC loop consists of SEQ ID NO: 83, the sequence of the DE loop consists of SEQ ID NO: 94, and the sequence of the FG loop consists of SEQ ID NO: 99.

[0157] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:84, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:84, the sequence of the DE loop consists of SEQ ID NO:95, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0158] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:85, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:85, the sequence of the DE loop consists of SEQ ID NO:94, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0159] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:86, the sequence of the DE loop comprises SEQ ID NO:96, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:86, the sequence of the DE loop consists of SEQ ID NO:96, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0160] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:87, the sequence of the DE loop comprises SEQ ID NO:97, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:87, the sequence of the DE loop consists of SEQ ID NO:97, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0161] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:88, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:88, the sequence of the DE loop consists of SEQ ID NO:95, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0162] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:89, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:89, the sequence of the DE loop consists of SEQ ID NO:94, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0163] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:90, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:90, the sequence of the DE loop consists of SEQ ID NO:94, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0164] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:91, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:91, the sequence of the DE loop consists of SEQ ID NO:95, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0165] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:92, the sequence of the DE loop comprises SEQ ID NO:98, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:92, the sequence of the DE loop consists of SEQ ID NO:98, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0166] In some embodiments, the sequence of the BC loop comprises SEQ ID NO:93, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139. In other embodiments, the sequence of the BC loop consists of SEQ ID NO:93, the sequence of the DE loop consists of SEQ ID NO:94, and the sequence of the FG loop consists of SEQ ID NO:9 or 139.

[0167] In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 168, the sequence of the DE loop comprises SEQ ID NO: 169, and the sequence of the FG loop comprises SEQ ID NO: 170. In other embodiments, the sequence of the BC loop consists of SEQ ID NO: 168, the sequence of the DE loop consists of SEQ ID NO: 169, and the sequence of the FG loop consists of SEQ ID NO: 170.

[0168] In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 100, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the BC loop consists of SEQ ID NO: 100, the sequence of the DE loop consists of SEQ ID NO: 118, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0169] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 101, the sequence of the DE loop comprises SEQ ID NO: 119, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 101, the sequence of the DE loop consists of SEQ ID NO: 119, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0170] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 102, the sequence of the DE loop comprises SEQ ID NO: 120, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 102, the sequence of the DE loop consists of SEQ ID NO: 120, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0171] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 103, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 103, the sequence of the DE loop consists of SEQ ID NO: 121, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0172] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 104, the sequence of the DE loop comprises SEQ ID NO: 122, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 104, the sequence of the DE loop consists of SEQ ID NO: 122, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0173] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 105, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 105, the sequence of the DE loop consists of SEQ ID NO: 121, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0174] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 106, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 106, the sequence of the DE loop consists of SEQ ID NO: 123, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0175] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 107, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 107, the sequence of the DE loop consists of SEQ ID NO: 123, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0176] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 108, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 108, the sequence of the DE loop consists of SEQ ID NO: 118, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0177] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 109, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 109, the sequence of the DE loop consists of SEQ ID NO: 123, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0178] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 110, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 110, the sequence of the DE loop consists of SEQ ID NO: 121, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0179] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 111, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 130. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 111, the sequence of the DE loop consists of SEQ ID NO: 123, and the sequence of the FG loop consists of SEQ ID NO: 130.

[0180] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 108, the sequence of the DE loop comprises SEQ ID NO: 121, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 108, the sequence of the DE loop consists of SEQ ID NO: 121, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0181] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 112, the sequence of the DE loop comprises SEQ ID NO: 124, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 112, the sequence of the DE loop consists of SEQ ID NO: 124, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0182] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 113, the sequence of the DE loop comprises SEQ ID NO: 125, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 113, the sequence of the DE loop consists of SEQ ID NO: 125, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0183] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 114, the sequence of the DE loop comprises SEQ ID NO: 118, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 114, the sequence of the DE loop consists of SEQ ID NO: 118, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0184] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 115, the sequence of the DE loop comprises SEQ ID NO: 126, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 115, the sequence of the DE loop consists of SEQ ID NO: 126, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0185] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 116, the sequence of the DE loop comprises SEQ ID NO: 127, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 116, the sequence of the DE loop consists of SEQ ID NO: 127, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0186] In some embodiments, the sequence of the AB loop comprises SEQ ID NO: 136, the sequence of the BC loop comprises SEQ ID NO: 117, the sequence of the DE loop comprises SEQ ID NO: 128, and the sequence of the FG loop comprises SEQ ID NO: 129. In other embodiments, the sequence of the AB loop consists of SEQ ID NO: 136, the sequence of the BC loop consists of SEQ ID NO: 117, the sequence of the DE loop consists of SEQ ID NO: 128, and the sequence of the FG loop consists of SEQ ID NO: 129.

[0187] In some embodiments, the sequence of the BC loop comprises SEQ ID NO: 174, the sequence of the DE loop comprises SEQ ID NO: 175, and the sequence of the FG loop comprises SEQ ID NO: 177. In other embodiments, the sequence of the BC loop consists of SEQ ID NO: 174, the sequence of the DE loop consists of SEQ ID NO: 175, and the sequence of the FG loop consists of SEQ ID NO: 177.

[0188] In some embodiments, the CD40L-specific monomeric subunit comprises a sequence selected from the group consisting of SEQ ID NOs: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 146. In other embodiments, the CD40L-specific monomeric subunit consists of a sequence selected from the group consisting of SEQ ID NOs: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 146.

[0189] In some embodiments, the CD40L-specific monomeric subunit comprises SEQ ID NO: 28 or 146. In other embodiments, the CD40L-specific monomeric subunit consists of SEQ ID NO: 28 or 146.

[0190] In some embodiments, the CD40L-specific Tn3 monomer subunit of the present invention has the amino acid sequence: IEVKDVTDTTALITWX 1 DX 2 X 3 X 4 X 5 X 6 X 7 X 8 CELTYGIKDVPGDRTTIDLWX 9 HX 10 AX 11 YSIGNLKPDTEYEVSLICRX 12 GDMSSNPAKETFTT (SEQ ID NO: 167) (In the formula, (a)X 1 represents the amino acid residues serine (S) or leucine (L); (b)X 2 represents the amino acid residues aspartic acid (D) or glutamic acid (E); (c)X 3 represents the amino acid residues histidine (H), isoleucine (I), valine (V), phenylalanine (F), or tryptophan (W); (d)X 4 represents the amino acid residues alanine (A), glycine (G), glutamic acid (E) or aspartic acid (D); (e)X5 represents the amino acid residue glutamic acid (E), leucine (L), glutamine (Q), serine (S), aspartic acid (D) or asparagine (N); (f)X 6 represents the amino acid residues phenylalanine (F) or tyrosine (Y); (g)X 7 represents the amino acid residues isoleucine (I), valine (V), histidine (H), glutamic acid (E), or aspartic acid (D); (h)X 8 represents the amino acid residue glycine (G), tryptophan (W) or valine (V); (i)X 9 represents the amino acid residues tryptophan (W), phenylalanine (F) or tyrosine (Y); (j)X 10 represents the amino acid residues serine (S), glutamine (Q), methionine (M) or histidine (H); (k)X 11 represents the amino acid residues tryptophan (W) or histidine (H); (l)X 12 represents the amino acid residue arginine (R) or serine (S) Includes.

[0191] In some embodiments, the CD40L-specific Tn3 monomer subunit of the present invention has the amino acid sequence: IEVKDVTDTTALITWX 1 DX 2 X 3 X 4 X 5 X 6 X 7 X 8 CELTYGIKDVPGDRTTIDLWX 9 HX 10 AX 11 YSIGNLKPDTEYEVSLICRX 12 GDMSSNPAKETFTT (SEQ ID NO: 167) (In the formula, (a)X 1represents the amino acid residues serine (S) or leucine (L); (b)X 2 represents the amino acid residues aspartic acid (D) or glutamic acid (E); (c)X 3 represents the amino acid residues histidine (H), isoleucine (I), valine (V), phenylalanine (F), or tryptophan (W); (d)X 4 represents the amino acid residues alanine (A), glycine (G), glutamic acid (E) or aspartic acid (D); (e)X 5 represents the amino acid residue glutamic acid (E), leucine (L), glutamine (Q), serine (S), aspartic acid (D) or asparagine (N); (f)X 6 represents the amino acid residues phenylalanine (F) or tyrosine (Y); (g)X 7 represents the amino acid residues isoleucine (I), valine (V), histidine (H), glutamic acid (E), or aspartic acid (D); (h)X 8 represents the amino acid residue glycine (G), tryptophan (W) or valine (V); (i)X 9 represents the amino acid residues tryptophan (W), phenylalanine (F) or tyrosine (Y); (j)X 10 represents the amino acid residues serine (S), glutamine (Q), methionine (M) or histidine (H); (k)X 11 represents the amino acid residues tryptophan (W) or histidine (H); (l)X 12 represents the amino acid residue arginine (R) or serine (S) It consists of:

[0192] In some embodiments, the CD40L-specific monomeric subunit comprises a sequence selected from the group consisting of SEQ ID NOs: 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, and 82. In some embodiments, the CD40L-specific monomeric subunit consists of a sequence selected from the group consisting of SEQ ID NOs: 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, and 82.

[0193] In some embodiments, the CD40L-specific Tn3 monomer subunit of the present invention has the amino acid sequence: IEVX 1 DVTDTTALITWX 2 X 3 RSX 4 X 5 X 6 X 7 X 8 X 9 X 10 CELX 11 YGIKDVPGDRTTIDLX 12 X 13 X 14 X 15 YVHYSIGNLKPDTX 16 YEVSLICLTTDGTYX 17 NPAKETFTT (SEQ ID NO: 171) (In the formula, (a)X 1 represents the amino acid residues lysine (K) or glutamic acid (E); (b)X 2 represents the amino acid residues threonine (T) or isoleucine (I); (c)X 3 represents the amino acid residues asparagine (N) or alanine (A); (d)X 4 represents the amino acid residues serine (S), leucine (L), alanine (A), phenylalanine (F) or tyrosine (Y); (e)X 5represents the amino acid residue tyrosine (Y), alanine (A), glycine (G), valine (V), isoleucine (I) or serine (S); (f)X 6 represents the amino acid residue tyrosine (Y), serine (S), alanine (A) or histidine (H); (g)X 7 represents the amino acid residues asparagine (N), aspartic acid (D), histidine (H) or tyrosine (Y); (h)X 8 represents the amino acid residue leucine (L), phenylalanine (F), histidine (H) or tyrosine (Y); (i)X 9 represents the amino acid residues histidine (H), proline (P), serine (S), leucine (L) or aspartic acid (D); (j)X 10 represents the amino acid residue glycine (G), phenylalanine (F), histidine (H) or tyrosine (Y); (k)X 11 represents the amino acid residues alanine (A) or threonine (T); (l)X 12 represents the amino acid residues serine (S), asparagine (N), glutamic acid (E), asparagine (R) or aspartic acid (D); (m)X 13 represents the amino acid residue serine (S), glutamine (Q), threonine (T), asparagine (N) or alanine (A); (n)X 14 represents the amino acid residues proline (P), valine (V), isoleucine (I) or alanine (A) or no amino acid; (o)X 15 represents the amino acid residue isoleucine (I) or no amino acid; (p)X 16 represents the amino acid residue glutamic acid (E) or lysine (K); (q)X 17 represents the amino acid residue serine (S) or asparagine (N) Includes.

[0194] In some embodiments, the CD40L-specific Tn3 monomer subunit of the present invention has the amino acid sequence: IEVX 1 DVTDTTALITWX 2 X 3 RSX 4 X 5 X 6 X 7 X 8 X 9 X 10 CELX 11 YGIKDVPGDRTTIDLX 12 X 13 X 14 X 15 YVHYSIGNLKPDTX 16 YEVSLICLTTDGTYX 17 NPAKETFTT (SEQ ID NO: 171) (In the formula, (a)X 1 represents the amino acid residues lysine (K) or glutamic acid (E); (b)X 2 represents the amino acid residues threonine (T) or isoleucine (I); (c)X 3 represents the amino acid residues asparagine (N) or alanine (A); (d)X 4 represents the amino acid residues serine (S), leucine (L), alanine (A), phenylalanine (F) or tyrosine (Y); (e)X 5 represents the amino acid residue tyrosine (Y), alanine (A), glycine (G), valine (V), isoleucine (I) or serine (S); (f)X 6 represents the amino acid residue tyrosine (Y), serine (S), alanine (A) or histidine (H); (g)X 7 represents the amino acid residues asparagine (N), aspartic acid (D), histidine (H) or tyrosine (Y); (h)X 8represents the amino acid residue leucine (L), phenylalanine (F), histidine (H) or tyrosine (Y); (i)X 9 represents the amino acid residues histidine (H), proline (P), serine (S), leucine (L) or aspartic acid (D); (j)X 10 represents the amino acid residue glycine (G), phenylalanine (F), histidine (H) or tyrosine (Y); (k)X 11 represents the amino acid residues alanine (A) or threonine (T); (l)X 12 represents the amino acid residues serine (S), asparagine (N), glutamic acid (E), asparagine (R) or aspartic acid (D); (m)X 13 represents the amino acid residue serine (S), glutamine (Q), threonine (T), asparagine (N) or alanine (A); (n)X 14 represents the amino acid residues proline (P), valine (V), isoleucine (I) or alanine (A) or no amino acid; (o)X 15 represents the amino acid residue isoleucine (I) or no amino acid; (p)X 16 represents the amino acid residue glutamic acid (E) or lysine (K); (q)X 17 represents the amino acid residue serine (S) or asparagine (N) It consists of:

[0195] In some embodiments, the CD40L-specific monomer scaffold comprises a Tn3 module in which one or more of the beta chains contain at least one amino acid substitution, except that the cysteine ​​residues in the C and F beta chains (SEQ ID NO: 13 or 14, respectively; and SEQ ID NO: 17) cannot be substituted.

[0196] The loops connecting the various beta strands of the CD40L-specific monomeric subunits can be randomized for length and / or sequence diversity. In one embodiment, the CD40L-specific monomeric subunit has at least one loop that is randomized for length and / or sequence diversity. In one embodiment, at least one, at least two, at least three, at least four, at least five or at least six loops of the CD40L-specific monomeric subunit are randomized for length and / or sequence diversity. In one embodiment, at least one loop of the CD40L-specific monomeric subunit is held constant while at least one additional loop is randomized for length and / or sequence diversity. In another embodiment, at least one, at least two or all three of loops AB, CD and EF are held constant while at least one, at least two or all three of loops BC, DE and FG are randomized for length or sequence diversity. In another embodiment, at least one, at least two, or at least all three of loops AB, CD, and EF are randomized, while at least one, at least two, or all three of loops BC, DE, and FG are randomized for length and / or sequence diversity. In yet another embodiment, at least one, at least two, at least three, at least four, at least five, or all six of loops AB, CD, EF, BC, DE, and FG are randomized for length or sequence diversity.

[0197] In some embodiments, one or more residues in the loop are held constant while other residues are randomized for length and / or sequence diversity. In some embodiments, one or more residues in the loop are held to a predetermined limited number of different amino acids while other residues are randomized for length and / or sequence diversity. Thus, the CD40L-specific monomeric subunits of the present invention may comprise one or more loops with a degenerate consensus sequence and / or one or more invariant amino acid residues.

[0198] In one embodiment, a CD40L-specific monomeric subunit of the invention comprises a randomized AB loop. In another embodiment, a CD40L-specific monomeric subunit of the invention comprises a randomized BC loop. In one embodiment, a CD40L-specific monomeric subunit of the invention comprises a randomized CD loop. In one embodiment, a CD40L-specific monomeric subunit of the invention comprises a randomized DE loop. In one embodiment, a CD40L-specific monomeric subunit of the invention comprises a randomized EF loop.

[0199] In one embodiment, the CD40L-specific monomeric subunits of the present invention comprise an FG loop that is retained to be at least one amino acid residue shorter than the cognate FG loop of the third FnIII domain of human tenascin-C, and further randomized at one or more positions.

[0200] In a specific embodiment, at least one of loops BC, DE, and FG is randomized, the A beta chain comprises SEQ ID NO: 10 or 11, the B beta chain comprises SEQ ID NO: 12, the C beta chain comprises SEQ ID NO: 13 or 14, the D beta chain comprises SEQ ID NO: 15, the E beta chain comprises SEQ ID NO: 16, the F beta chain comprises SEQ ID NO: 17, the G beta chain comprises SEQ ID NO: 18, the AB loop comprises SEQ ID NO: 4 or 136, the CD loop comprises SEQ ID NO: 6, and the EF loop comprises SEQ ID NO: 8 or 137.

[0201] In other specific embodiments, at least one of loops AB, CD, and EF is randomized, the A beta chain comprises SEQ ID NO: 10 or 11, the B beta chain comprises SEQ ID NO: 12, the C beta chain comprises SEQ ID NO: 13 or 14, the D beta chain comprises SEQ ID NO: 15, the E beta chain comprises SEQ ID NO: 16, the F beta chain comprises SEQ ID NO: 17, the G beta chain comprises SEQ ID NO: 18, the BC loop comprises SEQ ID NO: 5, the DE loop comprises SEQ ID NO: 7, and the FG loop comprises SEQ ID NO: 9 or 139.

[0202] Improved footing stability The stability of the Tn3 scaffold of the invention can be increased by many different approaches. In some embodiments, the Tn3 scaffold of the invention can be stabilized by extension of the N- and / or C-terminal regions. The N- and / or C-terminal regions can be extended by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or more amino acids. In other embodiments, the Tn3 scaffold of the invention can be stabilized by introducing changes that increase serum half-life as described herein. In yet another embodiment, the Tn3 scaffold of the invention comprises the addition, deletion, or substitution of at least one amino acid residue to stabilize the hydrophobic core of the scaffold.

[0203] The Tn3 scaffolds of the invention can be effectively stabilized by engineering non-native disulfide bonds, as disclosed in International Patent Application No. PCT / US2011 / 032184. In some embodiments, the scaffolds of the invention comprise non-native disulfide bonds, as described in PCT Publication No. WO 2009 / 058379. Bioinformatics approaches can be used to identify candidate positions suitable for engineering disulfide bonds.

[0204] In one embodiment, the Tn3 monomer scaffold of the present invention comprises at least one, at least two, at least three, at least four, or at least five non-natural intramolecular disulfide bonds. In one embodiment, the Tn3 monomer subunit of the present invention comprises at least one non-natural intramolecular disulfide bond, said at least one non-natural disulfide bond stabilizing the monomer. In yet another embodiment, the Tn3 scaffold of the present invention comprises at least one non-natural disulfide bond, the bond being located between two distinct monomeric or multimeric Tn3 scaffolds, i.e., the disulfide bond is an intermolecular disulfide bond. For example, the disulfide bond can bind distinct scaffolds (e.g., two CD40L-specific monomeric scaffolds), a Tn3 scaffold and a linker, a Tn3 scaffold and an Fc domain, or a Tn3 scaffold and an antibody or fragment thereof.

[0205] In some embodiments, the Tn3 scaffold of the invention comprises at least one non-natural intermolecular disulfide bond linking a Tn3 monomer subunit and an isolated heterologous moiety, a Tn3 monomer subunit and a heterologous moiety fused or conjugated to the same Tn3 scaffold, or a Tn3 monomer subunit and a heterologous moiety fused or conjugated to a different Tn3 scaffold.

[0206] In some embodiments, the Tn3 scaffold of the invention comprises disulfide bonds forming a Tn3 multimeric scaffold of at least two, at least three, at least four or more monomeric subunits.

[0207] In another embodiment, the Tn3 scaffold of the invention may comprise an extension of the N- and / or C-terminal region. In one embodiment, the Tn3 scaffold of the invention comprises an alteration to increase serum half-life as described herein. In yet another embodiment, the scaffold of the invention comprises the addition, deletion or substitution of at least one amino acid residue to stabilize the hydrophobic core of the scaffold.

[0208] Stability Measurement The stability of the Tn3 monomer subunits of the invention, either isolated or as part of a multimeric Tn3 scaffold, can be determined using techniques well known in the art, such as heat (T m ) and chaotropic denaturation (e.g., treatment with urea, or guanidine salts), protease treatment (e.g., treatment with thermolysin) or another art-recognized method of measuring protein stability. A comprehensive review of techniques used to measure protein stability can be found, for example, in "Current Protocols in Molecular Biology" and "Current Protocols in Protein Science" by John Wiley and Sons. 2007.

[0209] Multimeric Tn3 scaffolds One aspect of the present invention provides a Tn3 multimeric scaffold comprising at least two Tn3 monomer subunits of the present invention linked in tandem, where at least one of the monomers is a CD40L-specific monomer subunit. Such a multimeric Tn3 scaffold can be assembled into multiple formats. In a specific aspect, the present invention provides a multimeric Tn3 scaffold in which at least two CD40L-specific monomer subunits are linked in tandem via a peptide linker. In some embodiments, the multimeric Tn3 scaffold exhibits increased valency and / or avidity of target binding or other effects of the target. In some embodiments, increased valency and / or avidity of target binding is achieved when multiple monomer subunits bind to the same target. In some embodiments, increased valency improves specific effects on the target, for example, increased dimerization of the target protein.

[0210] In a specific embodiment, a multimeric Tn3 scaffold of the invention comprises at least two CD40L-specific monomeric subunits linked in tandem, each CD40L-specific monomeric subunit binds to at least one target, each CD40L-specific monomeric subunit comprises multiple beta strands attached to multiple loop regions, and at least one loop is a non-natural variant of the cognate loop in the parent Tn3 scaffold (SEQ ID NO: 3).

[0211] In one embodiment, the multimeric Tn3 scaffold is generated via a covalent bond between the CD40L-specific monomeric subunits, e.g., by directly linking the CD40L-specific monomeric subunits or by including a linker, e.g., a peptide linker. In certain instances, the covalent Tn3 scaffold is generated by constructing a fusion gene encoding the CD40L-specific monomeric subunits or by engineering codons for cysteine ​​residues into the CD40L-specific monomeric subunits to allow disulfide bond formation between the expression products.

[0212] In one embodiment, the multimeric Tn3 scaffold of the invention comprises at least two CD40L-specific monomeric subunits directly linked to each other without any additional intervening amino acids, hi another embodiment, the multimeric Tn3 scaffold of the invention comprises at least two CD40L-specific monomeric subunits linked in tandem via a linker, e.g., a peptide linker.

[0213] In specific embodiments, multimeric Tn3 scaffolds of the invention comprise at least two CD40L-specific monomeric subunits linked in tandem via a peptide linker, the peptide linker comprising 1 to about 1000, or 1 to about 500, or 1 to about 250, or 1 to about 100, or 1 to about 50, or 1 to about 25 amino acids. In specific embodiments, multimeric Tn3 scaffolds of the invention comprise at least two CD40L-specific monomeric subunits linked in tandem via a peptide linker, the peptide linker comprising 1 to about 20, or 1 to about 15, or 1 to about 10, or 1 to about 5 amino acids.

[0214] In a specific embodiment, the multimeric Tn3 scaffold of the present invention comprises at least two CD40L-specific monomer subunits linked in tandem via a linker, e.g., a peptide linker, where the linker is a functional moiety. The functional moiety is selected based on the desired function and / or characteristics of the multimeric Tn3 scaffold. For example, a functional moiety useful for purification (e.g., a histidine tag) can be used as a linker. Functional moieties useful as linkers include, but are not limited to, polyethylene glycol (PEG), cytotoxic agents, radionuclides, imaging agents, biotin, dimerization domains, human serum albumin (HSA) or its FcRn binding portion, antibody domains or fragments, single chain antibodies, domain antibodies, albumin binding domains, IgG molecules, enzymes, ligands, receptors, binding peptides, non-Tn3 scaffolds, epitope tags, recombinant polypeptide polymers, cytokines, and the like. Specific peptide linkers and functional moieties that can be used as linkers are disclosed below.

[0215] In a specific embodiment, the functional part is an immune disease or a fragment thereof. In some embodiments, the immunoglobulin or a fragment thereof comprises an Fc domain. In some embodiments, the Fc domain cannot induce at least one FcγR-mediated effector function, such as ADCC (antibody-dependent cell-mediated cytotoxicity). It is known in the art that the Fc domain can be altered to reduce or eliminate at least one FcγR-mediated effector function, see, for example, U.S. Patent No. 5,624,821 and U.S. Patent No. 6,737,056.

[0216] In some embodiments, the multimeric Tn3 scaffold comprises at least two CD40L-specific monomeric subunits linked via one or more linkers, where the linkers sandwiched between each CD40L-specific monomeric subunit may be the same or different linkers. In some embodiments, the linker may comprise multiple linkers, which may be the same or different linkers. In some embodiments, when multiple linkers are linked in a chain, some or all of the linkers may be functional moieties.

[0217] Scaffold binding stoichiometry In some embodiments, a monomeric or multimeric Tn3 scaffold may comprise CD40L-specific monomeric subunits specific for different epitopes, which may be different epitopes on a single CD40L molecule or on different CD40L target molecules, hi some embodiments, a multimeric Tn3 scaffold may comprise CD40L-specific monomeric subunits, each subunit targeting one or more different epitopes on one or more CD40L molecules.

[0218] In other embodiments, a monomeric or multimeric Tn3 scaffold can bind to two or more different epitopes on the same CD40L molecule. In some embodiments, the different epitopes are non-overlapping epitopes. In other embodiments, the different epitopes are overlapping epitopes.

[0219] In yet another specific embodiment, the monomeric or multimeric Tn3 scaffold binds to one or more epitopes on a CD40L molecule and may further bind to one or more epitopes on a second CD40L molecule. In some embodiments, the distinct target molecules are part of an oligomeric complex, e.g., a trimeric CD40L complex.

[0220] In yet another specific embodiment, a monomeric or multimeric Tn3 scaffold can bind to a single epitope on a CD40L trimer. In yet another specific embodiment, a monomeric or multimeric Tn3 scaffold can bind to the same epitope on at least two CD40L trimers.

[0221] In some embodiments, the monomeric or multimeric Tn3 scaffold can bind to the same epitope on two or more copies of the CD40L molecule on the surface of adjacent cells. In some embodiments, the monomeric or multimeric Tn3 scaffold can bind to the same epitope on two or more copies of the CD40L molecule in solution. In some embodiments, the monomeric or multimeric Tn3 scaffold can bind to the same epitope or different epitopes on CD40L with the same or different binding affinity and / or avidity.

[0222] In another embodiment, a monomeric or multimeric Tn3 scaffold may bind to an epitope on one or more copies of CD40L to achieve or enhance (e.g., synergistically) a desired effect on a target, e.g., to prevent binding to a receptor or to prevent oligomerization.

[0223] Furthermore, when a monomeric or multimeric Tn3 scaffold of the invention comprises multiple CD40L-specific monomeric subunits, e.g., different monomers, each monomer targeting a different epitope on CD40L, such monomeric subunits can be arranged according to a certain pattern or spatial orientation to achieve or enhance a certain biological effect. Such combinations of monomeric subunits can be assembled and subsequently evaluated using methods known in the art.

[0224] fusion The present invention provides a Tn3 scaffold in which at least one CD40L-specific monomer subunit may be fused to a heterologous moiety. In this regard, the heterologous moiety may provide additional functionality to the Tn3 scaffold, rather than being used as a spacer to bind the scaffold. In some embodiments, the heterologous moiety may also function as a linker. The present invention encompasses the use of a Tn3 scaffold that is conjugated or fused to one or more heterologous moieties, including but not limited to peptides, polypeptides, proteins, fusion proteins, nucleic acid molecules, small molecules, mimetics, synthetic drugs, inorganic molecules, and organic molecules. Thus, the present invention provides a polypeptide that includes one or more CD40L-specific Tn3 monomers, including but not limited to fusion proteins as described herein.

[0225] The present invention encompasses the use of the Tn3 scaffold that is recombinantly fused or chemically conjugated to heterologous protein or polypeptide or fragment thereof.Conjugation includes both covalent and non-covalent conjugation.In some embodiments, the Tn3 scaffold can be fused or chemically conjugated to a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 500, or at least 1000 amino acids) to generate a fusion protein.

[0226] Fusion or conjugation of the multimeric Tn3 scaffold to one or more heterologous moieties can be direct, i.e., without a linker interposed between the Tn3 scaffold and the heterologous moiety, or via one or more of the linker sequences described herein. In some embodiments, the scaffold can be used to target the heterologous polypeptide to a particular cell type in vitro or in vivo by fusing or conjugating the Tn3 scaffold to an antibody specific for a particular cell surface receptor in the target cell.

[0227] The Tn3 scaffold fused or conjugated to a heterologous polypeptide can also be used in in vitro immunoassays and purification methods using methods known in the art.See, for example, WO 93 / 21232; EP 439,095; Naramura et al. Immunol. Lett. 39:91-99, 1994; U.S. Patent No. 5,474,981; Gillies et al., PNAS 89:1428-1432, 1992; and Fell et al., J. Immunol. 146:2446-2452, 1991, which are incorporated by reference in their entirety.

[0228] In some embodiments, the Tn3 scaffold can be integrated into the human immune response by fusing or conjugating the scaffold to an immunoglobulin or a domain thereof, such as, but not limited to, the constant region of IgG (Fc), e.g., via the N- or C-terminus. Similarly, a fusion between the Tn3 scaffold and a complement protein, e.g., CIq, can be used to target cells.

[0229] Various publications describe methods to obtain physiologically active molecules with modified half-life by introducing FcRn-binding polypeptides into the molecule (see, for example, WO 97 / 43316; U.S. Pat. No. 5,869,046; U.S. Pat. No. 5,747,035; WO 96 / 32478; and WO 91 / 14438), by fusing the molecule with an antibody that has preserved FcRn-binding affinity but greatly reduced affinity for other Fc receptors (see, for example, WO 99 / 43713), or by fusing the molecule with an FcRn-binding domain of an antibody (see, for example, WO 00 / 09560; U.S. Pat. No. 4,703,0390). Specific techniques and methods for increasing the half-life of physiologically active molecules can also be found in U.S. Pat. No. 7,083,784. Specifically, it is contemplated that the Tn3 scaffold can be fused to an Fc region from an IgG, where the Fc region comprises amino acid residue mutations M252Y / S254T / T256E or H433K / N434F / Y436H, and the amino acid positions are named according to the Kabat numbering scheme. It is specifically contemplated that fusions of the Tn3 scaffold to the Fc domain variants cannot induce ADCC.

[0230] In some embodiments, the half-life of the Tn3 scaffold can be increased by genetically fusing the Tn3 scaffold to an essentially unstructured recombinant polypeptide (e.g., an XTEN™ polypeptide) or by conjugation with polyethylene glycol (PEG).

[0231] In some embodiments, the Tn3 scaffold can be fused with a molecule that increases or extends its in vivo or serum half-life. In some embodiments, the scaffold can be fused or conjugated to albumin, such as human serum albumin (HSA), its neonatal Fc receptor (FcRn) binding fragment, PEG, polysaccharides, antibodies, complement, hemoglobin, binding peptides, lipoproteins and other factors that increase its half-life in the bloodstream and / or its tissue penetration. Any of these fusions can be produced by standard methods, such as expressing the fusion protein from a recombinant fusion gene constructed using publicly available gene sequences.

[0232] In some embodiments, the properties of the Tn3 scaffold can be improved by conjugation or fusion to HSA variants, i.e., molecules derived from full-length HSA (SEQ ID NO: 139) that contain at least amino acid substitutions, deletions, or sequence truncations.

[0233] In some embodiments, the property that is improved by conjugation with HSA variant is plasma half-life. The improvement of the plasma half-life of the Tn3 scaffold can be a change in its properties, for example, an increase or decrease in plasma half-life, or a change in other pharmacokinetic parameters. In some embodiments, the HSA variant is a mutant derived from full-length HSA (SEQ ID NO: 138). In a specific embodiment, the HSA variant comprises a cysteine ​​to serine substitution at position 34 (SEQ ID NO: 133). HSA variants that can be used to modify the plasma half-life of the Tn3 scaffold are described, for example, in WO 2011 / 103076 and WO 2011 / 051489, both of which are incorporated by reference in their entirety. In some embodiments, the plasma half-life of the Tn3 scaffold of the present invention is increased by fusing it with an HSA variant that comprises at least one amino acid substitution in domain III of HSA.

[0234] In some embodiments, the Tn3 scaffold of the present invention comprises an HSA variant comprising the sequence of full-length mature HSA (SEQ ID NO: 138) or a fragment thereof, except for at least one amino acid substitution numbered relative to its position in full-length mature HSA at a position selected from the group consisting of 407, 415, 463, 500, 506, 508, 509, 511, 512, 515, 516, 521, 523, 524, 526, 535, 550, 557, 573, 574, and 580; wherein the at least one amino acid substitution does not include a substitution of lysine (K) to glutamic acid (E) at position 573, and wherein the Tn3 scaffold has a plasma half-life greater than the plasma half-life of a Tn3 scaffold not conjugated to the HSA variant.

[0235] In some other embodiments, at least one amino acid substitution, numbered relative to positions in full-length mature HSA, is at a position selected from the group consisting of 463, 508, 523, and 524, and the Tn3 scaffold has a plasma half-life greater than the plasma half-life of a Tn3 scaffold that is not conjugated to the HSA variant.

[0236] In other embodiments, the Tn3 scaffold of the invention comprises an HSA variant comprising the sequence of full-length mature HSA (SEQ ID NO: 133 or 138), or a fragment thereof, provided that: (a) substitution of leucine (L) with asparagine (N) or tyrosine (Y) at position 407; (b) substitution of valine (V) with threonine (T) at position 415; (c) substitution of leucine (L) with asparagine (N) at position 463; (d) substitution of lysine (K) with arginine (R) at position 500; (e) substitution of threonine (T) with tyrosine (Y) at position 506; (f) substitution of threonine (T) with arginine (R) at position 508; (g) substitution of phenylalanine (F) at position 509 with methionine (M) or tryptophan (W); (h) substitution of alanine (A) with phenylalanine (F) at position 511; (i) substitution of aspartic acid (D) with tyrosine (Y) at position 512; (j) substitution of threonine (T) with glutamine (Q) at position 515; (k) substitution of leucine (L) with threonine (T) or tryptophan (W) at position 516; (l) substitution of arginine (R) with tryptophan (W) at position 521; (m) substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (n) substitution of lysine (K) with leucine (L) at position 524; (o) substitution of glutamine (Q) with methionine (M) at position 526; (p) substitution of histidine (H) with proline (P) at position 535; (q) substitution of aspartic acid (D) with glutamic acid (E) at position 550; (r) substitution of lysine (K) with glycine (G) at position 557; (s) substitution of lysine (K) at position 573 with phenylalanine (F), histidine (H), proline (P), tryptophan (W), or tyrosine (Y); (t) substitution of lysine (K) with asparagine (N) at position 574; (u) substitution of glutamine (Q) with lysine (K) at position 580; and (v) a combination of two or more of the above substitutions. with the exception of at least one amino acid substitution numbered relative to its position in full length mature HSA selected from the group consisting of: The Tn3 scaffold has a plasma half-life that is greater than the plasma half-life of a Tn3 scaffold that is not conjugated to the HSA variant.

[0237] In some embodiments, the Tn3 scaffold comprises an HSA variant comprising the sequence of full-length mature HSA (SEQ ID NO: 133 or 138), or a fragment thereof, with the proviso that: (a) substitution of leucine (L) with asparagine (N) at position 463; (b) substitution of threonine (T) with arginine (R) at position 508; (c) substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (d) substitution of lysine (K) with leucine (L) at position 524; and (e) a combination of two or more of the above substitutions. with the exception of at least one amino acid substitution numbered relative to its position in full length mature HSA selected from the group consisting of: The Tn3 scaffold has a plasma half-life that is greater than the plasma half-life of a Tn3 scaffold that is not conjugated to the HSA variant.

[0238] Furthermore, the Tn3 scaffold of the present invention can be fused to a marker sequence, for example, a peptide to facilitate purification. In some embodiments, the marker amino acid sequence is a polyhistidine peptide (His tag), for example, an octahistidine tag (His-8-tag) or a hexahistidine tag (His-6-tag), for example, the tag provided in the pQE expression vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif, 91311), among many other commercially available vectors. For example, polyhistidine provides for easy purification of the fusion protein, as described in Gentz ​​et al., Proc. Natl. Acad. Sci. USA 86:821-824, 1989. Other peptide tags useful for purification include, but are not limited to, a hemagglutinin ("HA") tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (see, e.g., Wilson et al., Cell 37:767, 1984), a FLAG tag, a Strep tag, a myc tag, a V5 tag, a GFP tag, an AU1 tag, an AU5 tag, an ECS tag, a GST tag, or an OLLAS tag.

[0239] Additional fusion proteins comprising the Tn3 scaffold of the invention can be generated through the techniques of gene shuffling, motif shuffling, exon shuffling, and / or codon shuffling (collectively referred to as "DNA shuffling").

[0240] DNA shuffling can be used to alter the action of the Tn3 scaffold on a target (e.g., to generate a scaffold with higher affinity and lower dissociation rate). The Tn3 scaffold can be altered by random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. One or more portions of the polynucleotide encoding the scaffold that bind to a specific target can be recombined with one or more components, motifs, sections, portions, domains, fragments, etc., of one or more heterologous molecules.

[0241] Antibodies and Fc domain fusions In some embodiments, a Tn3 scaffold of the invention comprises a CD40L-specific monomeric subunit fused to a domain or fragment of an antibody (eg, IgG), such as, but not limited to, an Fc domain.

[0242] In some embodiments, only one CD40L-specific monomer subunit is conjugated or fused to an antibody domain or fragment. For example, a single CD40L-specific monomer subunit can be fused to the N-terminus of a polypeptide of an antibody domain or fragment (e.g., an antibody heavy or light chain). In other embodiments, a Tn3 scaffold is created by fusing or conjugating one or more CD40L-specific monomer subunits to the N-terminus and / or C-terminus of a polypeptide of an antibody domain or fragment (e.g., an antibody heavy and / or light chain, or an Fc domain).

[0243] In some embodiments, some or all of the CD40L-specific monomeric subunits fused to the antibody domains or fragments are identical, hi some other embodiments, some or all of the CD40L-specific monomeric subunits fused to the antibody domains or fragments are different.

[0244] In a specific embodiment, the Tn3 scaffold of the invention comprises one CD40L-specific monomer subunit fused to an Fc domain. In another embodiment, the Tn3 scaffold of the invention comprises at least two CD40L-specific monomer subunits fused to an Fc domain. In one specific embodiment, two of the CD40L-specific monomer subunits fused to the Fc domain are identical. In one specific embodiment, two of the CD40L-specific monomer subunits fused to the Fc domain are different. In one specific embodiment, the two CD40L-specific monomer subunits fused to the Fc domain are linked in tandem with each other, one of the CD40L-specific monomer subunits fused to the Fc domain.

[0245] In some embodiments, the different Tn3 scaffolds of the present invention can be dimerized by using Fc domain mutations that help form heterodimers. It is known in the art that variants of Fc regions (e.g., amino acid substitutions and / or additions and / or deletions) can improve or reduce the effector function of an antibody and change the pharmacokinetic properties (e.g., half-life) of the antibody. Thus, in some embodiments, the Tn3 scaffolds of the present invention comprise Fc domains that comprise altered Fc regions in which one or more changes are made in the Fc region to change the function and / or pharmacokinetic properties of the Tn3 scaffold. In some embodiments, the Tn3 scaffolds of the present invention comprise Fc domains that comprise altered Fc regions in which one or more changes are made in the Fc region to reduce or eliminate at least one Fc R-mediated effector function.

[0246] It is also known that glycosylation of the Fc region can be modified to increase or decrease effector function and / or anti-inflammatory activity. Thus, in one embodiment, the Tn3 scaffold of the invention comprises an Fc region with altered glycosylation of amino acid residues to alter the cytotoxic and / or anti-inflammatory properties of the Tn3 scaffold.

[0247] Tn3 scaffold topology The Tn3 scaffolds of the invention can be fused to the C-terminus of an Fc domain, an antibody light chain, and an antibody heavy chain in any suitable spatial arrangement, see, for example, PCT / US2011 / 032184 for a detailed description of contemplated scaffold topologies.

[0248] Generation of the scaffold of the present invention The Tn3 scaffold described herein can be used in any technique for evolving new or improved target binding proteins.In one particular example, the target is immobilized on a solid support, such as a column resin or a microtiter plate well, and the target is contacted with a library of candidate scaffold-based binding proteins.Such a library can consist of clones constructed from the Tn3 scaffold through randomization of the sequence and / or length of CDR-like loops.

[0249] In this regard, bacteriophage (phage) display is one well-known technique that allows screening of large oligopeptide libraries to identify members of these libraries that can specifically bind to a target. Phage display is a technique in which variant polypeptides are displayed as fusions to coat proteins on the surface of bacteriophage particles (Scott, JK and Smith, GP (1990) Science 249:386). Bioinformatics approaches can be used to measure the loop length and diversity preferences of natural FnIII domains. Using this analysis, the preferences for loop length and sequence diversity can be used to develop a "restricted randomization" approach. In this restricted randomization, the relative loop length and sequence preferences are incorporated into the development of library strategies. The integration of loop length and sequence diversity analysis into library development results in restricted randomization (i.e., certain positions within the randomized loop where amino acids can be located are limited).

[0250] The present invention also provides a recombinant library comprising a diverse population of non-natural Tn3 scaffolds. In one embodiment, the library comprises a non-natural Tn3 scaffold comprising a plurality of beta strand domains linked to a plurality of loop regions, one or more of the loops being varied by the deletion, substitution or addition of at least one amino acid. In a specific embodiment, the library comprises a Tn3 scaffold derived from a wild-type Tn3 scaffold.

[0251] As explained in detail above, the loops connecting the various beta strands of the scaffold can be randomized for length and / or sequence diversity. In one embodiment, the library of the present invention comprises a Tn3 scaffold with at least one loop randomized for length and / or sequence diversity. In one embodiment, at least one, at least two, at least three, at least four, at least five or at least six loops of the Tn3 scaffold are randomized for length and / or sequence diversity. In one embodiment, at least one loop is held constant while at least one additional loop is randomized for length and / or sequence diversity. In another embodiment, at least one, at least two or all three of loops AB, CD and EF are held constant while at least one, at least two or all three of loops BC, DE and FG are randomized for length or sequence diversity. In another embodiment, at least one, at least two, or at least all three of loops AB, CD, and EF are randomized, while at least one, at least two, or all three of loops BC, DE, and FG are randomized for length and / or sequence diversity.

[0252] In a specific embodiment, the library of the invention comprises an FnIII scaffold, wherein the A beta chain comprises SEQ ID NO: 10 or 11, the B beta chain comprises SEQ ID NO: 12, the C beta chain comprises SEQ ID NO: 13 or 14, the D beta chain comprises SEQ ID NO: 15, the E beta chain comprises SEQ ID NO: 16, the F beta chain comprises SEQ ID NO: 17, and the G beta chain comprises SEQ ID NO: 18.

[0253] In a specific embodiment, the library of the invention comprises an FnIII scaffold, wherein the Abeta chain consists of SEQ ID NO: 10 or 11, the B beta chain consists of SEQ ID NO: 12, the C beta chain consists of SEQ ID NO: 13 or 14, the D beta chain consists of SEQ ID NO: 15, the E beta chain consists of SEQ ID NO: 16, the F beta chain consists of SEQ ID NO: 17, and the G beta chain consists of SEQ ID NO: 18.

[0254] In a specific embodiment, the library of the invention comprises an FnIII scaffold, wherein the A beta chain consists essentially of SEQ ID NO: 10 or 11, the B beta chain consists essentially of SEQ ID NO: 12, the C beta chain consists essentially of SEQ ID NO: 13 or 14, the D beta chain consists essentially of SEQ ID NO: 15, the E beta chain consists essentially of SEQ ID NO: 16, the F beta chain consists essentially of SEQ ID NO: 17, and the G beta chain consists essentially of SEQ ID NO: 18.

[0255] As detailed above, one or more residues in the loop can be held constant while other residues are randomized for length and / or sequence diversity. Optionally, or alternatively, one or more residues in the loop can be held to a predetermined limited number of different amino acids while other residues are randomized for length and / or sequence diversity. Thus, the library of the present invention comprises a Tn3 scaffold that may comprise one or more loops with a degenerate consensus sequence and / or one or more invariant amino acid residues. In another embodiment, the library of the present invention comprises a Tn3 scaffold with a randomized BC loop. In another embodiment, the library of the present invention comprises a Tn3 scaffold with a randomized BC loop. In yet another embodiment, the library of the present invention comprises a Tn3 scaffold with a randomized BC loop.

[0256] In one embodiment, the library of the present invention comprises a Tn3 scaffold with a randomized DE loop. In one embodiment, the library of the present invention comprises a Tn3 scaffold with a randomized FG loop. In another embodiment, the library of the present invention comprises an FnIII scaffold with a randomized FG loop.

[0257] In a specific embodiment, the library of the invention comprises the amino acid sequence: IEV(X AB ) n ALITW(X BC ) n CELX 1YGI(X CD ) n TTIDL(X DE ) n YSI(X EF ) n YEVSLIC(X FG ) n KETFTT (In the formula, (a)X AB , X BC , X CD , X DE , X EF , and X FG represent the amino acid residues present in the sequences of the AB, BC, CD, DE, EF, and FG loops, respectively; (b)X 1 represents the amino acid residues A or T; (c) the length of the loop, n, is an integer between 2 and 26. The scaffold includes:

[0258] In some embodiments, the library of the invention comprises the amino acid sequence: IEVKDVTDTTALITWX 1 DX 2 X 3 X 4 X 5 X 6 X 7 X 8 CELTYGIKDVPGDRTTIDLWX 9 HX 10 AX 11 YSIGNLKPDTEYEVSLICRX 12 GDMSSNPAKETFTT (SEQ ID NO: 167) (In the formula, (a)X 1 represents the amino acid residues serine (S) or leucine (L); (b)X 2 represents the amino acid residues aspartic acid (D) or glutamic acid (E); (c)X 3 represents the amino acid residues histidine (H), isoleucine (I), valine (V), phenylalanine (F), or tryptophan (W); (d)X4 represents the amino acid residues alanine (A), glycine (G), glutamic acid (E) or aspartic acid (D); (e)X 5 represents the amino acid residue glutamic acid (E), leucine (L), glutamine (Q), serine (S), aspartic acid (D) or asparagine (N); (f)X 6 represents the amino acid residues phenylalanine (F) or tyrosine (Y); (g)X 7 represents the amino acid residues isoleucine (I), valine (V), histidine (H), glutamic acid (E), or aspartic acid (D); (h)X 8 represents the amino acid residue glycine (G), tryptophan (W) or valine (V); (i)X 9 represents the amino acid residues tryptophan (W), phenylalanine (F) or tyrosine (Y); (j)X 10 represents the amino acid residues serine (S), glutamine (Q), methionine (M) or histidine (H); (k)X 11 represents the amino acid residues tryptophan (W) or histidine (H); (l)X 12 represents the amino acid residue arginine (R) or serine (S) The CD40L-specific Tn3 monomer subunit of the present invention comprises:

[0259] In some embodiments, the library of the invention comprises the amino acid sequence: IEVX 1 DVTDTTALITWX 2 X 3 RSX 4 X 5 X 6 X 7 X 8 X 9 X 10 CELX 11 YGIKDVPGDRTTIDLX 12 X 13 X14 X 15 YVHYSIGNLKPDTX 16 YEVSLICLTTDGTYX 17 NPAKETFTT (SEQ ID NO: 171) (In the formula, (a)X 1 represents the amino acid residues lysine (K) or glutamic acid (E); (b)X 2 represents the amino acid residues threonine (T) or isoleucine (I); (c)X 3 represents the amino acid residues asparagine (N) or alanine (A); (d)X 4 represents the amino acid residues serine (S), leucine (L), alanine (A), phenylalanine (F) or tyrosine (Y); (e)X 5 represents the amino acid residue tyrosine (Y), alanine (A), glycine (G), valine (V), isoleucine (I) or serine (S); (f)X 6 represents the amino acid residue tyrosine (Y), serine (S), alanine (A) or histidine (H); (g)X 7 represents the amino acid residues asparagine (N), aspartic acid (D), histidine (H) or tyrosine (Y); (h)X 8 represents the amino acid residue leucine (L), phenylalanine (F), histidine (H) or tyrosine (Y); (i)X 9 represents the amino acid residues histidine (H), proline (P), serine (S), leucine (L) or aspartic acid (D); (j)X 10 represents the amino acid residue glycine (G), phenylalanine (F), histidine (H) or tyrosine (Y); (k)X 11 represents the amino acid residues alanine (A) or threonine (T); (l)X 12represents the amino acid residues serine (S), asparagine (N), glutamic acid (E), asparagine (R) or aspartic acid (D); (m)X 13 represents the amino acid residue serine (S), glutamine (Q), threonine (T), asparagine (N) or alanine (A); (n)X 14 represents the amino acid residues proline (P), valine (V), isoleucine (I) or alanine (A) or no amino acid; (o)X 15 represents the amino acid residue isoleucine (I) or no amino acid; (p)X 16 represents the amino acid residue glutamic acid (E) or lysine (K); (q)X 17 represents the amino acid residue serine (S) or asparagine (N) The CD40L-specific Tn3 monomer subunit of the present invention comprises:

[0260] The invention further provides methods for identifying recombinant Tn3 scaffolds that bind to a target, e.g., CD40L, and have increased stability or improved effect on a target, e.g., CD40L, compared to the parent Tn3 scaffold, by screening the libraries of the invention.

[0261] In one embodiment, a method for identifying a recombinant Tn3 scaffold that has increased protein stability and specifically binds to a target as compared to a parental Tn3 scaffold comprises: contacting the target ligand with a library of the invention under conditions suitable for the formation of a scaffold:target ligand complex; obtaining a scaffold from the complex that binds to a target ligand; Determining whether the stability of the scaffold obtained in step (b) is greater than that of the wild-type Tn3 scaffold. Includes.

[0262] The same method can be used to identify recombinant Tn3 scaffolds with improved binding affinity, avidity, etc. for the target. In one embodiment, in step (a), the scaffold library of the present invention is incubated with the immobilized target. In one embodiment, in step (b), the scaffold:target ligand complex is washed to remove non-specific binders, and the tightest binders are eluted under highly stringent conditions and subjected to PCR to recover sequence information. It is specifically contemplated that the binders and / or sequence information obtained in step (b) can be used to generate new libraries using methods disclosed herein or known to those skilled in the art, and can be used to repeat the selection process with or without further sequence mutagenesis. In some embodiments, many rounds of selection can be performed until binders with sufficient affinity for the antigen are obtained.

[0263] A further embodiment of the present invention is a collection of isolated nucleic acid molecules encoding the invention and libraries comprising the scaffolds described above.

[0264] The scaffold of the present invention can be subjected to affinity maturation. In this art-recognized process, specific binding proteins are subjected to a selection scheme for increased affinity for a specific target (see Wu et al., Proc Natl Acad Sci USA. 95(11):6037-42). The resulting scaffold of the present invention can exhibit binding properties at least as high as those of the scaffold before affinity maturation.

[0265] The present invention also provides a method for identifying the amino acid sequence of a protein scaffold that can bind to a target to form a scaffold:target complex. In one embodiment, the method includes: (a) contacting the library of the present invention with an immobilized or separable target; (b) separating the scaffold:target complex from the free scaffold; (c) causing replication of the separated scaffold of (b), resulting in a new polypeptide display library that is distinct from that in (a) by having reduced diversity and by enrichment of the displayed scaffold that can bind to the target; d) optionally repeating steps (a) and (b) with the new library of (c); and e) determining the nucleic acid sequence of the region that codes for the displayed scaffold of the species from (d), thereby deducing the peptide sequence that can bind to the target.

[0266] In another embodiment, the Tn3 scaffold of the present invention can be further randomized after identification from the library screen. In one embodiment, the method of the present invention comprises further randomizing at least one, at least two, at least three, at least four, at least five or at least six loops of the scaffold identified from the library using the methods described herein. In another embodiment, the further randomized scaffold is subjected to a subsequent method of identifying a scaffold capable of binding to a target. This method comprises: (a) contacting the further randomized scaffold with an immobilized or separable target; (b) separating the further randomized scaffold:target complex from the free scaffold; (c) causing replication of the separated scaffold of (b), optionally repeating steps (a)-(c); and (d) determining the nucleic acid sequence of the region encoding the further randomized scaffold, thereby deducing a peptide sequence capable of binding to the target.

[0267] In further embodiments, the further randomized scaffold comprises at least one, at least two, at least three, at least four, at least five, or at least six randomized loops that were pre-randomized in the initial library. In alternative further embodiments, the further randomized scaffold comprises at least one, at least two, at least three, at least four, at least five, or at least six randomized loops that were not pre-randomized in the initial library.

[0268] The present invention also provides a method for obtaining at least two Tn3 scaffolds that bind to at least one or more targets. This method allows screening of agents that act in concert to induce a specific response. When agonistic activity is required that requires the cooperation of two or more scaffolds, it may be advantageous to use such a screen. This method allows screening of cooperative agents without reformatting the library to form a multimeric complex. In one embodiment, the method of the present invention includes contacting a target ligand with a library of the present invention under conditions that allow the formation of a scaffold:target ligand complex, associating the scaffold with a crosslinking agent (defined as an agent that brings at least two identical or distinct scaffolds into close proximity), where crosslinking of the scaffolds induces a detectable response, and obtaining from the complex a scaffold that binds to the target. In a further embodiment, the crosslinking agent is a scaffold-specific antibody, or a fragment thereof, an epitope tag-specific antibody, or a fragment thereof, a dimerization domain, such as an Fc region, a coiled-coil motif (such as, but not limited to, a leucine zipper), a chemical crosslinking agent, or another dimerization domain known in the art.

[0269] The present invention also provides a method for detecting a compound utilizing the Tn3 scaffold of the present invention. Based on the binding specificity of the Tn3 scaffold obtained by library screening, such a Tn3 scaffold can be used in an assay, for example, in a diagnostic method, to detect a specific target in a sample. In one embodiment, the method for detecting a compound comprises contacting the compound in a sample with the Tn3 scaffold of the present invention under conditions that allow the formation of a compound:scaffold complex, and detecting the scaffold, thereby detecting the compound in the sample. In a further embodiment, the scaffold is labeled (i.e., radiolabeled, fluorescent, enzyme-linked or colorimetric) to facilitate detection of the compound.

[0270] The present invention also provides a method for capturing a compound using the Tn3 scaffold of the present invention. Based on the binding specificity of the Tn3 scaffold obtained by library screening, such a Tn3 scaffold can be used in an assay for capturing a specific target in a sample, for example, in a purification method. In one embodiment, the method for capturing a compound in a sample includes contacting the compound in the sample with a scaffold of the present invention under conditions that allow the formation of a compound:scaffold complex, and removing the complex from the sample, thereby capturing the compound in the sample. In a further embodiment, the Tn3 scaffold is immobilized to facilitate the removal of the compound:scaffold complex.

[0271] In some embodiments, the Tn3 scaffold isolated from the library of the present invention comprises at least one, at least two, at least four, at least five, at least six or more randomized loops. In some embodiments, the isolated Tn3 scaffold loop sequence can be swapped from the donor scaffold to the FnIII receiver scaffold, for example, but not limited to, any loop in the Tn3 receiver scaffold (e.g., the FG loop sequence from the donor scaffold can be transferred to any loop in the receiver FnIII scaffold). In a specific embodiment, the isolated loop sequence can be transferred to the cognate loop of the receiver scaffold (e.g., the FG loop sequence from the donor scaffold can be transferred to the FnIII receiver scaffold in the FG loop position). In some embodiments, the isolated loop sequence can be "mixed and matched" randomly with various receiver scaffolds.

[0272] In other embodiments, isolated Tn3 scaffold sequences can be identified by loop sequences. For example, the library is used to pan against a specific target, and a collection of specific binders is isolated. The randomized loop sequences can be characterized as specific sequences independent of the Tn3 scaffold background (i.e., a scaffold that binds to target X, comprising an FG loop sequence of SEQ ID NO:X). In an alternative embodiment, if a scaffold exhibits two loop sequences that bind to target X, the loop sequences can be characterized as binding target X in the absence of scaffold sequences. In other words, it is contemplated that scaffolds isolated from libraries that bind to a specific target can be expressed as variable loop sequences that bind to the target independent of the scaffold backbone. This process is similar to the concept of CDRs of the variable region of an antibody.

[0273] affinity maturation The development of the Tn3 scaffold of the present invention may include one or more in vitro or in vivo affinity maturation steps. In some embodiments, the Tn3 monomer subunit may undergo a single affinity maturation step. In other embodiments, the Tn3 monomer subunit may undergo two or more affinity maturation steps. In general, any affinity maturation approach may be used that results in amino acid changes in the parent Tn3 scaffold, or specifically in the parent Tn3 scaffold loops, that improve the binding of the affinity matured Tn3 scaffold to the desired antigen.

[0274] These amino acid changes can be achieved, for example, via random mutagenesis, "walk through" mutagenesis, and "look through" mutagenesis. Such mutagenesis can be achieved, for example, by using error-prone PCR, yeast or bacterial "mutagene" strains, and incorporation of random or defined nucleic acid changes during ab initio synthesis of all or part of the FnIII-based binding molecule. Methods for performing affinity maturation and / or mutagenesis are described, for example, in U.S. Pat. Nos. 7,195,880; 6,951,725; 7,078,197; 7,022,479; 5,922,545; 5,830,721; 5,605,793; 5,830,650; 6,194,550; 6,699,658; 7,063,943; 5,866,344 and PCT Publication WO 06023144.

[0275] Such affinity maturation methods may further require increasing the stringency of antigen-binding screening assays to select Tn3 scaffolds with improved affinity for antigen.Artificially accepted methods for increasing the stringency of protein-protein interaction assays can be used herein.In one embodiment, one or more of the assay conditions are varied (e.g., the salt concentration of the assay buffer) to reduce the affinity of the Tn3 scaffold for the desired antigen.In another embodiment, the length of time that the Tn3 scaffold is allowed to bind to the desired antigen is reduced.

[0276] In another embodiment, a competitive binding step can be added to protein-protein interaction assay.For example, Tn3 scaffold can be first bound to desired immobilized antigen.Then, a defined concentration of non-immobilized antigen is added to compete with immobilized antigen for binding, thereby eluting the Tn3 scaffold with the lowest affinity for antigen from immobilized antigen, resulting in the selection of Tn3 scaffold with improved antigen binding affinity.The stringency of the assay conditions can be further increased by increasing the concentration of non-immobilized antigen added to the assay.

[0277] The screening method may also require multiple selection rounds to enrich one or more Tn3 scaffolds with improved antigen binding.In one embodiment, in each selection round, additional amino acid mutations are introduced into the Tn3 scaffold.In another embodiment, in each selection round, the stringency of binding to the desired antigen is increased to select the Tn3 scaffold with increased affinity for the antigen.

[0278] In some embodiments, affinity maturation is performed by saturation mutagenesis of portions of the BC, DE, and FG loops of Tn3. In some embodiments, saturation mutagenesis is performed using Kunkel mutagenesis. In other embodiments, saturation mutagenesis is performed using PCR.

[0279] In some embodiments, at least one, at least two, at least three, at least four, at least five, or more than five affinity maturation rounds are applied. In some embodiments, saturation mutagenesis is applied to only one loop, while in some other embodiments, only one loop or part of a loop is mutated during one affinity maturation round. In some embodiments, two or more loops or parts of one or more loops are mutated during the same affinity maturation round.

[0280] In other embodiments, the BC, DE, and FG loops are mutated simultaneously during the same affinity maturation round.

[0281] When monomers are assembled into multimeric Tn3 scaffolds that bind different epitopes of the same target, or in the case of bispecific Tn3 scaffolds, each binding specificity can be screened independently.

[0282] In some embodiments, the loops are randomized using a phage display library. In some embodiments, the binding of the Tn3 scaffold to a desired target can be measured using art-recognized methods. The amino acid sequence of the Tn3 scaffold identified in the screen can also be determined using art-recognized methods.

[0283] In some embodiments, monomeric affinity matured scaffolds of the invention exhibit an increase in affinity for CD40L of at least 5-fold, at least 10-fold, at least 20-fold, at least 40-fold, at least 60-fold, at least 80-fold, or at least 100-fold or more compared to the identical Tn3 scaffold prior to affinity maturation, as measured by surface plasmon resonance or other assays known in the art. In some embodiments, monomeric affinity matured scaffolds of the invention exhibit a dissociation constant (K) of less than 5 μM, less than 1 μM, less than 500 μM, less than 250 μM, less than 100 μM, or less than 50 μM, as measured by surface plasmon resonance or other assays known in the art.d ).

[0284] These affinity maturation methods can be applied to develop Tn3 scaffolds with desirable improved binding properties, e.g., increased affinity, or other desirable characteristics, e.g., favorable pharmacokinetic properties, high potency, low immunogenicity, increased or decreased cross-reactivity, etc.

[0285] Generation of tandem repeats Linking of tandem constructs, which are dimers formed by linking two CD40L-specific monomeric subunits, can be generated by ligation of oligonucleotides at restriction enzyme sites using restriction enzymes known in the art, including but not limited to type II and type IIS restriction enzymes.

[0286] Multimeric Tn3 scaffolds of the invention may include linkers at the C-terminus and / or N-terminus and / or between the domains described herein. Additionally, scaffolds of the invention, including at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or polypeptide scaffolds, can be fused or conjugated to a dimerization domain, for example, an antibody moiety selected from, but not limited to, the following: (i) a Fab fragment having the VL, CL, VH and CH1 domains; (ii) a Fab' fragment, which is a Fab fragment having one or more cysteine ​​residues at the C-terminus of the CH1 domain; (iii) an Fd fragment having the VH and CH1 domains; (iv) an Fd′ fragment having the VH and CH1 domains and one or more cysteine ​​residues at the C-terminus of the CH1 domain; (v) an Fv fragment having the VL and VH domains of an antibody single arm; (vi) a dAb fragment consisting of the VH domain; (vii) an isolated CDR region; (viii) F(ab'), a bivalent fragment comprising two Fab' fragments linked by disulfide bridges in the hinge region. 2 piece; (ix) single chain antibody molecules (e.g., single chain Fv; scFv); (x) a "diabody", which has two antigen-binding sites comprising a heavy-chain variable domain (VH) linked to a light-chain variable domain (VL) in the same polypeptide chain; (xi) a "linear antibody" comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen-binding regions; (xii) a full-length antibody; and (xiii) An Fc region comprising CH2-CH3 and which may further comprise all or a portion of the hinge region and / or CH1 region.

[0287] Production of Tn3 scaffolds Recombinant expression of the Tn3 scaffold of the present invention requires the construction of an expression vector containing a polynucleotide encoding the Tn3 scaffold. Once the polynucleotide encoding the Tn3 scaffold is obtained, a vector for Tn3 scaffold production can be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing a Tn3 scaffold encoding nucleotide sequence are described herein. Methods well known to those skilled in the art can be used to construct an expression vector containing a scaffold polypeptide coding sequence and appropriate transcription and transcription control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination techniques. Thus, the present invention provides a replicable vector containing a nucleotide sequence encoding the Tn3 scaffold of the present invention operably linked to a promoter.

[0288] The expression vector is transferred into a host cell by conventional techniques, and the transfected cells are then cultured by conventional techniques to produce the Tn3 scaffold of the invention. Thus, the invention includes a host cell that contains a polynucleotide encoding the scaffold of the invention operably linked to a heterologous promoter. Suitable host cells include, but are not limited to, microorganisms, such as bacteria (e.g., E. coli and B. subtilis).

[0289] A variety of host expression vector systems can be utilized to express the Tn3 scaffold of the present invention. Such host expression systems represent vehicles that can produce and subsequently purify the coding sequence of interest, but also represent cells that can express the scaffold of the present invention in situ when transformed or transfected with the appropriate nucleotide coding sequence. These include, but are not limited to, microorganisms, such as bacteria (e.g., E. coli and B. subtilis) or mammalian cell lines (e.g., COS, CHO, BHK, 293, NSO, and 3T3 cells) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the scaffold coding sequence.

[0290] Methods useful for producing the Tn3 scaffold of the invention are disclosed, for example, in International Patent Application Publication No. WO 2009 / 058379. Once the scaffold of the invention has been produced by recombinant expression, it can be purified by any method known in the art for purifying proteins.

[0291] In some embodiments, the scaffolds of the present invention can be produced in a non-glycosylated form by replacing amino acid residues that can be glycosylated during recombinant expression. In one specific embodiment, the serine amino acid in the glycine-serine linker (e.g., SEQ ID NO: 131 or SEQ ID NO: 132) can be replaced with other amino acid residues, such as alanine, glycine, leucine, isoleucine, or valine (see, e.g., SEQ ID NOs: 140, 141, 142, and 143), to prevent glycosylation during recombinant expression. In some specific embodiments, N-glycosylation sites are removed from the Tn3 scaffolds of the present invention. In other embodiments, the scaffolds of the present invention can be deglycosylated after recombinant expression. For example, methods for in vitro deglycosylation after recombinant expression using enzyme cocktails are known in the art (e.g., PFGase F, Enodo F Multi, Orela O-linked Glycan Release, Enzymatic CarboRelease, and Enzymatic DeGlycoMx deglycosylation kits available commercially from QA-bio, Palm Desert, Calif.).

[0292] Production of the Tn3 scaffold of the invention in the laboratory can be scaled up to produce the scaffold in analytical or production scale reactors as described in US Patent Application Publication No. 2010-0298541A1.

[0293] Scalable production of secreted Tn3 scaffolds The Tn3 scaffold of the present invention can be produced intracellularly or as a secreted form. In some embodiments, the secreted scaffold is properly folded and fully functional. The Tn3 scaffold of the present invention can be produced by a scalable process. In some embodiments, the scaffold can be produced by a scalable process of the present invention in a laboratory that can be scaled up to produce the scaffold of the present invention in an analytical scale bioreactor (such as, but not limited to, 5L, 10L, 15L, 30L, or 50L bioreactor). In other embodiments, the Tn3 scaffold can be produced by a scalable process of the present invention in a laboratory that can be scaled up to produce the Tn3 scaffold of the present invention in a production scale bioreactor (such as, but not limited to, 75L, 100L, 150L, ​​300L, or 500L). In some embodiments, the scalable process of the present invention results in little or no reduction in production efficiency compared to the production process carried out in the laboratory.

[0294] Linker The monomeric subunits in the multimeric Tn3 scaffold can be linked by protein and / or non-protein linkers, with each linker being fused to at least two monomeric subunits. Suitable linkers can consist of protein linkers, non-protein linkers, and combinations thereof. Linker combinations can be homomeric or heteromeric. In some embodiments, the multimeric Tn3 scaffold of the present invention comprises multiple monomeric subunits, and all linkers are identical. In other embodiments, the multimeric Tn3 scaffold comprises multiple monomeric subunits, and at least one of the linkers is functionally or structurally different from the remaining linkers. In some embodiments, the linker can contribute to the activity of the multimeric Tn3 scaffold itself by participating directly or indirectly in binding to the target.

[0295] In some embodiments, the protein linker is a polypeptide. The linker polypeptide should be of an appropriate length to link two or more monomeric subunits together in a manner that allows them to assume the correct conformation relative to one another so that they retain the desired activity.

[0296] In one embodiment, the polypeptide linker comprises 1 to about 1000 amino acid residues, 1 to about 50 amino acid residues, 1 to 25 amino acid residues, 1 to 20 amino acid residues, 1 to 15 amino acid residues, 1 to 10 amino acid residues, 1 to 5 amino acid residues, 1 to 3 amino acid residues. The invention further provides a nucleic acid, e.g., DNA, RNA, or a combination of both, encoding a polypeptide linker sequence. The amino acid residues selected for inclusion in the polypeptide linker should exhibit properties that do not significantly interfere with the activity or function of the multimeric Tn3 scaffold of the invention. Thus, the polypeptide linker as a whole should not exhibit charges that are inconsistent with the activity or function of the Tn3 multimeric scaffold of the invention, charges that interfere with internal folding, or charges that form bonds or other interactions with one or more amino acid residues of the monomer subunits that significantly impair the binding of the Tn3 multimeric scaffold of the invention to CD40L.

[0297] The use of natural and artificial peptide linkers to link polypeptides to novel binding fusion polypeptides is well known in the literature.Therefore, the linker that fuses two or more monomer subunits is natural linker, artificial linker, or a combination thereof.In some embodiments, the amino acid sequences of all peptide linkers present in the Tn3 multimer scaffold of the present invention are identical.In other embodiments, the amino acid sequences of at least two of the peptide linkers present in the multimer Tn3 scaffold of the present invention are different.

[0298] In some embodiments, the polypeptide linker has conformational flexibility. In some embodiments, the polypeptide linker sequence is (GGGGX) mIn a specific embodiment, the polypeptide linker sequence comprises the amino acid sequence: (GGGGS) m In another specific embodiment, the polypeptide linker sequence comprises the amino acid sequence (GGGGG) m In yet another specific embodiment, the polypeptide linker sequence comprises the amino acid sequence (GGGGA) m The formula includes an amino acid sequence, where m is a positive integer (see, e.g., SEQ ID NO: 149). In some embodiments, the polypeptide linker is a naturally occurring or artificial polypeptide that is essentially structureless (see, e.g., Schellenberger et al., Nature Biotechnol. 27:1186-1190, 2009; see also Sickmeier et al., Nucleic Acids Res. 35:D786-93, 2007).

[0299] The peptide linker can be modified to introduce an amino acid residue that contains an attachment group for a non-polypeptide moiety. An example of such an amino acid residue can be a cysteine ​​residue (to which the non-polypeptide moiety is subsequently attached), or the amino acid sequence can contain an in vivo N-glycosylation site (to allow for the attachment of a sugar moiety (in vivo) to the peptide linker).

[0300] In some embodiments, the amino acid sequences of all peptide linkers present in a polypeptide multimer are identical. Alternatively, the amino acid sequences of all peptide linkers present in a polypeptide multimer can be different.

[0301] Labeling or conjugation of Tn3 scaffold The Tn3 scaffold of the present invention can be used in unconjugated form or can be conjugated to at least one of a variety of heterologous moieties to facilitate target detection or for imaging or therapy. The Tn3 scaffold can be labeled or conjugated either before or after purification, if purification is performed.

[0302] Many heterologous moieties lack suitable functional groups that can be attached to the Tn3 scaffold of the present invention. Thus, in some embodiments, the effector molecule is attached to the scaffold via a linker, which includes a reactive group for conjugation. In some embodiments, the heterologous moiety that is conjugated to the Tn3 scaffold of the present invention can function as a linker. In other embodiments, the moiety is conjugated to the Tn3 scaffold via a linker that can be cleavable or non-cleavable. In one embodiment, the cleavable binding molecule is a redox cleavable binding molecule, so that the binding molecule can be cleaved in an environment with a lower redox potential, such as the cytoplasm and other regions that have a higher concentration of molecules with free sulfhydryl groups. Examples of binding molecules that can be cleaved due to changes in redox potential include molecules that contain disulfides.

[0303] In some embodiments, the Tn3 scaffold of the present invention is engineered to provide reactive groups for conjugation.In such scaffolds, the N-terminus and / or C-terminus can also function to provide reactive groups for conjugation.In other embodiments, the N-terminus can be conjugated to one moiety (such as, but not limited to, PEG), while the C-terminus can be conjugated to another moiety (such as, but not limited to, biotin), or vice versa.

[0304] The term "polyethylene glycol" or "PEG" refers to a polyethylene glycol compound or derivatives thereof, with or without a coupling agent, coupling or activating moiety (e.g., with a thiol, triflate, tresylate, aziridine, oxirane, N-hydroxysuccinimide or maleimide moiety). The term "PEG" is intended to indicate, for example, polyethylene glycol (including analogs thereof) of molecular weight between 500 and 150,000 Da, in which the terminal OH group has been replaced by a methoxy group (referred to as mPEG).

[0305] The Tn3 scaffold of the present invention can be derivatized with polyethylene glycol (PEG). PEG is a linear water-soluble polymer of ethylene oxide repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weight, which typically ranges from about 500 daltons to about 40,000 daltons. In a specific embodiment, the PEG used has a molecular weight ranging from 5,000 daltons to about 20,000 daltons. The PEG coupled to the scaffold of the present invention can be branched or unbranched. See, for example, Monfardini, C. et al. 1995 Bioconjugate Chem 6:62-69. PEG is commercially available from Nektar Inc., Sigma Chemical Co. and other companies. Such PEGs include, but are not limited to, monomethoxypolyethyleneglycol (MePEG-OH), monomethoxypolyethyleneglycol-succinate (MePEG-S), monomethoxypolyethyleneglycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethyleneglycol-amine (MePEG-NH2), monomethoxypolyethyleneglycol-tresylate (MePEG-TRES), and monomethoxypolyethyleneglycol-imidazolyl-carbonyl (MePEG-IM).

[0306] Briefly, the hydrophilic polymer used, e.g., PEG, is capped at one end with a non-reactive group, e.g., a methoxy or ethoxy group. The polymer is then activated at the other end by reaction with a suitable activating agent, e.g., a cyanuric halide (e.g., cyanuric chloride, bromide or fluoride), carbonyldiimidazole, anhydride reagent (e.g., dihalosuccinic anhydride, e.g., dibromosuccinic anhydride), acyl azide, p-diazonium benzoyl ether, 3-(p-diazonium phenoxy)-2-hydroxypropyl ether), etc. The activated polymer is then reacted with the polypeptide described herein to produce a polymer-derivatized polypeptide. Alternatively, the functional group in the Tn3 scaffold of the present invention can be activated for reaction with the polymer, or the two groups can be joined in a concerted coupling reaction using known coupling methods. It is readily recognized that the polypeptide of the present invention can be derivatized with PEG using numerous other reaction schemes known and used by those skilled in the art. PEG can be coupled to the scaffolds of the invention at either end of the Tn3 scaffold or at one or more functional groups within the Tn3 scaffold, hi some embodiments, PEG is coupled at either the N-terminus or C-terminus.

[0307] In other embodiments, the Tn3 scaffolds, analogs or derivatives thereof of the present invention can be conjugated to diagnostic or detection agents. Such Tn3 scaffolds can be useful for monitoring or prognostic diagnosis of disease onset or progression as part of a clinical trial procedure, for example to determine the efficacy of a particular therapeutic approach.

[0308] The present invention further encompasses the use of the Tn3 scaffold conjugated to a therapeutic moiety.The Tn3 scaffold can be conjugated to a therapeutic moiety, such as a cytotoxin, such as a bacteriostatic or cytocidal agent, a therapeutic agent, or a radioactive metal ion, such as an alpha emitter.Cytotoxins or cytotoxic agents include any agent that is harmful to cells.

[0309] Tn3 scaffold assay The binding affinity and other binding properties of the Tn3 scaffold to the antigen can be measured by a variety of in vitro assay methods known in the art, such as, for example, equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA) or kinetics (e.g., BIACORE® analysis), as well as other methods such as indirect binding assays, competitive binding assays, gel electrophoresis and chromatography (e.g., gel filtration). These and other methods may utilize a label on one or more of the components being tested and / or may use a variety of detection methods, such as, but not limited to, chromogenic, fluorescent, luminescent, or isotopic labels. A detailed description of binding affinity and kinetics can be found in Paul, WE, ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999).

[0310] In some embodiments, the Tn3 scaffold of the invention specifically binds to a target with defined kinetics. In some embodiments, the Tn3 scaffold of the invention specifically binds to a target with defined kinetics. -2 M, 1×10 -3 M, 1×10 -4 M, 1×10 -5 M, 1×10 -6 M, 1×10 -7 M, 1×10 -8 M, 1×10 -9 M, 1×10 -10 M, 1×10 -11 M, 1×10 -12 M, 1×10 -13 M, 1×10 -14 Less than M or 1×10 -15 Dissociation constant or K less than M d (k off / k on In specific embodiments, the Tn3 scaffolds of the invention may have a K of 500 μM, 100 μM, 500 nM, 100 nM, 1 nM, 500 pM, 100 pM, or less as measured by a BIAcore assay® or other assays known in the art. dhas.

[0311] In an alternative embodiment, the affinity of the Tn3 scaffold of the invention is at least 1×10 2 M -1 , 1×10 3 M -1 , 1×10 4 M -1 , 1×10 5 M -1 , 1×10 6 M -1 , 1×10 7 M -1 , 1×10 8 M -1 , 1×10 9 M -1 , 1×10 10 M -1 1×10 11 M -1 1×10 12 M -1 , 1×10 13 M -1 , 1×10 14 M -1 , 1×10 15 M -1 , or at least 5 × l0 15 M -1 k on / k off The association constant (K a ) units.

[0312] In one embodiment, the rate at which a Tn3 scaffold of the invention dissociates from a target epitope is K d or K a In some embodiments, the Tn3 scaffold of the present invention has a value of 10 -3 s -1 Less than 5×10 -3 s -1 Less than 10 -4 s -1 Less than 5×10 -4 s -1 Less than 10 -5 s -1 Less than 5×10 -5 s -1 Less than 10 -6 s-1 Less than 5×10 -6 s -1 Less than 10 -7 s -1 Less than 5×10 -7 s -1 Less than 10 -8 s -1 Less than 5×10 -8 s -1 Less than 10 -9 s -1 Less than 5×10 -9 s -1 Less than or equal to 10 -10 s -1 Less than k off has.

[0313] In certain other embodiments, the rate at which a Tn3 scaffold of the invention associates with a target epitope is determined by the K d or K a In this case, the Tn3 scaffold of the present invention has a value of at least 10 5 M -1 s -1 , at least 5 × 10 5 M -1 s -1 , at least 10 6 M -1 s -1 , at least 5 × 10 6 M -1 s -1 , at least 10 7 M -1 s -1 , at least 5 × 10 7 M -1 s -1 , or at least 10 8 M -1 s -1 , or at least 10 9 M -1 s -1 k on It binds to the target at high speed.

[0314] The Tn3 scaffolds of the invention can also be attached to solid supports, which are particularly useful for immunoassays or purification of target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0315] CD40L-specific Tn3 scaffold The present invention provides a Tn3 scaffold that specifically binds to CD40L. In a specific embodiment, the scaffold of the present invention specifically binds to human CD40L. In other specific embodiments, the Tn3 scaffold of the present invention binds to CD40L homologues from mouse, chicken, rhesus monkey, cynomolgus monkey, rat, or rabbit. In some embodiments, the Tn3 scaffold of the present invention binds to exposed epitopes of CD40L. Such embodiments include cells that are transfected to ectopically express CD40L and / or receptors that are endogenously expressed on the cells.

[0316] In some embodiments, the Tn3 scaffold of the invention recognizes an epitope displayed on monomeric CD40L. In other embodiments, the Tn3 scaffold of the invention recognizes an epitope displayed on a trimer form of CD40L. In other embodiments, the Tn3 scaffold of the invention recognizes an epitope displayed on membrane-bound CD40L. In other embodiments, the Tn3 scaffold of the invention recognizes an epitope displayed on soluble CD40L.

[0317] In yet other embodiments, the Tn3 scaffolds of the invention bind monomeric CD40L and prevent or interfere with oligomerization of the CD40L molecule. In yet other embodiments, the scaffolds of the invention reduce or inhibit the interaction of CD40L with CD40. In other embodiments, the Tn3 scaffolds of the invention agonize cell signaling mediated by CD40L. In yet other embodiments, the Tn3 scaffolds of the invention antagonize cell signaling mediated by CD40L.

[0318] The present invention also provides a method of modulating CD40L activity using the Tn3 scaffold described herein. In some embodiments, the method of the present invention comprises contacting CD40L with a CD40L-specific scaffold and blocking the interaction between CD40 and CD40L. In other embodiments, the method of the present invention comprises contacting a CD40L-expressing cell with a CD40L-specific Tn3 scaffold and preventing proteolytic cleavage of CD40L from the cell surface. In other embodiments, the method of the present invention comprises contacting a CD40L monomer with a CD40L-specific Tn3 scaffold and preventing CD40L oligomerization. In other embodiments, CD40L dimerization or oligomerization can be achieved through the use of a multimeric Tn3 scaffold.

[0319] In some embodiments, the methods of the invention include administration of a CD40L-specific scaffold that reduces a CD40-mediated immune response (see, e.g., Elqueta et al. 229:152-172, 2009) as measured by routine assays known in the art, or downstream signaling pathways initiated by CD40 binding to CD40L.

[0320] Without being bound by any particular theory, the CD40L scaffolds of the invention may function by interfering with binding of CD40L to CD40, by binding and sequestering soluble CD40L, by altering the interaction of CD40L with CD40 but not interfering with binding, by interfering with or enhancing metalloprotease-mediated enzymatic cleavage of CD40L from the cell surface to generate soluble CD40L, by interfering with or enhancing cell surface CD40L endocytosis, etc.

[0321] Specific CD40L binding sequence In some embodiments, a Tn3 scaffold of the invention comprises a CD40L-specific monomeric subunit that comprises at least one, at least two, at least three, at least four, at least five, or at least six CD40L-binding loop sequences.

[0322] In some embodiments, the CD40L-specific monomer subunit comprises at least one, at least two, at least three, at least four, at least five, or at least six loop sequences of a CD40L-binding monomer clone selected from: 309 (parental 309 family clone isolated from a naive Tn3 library; SEQ ID NO:20), 309FGwt (parental 309 clone with a humanized FG loop; SEQ ID NO:22), 340 (affinity matured 309 clone; SEQ ID NO:24), 341 (affinity matured 309 clone; SEQ ID NO:26). , 342 (affinity matured 309 clone; SEQ ID NO:28 or SEQ ID NO:146), 343 (affinity matured 309 clone; SEQ ID NO:30), 344 (affinity matured 309 clone; SEQ ID NO:32), 345 (affinity matured 309 clone; SEQ ID NO:34), 346 (affinity matured 309 clone; SEQ ID NO:36), 347 (affinity matured 309 clone; SEQ ID NO:38), 348 (affinity matured 309 clone; SEQ ID NO:40), 349 (affinity matured 309 clone; SEQ ID NO:42), 311 (parental 311 family clone isolated from a naive Tn3 library; column no. 44), 311K4E (variant 311 family clone from the first affinity maturation round; SEQ ID NO: 46); 311K4E_1 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 48), 311K4E_2 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 50), 311K4E_3 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 52), 311K4E_4 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: column no. 54), 311K4E_5 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 56), 311K4E_7 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 58), 311K4E_8 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 60), 311K4E_9 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 62), 311K4E_10 (variant 311 family clone from the second affinity maturation round;SEQ ID NO: 64), 311K4E_11 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 66), 311K4E_12 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 68), 311K4E_13 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 70), 311K4E_14 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 72), 311K4E_15 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 73), 311K4E_16 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 74), 311K4E_17 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 75), 311K4E_18 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 76), 311K4E_19 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 77), 311K4E_20 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 78), 311K4E_21 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 79), 311K4E_22 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 80), 311K4E_23 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 81), 311K4E_24 (variant 311 family clone from the (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 74), 311K4E_16 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 76), 311K4E_19 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 78), 311K4E_20 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 80), and 311K4E_21 (variant 311 family clone from the second affinity maturation round; SEQ ID NO: 82);

[0323] In some embodiments, the CD40L-specific monomeric subunit comprises at least one loop sequence selected from the loop sequences listed in Table 2. In other embodiments, the CD40L-specific monomeric subunit comprises at least one BC loop sequence selected from the BC loop sequences listed in Table 2. In other embodiments, the CD40L-specific monomeric subunit comprises at least one DE loop sequence selected from the DE loop sequences listed in Table 2. In other embodiments, the CD40L-specific monomeric subunit comprises at least one FG loop sequence selected from the FG loop sequences listed in Table 2.

[0324] In some embodiments, the CD40L-specific monomeric subunit comprises a BC loop sequence selected from the BC loop sequences listed in Table 2; and a DE loop sequence selected from the DE loop sequences listed in Table 2. In other embodiments, the CD40L-specific monomeric subunit comprises a BC loop sequence selected from the BC loop sequences listed in Table 2; and a FG loop sequence selected from the FG loop sequences listed in Table 2. In other embodiments, the CD40L-specific monomeric subunit comprises a DE loop sequence selected from the DE loop sequences listed in Table 2; and a FG loop sequence selected from the FG loop sequences listed in Table 2. In some embodiments, the CD40L-specific monomeric subunit comprises loop sequences corresponding to loop sequences from one, two or three different Tn3 clones.

[0325] In certain embodiments, where the CD40L-specific monomer scaffold sequence contains a linker and / or a histidine tag (e.g., a His-8 tag) at the C-terminus of the sequence, or additional N-terminal amino acids, these C-terminal linkers and / or histidine tags and the additional N-terminal amino acids can be removed, such that the corresponding amino acid sequence contains the C-terminal linker and His tag sequence as well as a deletion of one or more N-terminal additional amino acids.

[0326] In some embodiments, the CD40L-specific Tn3 scaffold comprises a single monomeric subunit, e.g., the 342 clone sequence (affinity matured 309 clone; SEQ ID NO:28 and / or SEQ ID NO:146). In other embodiments, the CD40L-specific scaffold comprises two or more monomeric subunits, e.g., two 342 clone monomeric subunits (SEQ ID NO:28 and / or SEQ ID NO:146) in tandem (see, e.g., SEQ ID NO:135). In a specific embodiment, the Tn3 scaffold of the present invention is conjugated to a variant HSA (see, e.g., SEQ ID NO:134 and SEQ ID NO:135). In further embodiments, the HSA can be conjugated at either the N-terminus or C-terminus of the multimeric Tn3 scaffold.

[0327] In a specific embodiment, the CD40L-specific Tn3 scaffold comprises a single 311K4E_12 monomer subunit, a GS linker, and a C34S HSA variant (see, e.g., SEQ ID NO: 201). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises a single 311K4E_12 monomer subunit with a beta chain C CELTYG variant, an all-glycine linker, and a C34S HSA variant (see, e.g., SEQ ID NO: 202). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 311K4E_12 subunits in tandem and two GS linkers, one GS linker linking the subunits to each other and a second GS linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO: 203). In yet another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 311K4E_12 subunits in tandem and two all-glycine linkers, one all-glycine linker linking the subunits to each other and a second all-glycine linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO:204).

[0328] In one specific embodiment, the CD40L-specific Tn3 scaffold comprises two 309 subunits linked in tandem via a GS linker (see, for example, SEQ ID NO: 205). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises a single 309 subunit linked to a C34S HSA variant (see, for example, SEQ ID NO: 206). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 309 subunits in tandem and two GS linkers, one GS linker links the subunits to each other and a second GS linker links one subunit to the C34S HSA variant (see, for example, SEQ ID NO: 207).

[0329] In a specific embodiment, the CD40L-specific Tn3 scaffold comprises a single 342 monomer subunit, a GS linker, and a C34S HSA variant (see, e.g., SEQ ID NO: 134). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises a single 342 monomer subunit, an all-glycine linker, and a C34S HSA variant (see, e.g., SEQ ID NO: 144). In another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 342 subunits in tandem, and two GS linkers, one GS linker linking the subunits to each other and a second GS linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO: 135). In yet another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 342 subunits in tandem and two all-glycine linkers, one all-glycine linker linking the subunits to each other and a second all-glycine linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO: 145).In yet another specific embodiment, the CD40L-specific Tn3 scaffold comprises two 342 subunits linked in tandem by a GS linker (see, e.g., SEQ ID NO: 208).

[0330] In a specific embodiment, the CD40L-specific Tn3 scaffold comprises, and in another specific embodiment, the CD40L-specific Tn3 scaffold comprises a 311 subunit, or a 311-derived subunit (e.g., 311K4E_12) and a 309 subunit, or a tandem 309-derived subunit (e.g., 342) and two GS linkers, one GS linker linking the subunits to each other and a second GS linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO: 135). In yet another specific embodiment, the CD40L-specific Tn3 scaffold comprises a 311 subunit, or a 311-derived subunit (e.g., 311K4E_12) and a 309 subunit, or a tandem 309-derived subunit (e.g., 342), and two all-glycine linkers, one all-glycine linker linking the subunits to each other and a second all-glycine linker linking one subunit to the C34S HSA variant (see, e.g., SEQ ID NO: 145).

[0331] An example of a CD40L-specific tandem bivalent Tn3 scaffold and serum albumin (SA) fusion is shown in Figure 2A (see also Figure 9A). A specific linker is provided in Figure 2A, but other linkers are contemplated as provided herein. Wild-type mature SA, e.g., murine serum albumin (MSA) or human serum albumin (HSA), can be used, but it is contemplated that one or more cysteine ​​(C) amino acid residues in the mature SA can be replaced, e.g., by serine (S), alanine (A), glycine (G), etc.

[0332] A representative construct is shown below. The sequence of SA is underlined. The linker is boxed. It is understood that numerous variations are within the scope of the present invention. For example, the linker can be altered (several non-limiting examples are provided herein), the first one or two N-terminal amino acid residues (SQ) can be absent and / or replaced by alternative amino acid residues, a tag (e.g., a 6xHis tag) can be incorporated, an alternative CD40L-specific scaffold (e.g., a scaffold based on the 10th Fn3 domain of fibronectin) can be utilized in similar constructs, and so forth. [ka] [ka] [ka]

[0333] Pharmaceutical Compositions In another aspect, the present invention provides compositions, including but not limited to pharmaceutical compositions, containing one or a combination of the Tn3 scaffolds of the present invention, formulated together with a pharma- ceutically acceptable carrier. Such compositions may include, but are not limited to, one or a combination of two or more different Tn3 scaffolds of the present invention. For example, the pharmaceutical composition of the present invention may include a combination of Tn3 scaffolds that bind to different epitopes on a target antigen or have complementary activities. In a specific embodiment, the pharmaceutical composition includes a single monomeric Tn3 scaffold of the present invention. In a specific embodiment, the pharmaceutical composition includes a multimeric Tn3 scaffold of the present invention. In yet another specific embodiment, the pharmaceutical composition includes a dimeric Tn3 scaffold of the present invention.

[0334] The pharmaceutical composition of the present invention can also be administered in combination therapy, for example, in combination with other drugs.For example, the combination therapy can include the Tn3 scaffold of the present invention combined with at least one other therapy, which can be immunotherapy, chemotherapy, radiation therapy, or drug therapy.The pharmaceutical compound of the present invention can include one or more pharmacologic acceptable salts.

[0335] How to use scaffolding The Tn3 scaffolds of the invention have diagnostic and therapeutic utilities in vitro and in vivo, for example, these molecules can be administered to cells in culture, e.g., in vitro or ex vivo, or in a subject, e.g., in vivo, to treat, prevent or diagnose various disorders.

[0336] The present invention also provides a method of using the Tn3 scaffold of the present invention.The present invention also encompasses the use of the Tn3 scaffold of the present invention, either alone or in combination with other therapies, for the prevention, diagnosis, management, treatment or amelioration of one or more symptoms associated with a disease, disorder or infection, including but not limited to cancer, inflammation and autoimmune disease, infectious disease.The present invention also encompasses the use of the Tn3 scaffold of the present invention, conjugated or fused to a moiety (e.g., a therapeutic agent or drug), either alone or in combination with other therapies, for the prevention, diagnosis, management, treatment or amelioration of one or more symptoms associated with a disease, disorder or infection, including but not limited to cancer, inflammation and autoimmune disease, infectious disease.

[0337] The present invention also provides a method to target epitopes not easily reached by conventional antibodies. For example, in one embodiment, the Tn3 scaffold of the present invention can be used to first target adjacent antigens, and during binding, a separate binding domain can associate with the cryptic antigen.

[0338] The present invention also provides a method of using the Tn3 scaffold of the present invention to bring together distinct cell types. In one embodiment, the protein of the present invention can bind to a target cell with one binding domain and recruit another cell via another binding domain. In another embodiment, the first cell can be a cancer cell and the second cell is an immune effector cell, for example, a NK cell. In another embodiment, the Tn3 scaffold of the present invention can be used to enhance the interaction between two distinct cells, for example, between an antigen-presenting cell and a T cell, which may boost immune response.

[0339] The present invention also provides methods of using the Tn3 scaffold to deplete cell populations. In one embodiment, the methods of the present invention are useful in the depletion of the following cell types: eosinophils, basophils, neutrophils, T cells, B cells, mast cells, monocytes and tumor cells.

[0340] The present invention also provides methods of using the Tn3 scaffold as a diagnostic reagent that can be used to test for the presence or absence of CD40L, the presence of the CD40 receptor, the binding efficiency of CD40L to the CD40 receptor, free CD40L in a patient, free CD40L in a sample, or CD40L bound to the CD40 receptor in a sample.

[0341] The Tn3 scaffolds of the invention and compositions comprising same are useful for many purposes, including as therapeutic agents for a wide range of chronic and acute diseases and disorders, including, but not limited to, autoimmune and / or inflammatory diseases. The compositions and methods of the invention described herein are useful for the prevention or treatment of autoimmune and / or inflammatory disorders.

[0342] Examples of autoimmune and / or inflammatory disorders include, but are not limited to, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune disease of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, Sjogren's syndrome, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasia (including Graves' disease), corneal and other tissue transplants, as well as chronic inflammation, sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis (e.g., psoriatic arthritis), anaphylactic shock, organ ischemia, reperfusion injury, spinal cord injury, and allograft rejection. Autoimmune thrombocytopenia, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis , type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis, such as dermatitis herpetiformis vasculitis, vitiligo, and Wegener's granulomatosis.

[0343] Examples of inflammatory disorders include, but are not limited to, asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacterial infection. The compositions and methods of the present invention can be used in conjunction with one or more conventional therapies used to prevent, manage, or treat the above diseases.

[0344] The present invention provides a method for preventing, managing, treating or ameliorating cancer, autoimmune, inflammatory or infectious disease or one or more symptoms thereof or one or more symptoms thereof comprising administering to a subject in need thereof one or more Tn3 scaffolds of the present invention in combination with one or more therapeutic agents that are not cancer therapeutic agents (aka non-cancer therapeutics).

[0345] Examples of such agents include, but are not limited to, antiemetics, antifungals, antibacterials, such as antibiotics, anti-inflammatory agents, and antivirals. Non-limiting examples of antiemetics include metopimazine and metoclopramide. Non-limiting examples of antifungals include azole drugs, imidazoles, triazoles, polyenes, amphotericin, and ryrimidine. Non-limiting examples of antibacterial agents include dactinomycin, bleomycin, erythromycin, penicillin, mithramycin, cephalosporins, imipenem, axtreonam, vancomycin, cycloserine, bacitracin, chloramphenicol, clindamycin, tetracycline, streptomycin, tobramycin, gentamicin, amikacin, kanamycin, neomycin, spectinomycin, trimethoprim, norfloxacin, refampin, polymyxin, amphotericin B, nystatin, ketocanazole, isoniazid, metronidazole, and pentamidine. Non-limiting examples of antiviral agents include nucleoside analogs (e.g., zidovudine, acyclovir, ganciclovir, vidarbine, idoxuridine, trifluridine, and ribavirin), foscaret, amantadine, rimantadine, saquinavir, indinavir, ritonavir, interferon ("IFN")-α, β, or γ, and AZT. Non-limiting examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs ("NSAIDs"), steroidal anti-inflammatory drugs, beta-agonists, anticholinergics, and methylxanthines.

[0346] In one embodiment, the present invention comprises a composition that can treat chronic inflammation. In one embodiment, the composition is useful in targeting immune cells for destruction or inactivation. In one embodiment, the composition is useful in targeting activated T cells, resting T cells, B cells, neutrophils, eosinophils, basophils, adipocytes, or dendritic cells. In another embodiment, the present invention comprises a composition that can reduce immune cell function. In another embodiment, the composition can eliminate immune cell function.

[0347] In another embodiment, the present invention includes a composition useful for treating diseases of the gastrointestinal tract. The scaffold of the present invention exhibits a high level of stability under low pH conditions. The stability at low pH suggests that the composition is suitable for oral administration for various gastrointestinal disorders, such as irritable bowel syndrome, gastroesophageal reflux, intestinal pseudo-obstruction, dumping syndrome, refractory nausea, peptic ulcer, appendicitis, ischemic colitis, ulcerative colitis, gastritis, Helicobacter pylori disease, Crohn's disease, Whipple's disease, celiac sprue, diverticulitis, diverticulosis, dysphagia, hiatal hernia, infectious esophageal disorders, hiccups, rumination, etc.

[0348] The present invention further provides combination compositions and methods of using such compositions in preventing, treating, reducing, or improving disease or its symptoms. The Tn3 scaffold of the present invention can be combined with conventional therapies suitable for preventing, treating, reducing, or improving disease or its symptoms. Exemplary conventional therapies can be found in the Physician's Desk Reference (56th ed., 2002 and 57th ed., 2003). In some embodiments, the Tn3 scaffold of the present invention can be combined with chemotherapy, radiation therapy, surgery, immunotherapy using biological agents (antibodies or peptides), small molecules, or other therapies known in the art. In some embodiments, the combination therapy is administered together. In other embodiments, the combination therapy is administered separately.

[0349] The present invention also provides a method for diagnosing a disease. The Tn3 scaffold of the present invention, which binds to a specific target associated with a disease, can be incorporated into a method used to diagnose said disease. In one embodiment, the Tn3 scaffold of the present invention is used in a method for diagnosing a disease in a subject, comprising obtaining a sample from the subject, contacting the target with the Tn3 scaffold in the sample under conditions that allow the formation of a target:scaffold interaction, identifying the target:scaffold complex, and thereby detecting the target in the sample. In another embodiment, the disease to be diagnosed is described herein.

[0350] The present invention also provides a method for imaging specific targets.In one embodiment, the Tn3 scaffold of the present invention conjugated to an imaging agent, such as green fluorescent protein, other fluorescent tags (Cy3, Cy5, rhodamine, etc.), biotin, or radionuclides, can be used in a method for imaging the presence, location, or progression of specific targets.In some embodiments, the method for imaging targets comprising the Tn3 scaffold of the present invention is carried out in vitro.In other embodiments, the method for imaging targets comprising the Tn3 scaffold of the present invention is carried out in vivo.In other embodiments, the method for imaging targets comprising the Tn3 scaffold of the present invention is carried out by MRI, PET scan, X-ray, fluorescence detection, or other detection methods known in the art.

[0351] The invention also provides methods of monitoring disease progression, recurrence, treatment, or amelioration using the scaffolds of the invention. In one embodiment, the methods of monitoring disease progression, recurrence, treatment, or amelioration are accomplished by imaging, diagnostic methods, or contacting compounds / targets with the Tn3 scaffolds of the invention as provided herein.

[0352] Pharmaceutical Dosage and Administration To prepare a pharmaceutical or sterile composition comprising the Tn3 scaffold of the present invention, the scaffold is mixed with a pharma- ceutically acceptable carrier or excipient. For administration, the composition is preferably pyrogen-free and substantially free of endotoxins and / or related pyrogens. The choice of dosage regimen for a therapeutic agent depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of target cells in the biological matrix. In one embodiment, the dosage regimen maximizes the amount of therapeutic agent delivered to the patient consistent with an acceptable level of side effects.

[0353] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective for achieving the desired therapeutic response for a particular patient, composition, and mode of administration without causing toxicity to the patient.The dosage level selected depends on various pharmacokinetic factors, such as the activity of the particular composition of the present invention used, or its ester, salt, or amide, the route of administration, the time of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds, and / or materials in combination with the particular composition used, the age, sex, weight, disease state, general health and medical history of the patient being treated, and similar factors well known in the medical field.

[0354] The compositions of the invention may also be administered via one or more routes of administration using one or more of a variety of methods known in the art, hi certain embodiments, the Tn3 scaffolds of the invention may be formulated to ensure proper distribution in vivo.

[0355] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims.

[0356] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference herein. EXAMPLES

[0357] The present invention will now be described with reference to the following examples, which are illustrative only and the present invention should not be construed as being limited to these examples in any way, but rather as embracing any and all variations that become evident as a result of the teachings provided herein.

[0358] Example 1 Construction of a three-loop library based on the parental Tn3 scaffold The library was constructed based on the parent Tn3 scaffold described in International Patent Application Publication WO 2009 / 058379, named "Tn3SS4". The library contained randomized regions of the BC, DE and FG loops. This design incorporated characterized sequence and loop length diversity into the Tn3 library that matches the diversity pattern described for the natural FnIII domain, three different lengths for the BC and FG loops, and used the "NHT" mixed codon scheme to introduce diversity into the library (H=A, T, C). This scheme generated 12 codons that encoded 12 / 20 amino acids (see Table 3), i.e., each codon encoded a unique amino acid. In addition, there were no stop codons or cysteine ​​(Cys) codons. [Table 3]

[0359] Library diversity was generated using the degenerate oligonucleotides shown in Table 4. [Table 4]

[0360] The library was assembled using the oligonucleotides shown in Table 5. [Table 5]

[0361] A mixture of degenerate oligonucleotides (equimolar ratios of oligonucleotides corresponding to the BC and FG loops, respectively), BCX-DE bridge v2, DE-FGX bridge v2, and KpnI amp rev v2, was assembled without excess of external primers in a 20-cycle PCR reaction. This product was diluted and amplified in a regular PCR reaction using primers BC library amp v2 and KpnI reverse v2. The resulting PCR product generated the complete Tn3 gene, which was then digested with NcoI and KpnI and ligated into a phage display vector (described in WO 2009 / 058379). The DNA was transformed into E. coli by electroporation. The final diversity of the library was approximately 7.9×10 10 It was estimated that there were members.

[0362] After electroporation, the library was incubated for 1 hour with shaking at 37° C. M13K07 helper phage was added and after 1 hour the cells were diluted into a larger volume and grown overnight with shaking at 37° C. The next day phage were harvested and concentrated from the supernatant by precipitation with PEG8000.

[0363] Example 2 Panning of libraries on human CD40L-specific Tn3 scaffolds >10 10 Phage-displayed Tn3 libraries containing unique sequences were panned against CD40L. The diversity of these libraries came from the variability in sequence and length of the BC, DE and FG loops, which are analogous to the three CDR loops in the antibody variable domain. Selection of lead Tn3 proteins was performed by panning the library against recombinant biotinylated human CD40L and a CD40L-overexpressing CHO cell line. Alternating panning rounds against these two reagents were used to ensure that the lead recognized recombinant extracellular domain and native membrane-anchored CD40L.

[0364] Recombinant human CD40L (human MegaCD40L; Axxora) was biotinylated with EZ-Link Sulfo-NHS-biotin (Pierce, Rockford, IL) using a 5-fold molar excess of biotinylation reagent. After 1 hour incubation at room temperature, samples were dialyzed overnight in PBS to remove unconjugated biotin. 10 μg of biotinylated CD40L was immobilized on M280 streptavidin beads (Dynal, Carlsbad, CA) and then blocked for 2 hours in PBS containing 10 mg / ml BSA. Input consisted of libraries developed as described in Example 1 or further developed using standard construction techniques, such as those described in WO 2009 / 058379.

[0365] Phages were blocked for 2 hours in PBS containing 10 mg / ml BSA. Blocked inputs were added to blocked M280 streptavidin control beads (no target) and incubated on a rocker at room temperature for 2 hours to deplete the library of binders to the beads. The depleted library was then added to CD40L-coated beads and incubated on a rocking platform at room temperature for 2 hours. After washing three times with PBST (PBS + 0.1% Tween) to remove unbound phage, the beads were added to exponentially growing E. coli XL-1Blue cells, which were subsequently co-infected with M13KO7 helper phage in 60 ml of 2xYT medium containing 50 μg / ml carbenicillin. Phages were grown overnight at 37°C with shaking and then harvested from the overnight culture medium by PEG precipitation.

[0366] The second panning round (round 2) was performed on a CD40L-overexpressing CHO cell line. The phage library was blocked in 3% BSA / PBS for 1 h at room temperature with rocking. Cells were detached with Accutase (Invitrogen), washed twice with 5 ml PBS, and aliquoted from 10 7The cells were blocked in 1 ml of 3% BSA / PBS for 30 min with rocking at room temperature. The blocked cells were spun down at 500×g for 5 min, gently resuspended in blocked phage library solution, and incubated at room temperature for 1 h. Unbound phage were removed by gently washing the cells three times in 1 ml of 3% BSA / PBS and once in PBS, pelleting the cells by centrifugation at 500×g for 5 min in a microcentrifuge using a new Eppendorf tube for each wash. The cell pellet was added directly to exponentially growing E. coli XL-1Blue, which was then processed as described for round 1.

[0367] Panning round 3 was performed as described in round 1, except that bound phage were eluted by adding 100 mM HCl followed by neutralization with 1 M Tris-HCl, pH 8. Eluted and neutralized phage were used to infect E. coli XL1Blue cells as described in round 1.

[0368] Panning round 4 was also performed on cells as described in round 2, except that 5 washes in 3% BSA / PBS were performed. Round 5 was performed using 5 μg of biotinylated MegaCD40L, but otherwise as described in round 3.

[0369] After five panning rounds, screening of the resulting Tn3 variants as soluble proteins was performed. The amplified and PEG-precipitated phage stock solution was used in PCR to amplify a pool of fragments encompassing the encoded Tn3 sequence. This fragment pool was digested with NcoI+KpnI and cloned into the corresponding NcoI-KpnI sites of the plasmid pSec-oppA(L25M)-Tn3 (see, for example, WO 2009 / 058379). E. coli BL21DE3 cells transformed with pSec-oppA(L25M)-Tn3-derived constructs were inoculated into autoinducing MagicMedia (Invitrogen) containing carbenicillin (100 μg / ml) in a 96-well deep-well plate. The culture was grown at 37° C. with shaking for 18 hours, and the cells were separated from the medium by centrifugation. The medium containing the secreted soluble Tn3 variants was used directly in screening assays for CD40L binding.

[0370] Ten sets of 96 clones were screened to identify Tn3 proteins that specifically bound recombinant CD40L. Briefly, the screening assay utilized capture of soluble His-tagged Tn3 variants secreted into the medium via binding to anti-His antibodies immobilized in the wells of a microplate. After capture, the medium and excess proteins were washed away, and the interaction of the captured Tn3 variants with CD40L was monitored using biotinylated human MegaCD40L and measuring the remaining target (after plate washing) with SA-HRP and conventional ELISA reagents.

[0371] In the capture step, the immobilized anti-His antibody was saturated with Tn3, such that the molar amount of captured Tn3 in each well was virtually identical regardless of the expression level of the individual clones. This normalization of Tn3 levels resulted in an assay level that was proportional to the efficiency of target interaction and was not affected by potential differences in protein expression levels.

[0372] Positives from this assay were sequenced to identify 34 unique Tn3 sequences that bound recombinant CD40L. From the panel of unique CD40L-binding Tn3 sequences, a subset of 24 clones with robust assay signal and good expression levels as judged by SDS-PAGE of culture supernatants were subjected to re-expression and small-scale purification.

[0373] Briefly, Superbroth medium containing carbenicillin (100 μg / mL) with 1% glucose) was inoculated with E. coli BL21DE3 cells transformed with pSec-oppA(L25M)-Tn3 derived constructs. Cultures were grown at 37°C to an optical density (OD) of 0.5-0.8 and then induced with 0.2 mM IPTG. After shaking at 37°C for 5 h, cells were separated from the medium by centrifugation. Purification of the Tn3 scaffold from the medium was performed by batch purification using Ni-NTA Superflow (Qiagen), washed in 2×PBS with 20 mM imidazole, and eluted with 2×PBS with 250 mM imidazole. Samples were dialyzed in PBS and concentrations were measured by UV absorbance at 280 nm according to Gill and von Hippel (Anal. Biochem. 182:319, 1989).

[0374] Based on assay ranking and SEC behavior, expression of eight leads was scaled up and purified to low endotoxin levels (<1EU / mg) for testing in functional cellular assays.

[0375] Two Tn3 clones (designated 309 and 311) showed similar activity in biochemical and cell-based assays (Figures 6A, 6B, 6C) and were 3- to 5-fold more potent than their closest competitor clones.

[0376] Human CD40L-specific monovalent Tn3 scaffolds 309 and 311 inhibited total B cell numbers, plasma cell numbers and Ig class switching (Figures 6A, 6B and 6C). Figure 6A shows the inhibitory effect of 309 and 311 on HuCD40L-induced CD86 expression on CD19-positive human PBMC stimulated with Jurkat D1.1 cells; Figure 6B shows the inhibition of HuCD40L-stimulated B cell proliferation by 309 and 311; Figure 6CC shows the inhibition of plasma cell numbers in T / B cell co-cultures. 309 was also shown to bind to activated primary T cells by FACS (data not shown). PBMCs were stimulated with recombinant human MegaCD40L (Axxora) or human CD40L-expressing Jurkat cells (D1.1, ATCC) and the percentage of CD19+ / CD86+ cells was measured by FACS 24 hours later.

[0377] The 309 and 311 lead clones were monodispersed and showed no tendency to aggregate or form higher order oligomers in solution, as determined by size-exclusion chromatography (SEC) analysis of purified samples (Figure 7A).

[0378] The thermal stability of the 309 and 311 lead clones was measured by differential scanning calorimetry (DSC) using protein samples at 1 mg / mL in PBS pH 7.2 and compared to that of the parental Tn3 protein (Figure 7B). The 309 and 3011 lead clones had a T m which has the T m (72°C).

[0379] As no murine cross-reactive clones were identified, a similar panning process as described above was performed to identify a murine-specific Tn3, designated M13, which also showed activity in a PBMC cell-based assay (see FIG. 1A).

[0380] Example 3 CD40L-specific Tn3 scaffold lead optimization Affinity optimization was used to increase the potency of selected Tn3 leads: generally, one or more rounds of mutagenesis within the Tn3 loops that contact the target were performed, and improved variants were selected from a combinatorial phage display library.

[0381] 3.1 Loop swapping To determine which of the three loops in the two leads are involved in the interaction with CD40L, constructs were generated in which each single loop sequence was changed to the parental Tn3 loop sequence found in human tenascin-C. The activity of the mutant variants was compared to the original variant in binding assays performed as described in the screening assay above (Figure 10A). For both leads, mutation of the BC and DE loops resulted in a complete loss of binding to CD40L, while changing the FG loop to the parental Tn3 sequence had no effect (for 309) or a limited effect on binding (311). Thus, the BC and DE loops were believed to contain sequences primarily responsible for contacting CD40L and were therefore selected first for affinity optimization.

[0382] 3.2 CD40L-specific Tn3 scaffold 309 lead optimization Since loop swapping experiments showed that the 309FG loop sequence could be replaced by the parental Tn3FG loop sequence without substantial loss of binding potency, it was decided to use this construct (designated 309FGwt) as a backbone for affinity maturation. This eliminates non-essential mutations that deviate from the parental tenascin-C sequence to reduce possible immunogenicity risks. It should be noted that the parental Tn3FG loop sequence contained an RGD motif that was later eliminated by mutation in the final lead molecule. Three BC loop libraries and one DE loop library were generated.

[0383] For the three BC loop libraries, three PCR rounds were performed using the degenerate oligos BC9PCR, BC9-LoopNNK and 309BC-LoopNNK dope (Table 6) together with the reverse primer Kpn1 amp rev v2 (Table 5) using the 309FGwt derived template in which the BC loop codon was replaced by a stop codon. The full length Tn3 library fragments were subsequently obtained by PCR amplification of those fragments using primers BC library amp v2 (Table 5) and KpnI reverse v2.

[0384] For the DE loop library, a fragment containing the randomized DE loop and wild-type Tn3FG loop was obtained by PCR amplification using DE PCR and KpnI amp reverse v2 on the 309FGwt-derived template (in which the DE-loop codon was replaced by a stop codon) and combined with a fragment encoding the Tn3 region upstream of the DE loop generated by PCR using BC library amp v2 and BCX-DE bridge v2 on the 309 template. The two fragments were joined in an overlap PCR using the external primers BC library amp v2 and KpnI reverse v2. [Table 6]

[0385] The NcoI-KpnI fragment was cloned into a phage display vector and a phage library was generated as described in Example 1.

[0386] The four libraries were panned separately against biotinylated human MegaCD40L as described in the first round of Example 2, using 4 μg of CD40L in round 1 and 1 μg in round 2. After amplification of the phage output after round 2, single-stranded DNA was isolated using the Qiagen Spin M13 kit (Qiagen, Valencia, CA) and a pool of BC loops containing fragments from the BC loop library was amplified using BC lib amp v2 and BC shuffle rev, while a pool of DE loop-containing fragments was amplified from the DE loop library using primers DE-shuffle FWD and KpnI reverse v2. The PCR fragments were gel purified and assembled via their overlapping sequences using external primers BC lib amp v2 and KpnI reverse v2. The resulting PCR fragments were used to generate libraries in phage vectors as described above. The library was panned against biotinylated human MegaCD40L as described in Example 2 for a total of five rounds, except that for rounds 1 to 4, the library was first contacted with the target at concentrations of 50 nM, 20 nM, 20 nM, and 10 nM (in a total volume of 50 μl) for 2 hours, then incubated with blocked M280 streptavidinylated magnetic beads for 10 minutes and then washed.

[0387] The output was pool cloned into the NcoI-KpnI sites of the plasmid pSec-oppA(L25M)-Tn3pSec and sixteen 96-well plates were screened for CD40L binding using soluble protein in the screening assay described above. The 270 top scoring clones were picked, re-assayed and sequenced. Ten clones were selected for further characterization based on binding assays and sequencing. This included evaluation of potency in the PBMC assay, K for binding to CD40L in the biosensor assay, and K for binding to CD40L in the biosensor assay. dThese included thermal stability as measured by differential scanning calorimetry, thermodynamic stability as measured by differential scanning calorimetry, and tendency to aggregate or form higher order oligomers in solution by size exclusion chromatography analysis. The results are summarized in Table 7. The sequences of the 309 and 309FGwt clones aligned with the 10 optimized clones (designated 340, 341, 342, 343, 344, 345, 346, 347, 348 and 349) are shown in Figures 11A and 11B.

[0388] The affinity matured variants exhibited 1-3 log higher potency than the 309 clone, retained high stability as measured by DSC, and were largely monodispersed as measured by SEC. [Table 7]

[0389] PBMC assays were performed by stimulating PBMCs with human CD40L-expressing Jurkat cells (D1.1, ATCC) and measuring the percentage of CD19+ / CD86+ cells by FACS after 24 hours. This assay was used to test and rank a panel of leading Tn3 scaffolds to emerge from prioritization based on biochemical criteria. The results of the PBMC assay are shown in Figure 10B and summarized in Table 7.

[0390] Affinity measurements were performed on a ProteOn XPR36 Protein Interaction Array System (Bio-Rad, Hercules, CA) using a GLC sensor chip at 25°C. ProteOn phosphate buffered saline (PBS / Tween) with 0.005% Tween 20, pH 7.4 was used as the running buffer. Human MegaCD40L was immobilized on the chip at a surface density of approximately 2300 RU. Two-fold dilutions of Tn3 variants (340, 342, 343, 345, 346, 347, 348, and 349) were prepared (150 to 4.7 nM) in PBS / Tween / 0.5 mg / ml BSA, pH 7.4. Samples of each concentration were injected for 300 seconds into the six analytical channels at a flow rate of 30 μl / min. K dwas measured by using the equilibrium analysis setting in the ProteOn software. The results are shown in Table 7.

[0391] Ten TCD40L-specific Tn3 variants were analyzed for stability by DSC. Briefly, DSC measurements were performed on a VP-Capillary DSC (MicroCal). Proteins were exchanged into PBS (pH 7.2) via large-scale dialysis and adjusted to concentrations of 0.25-0.5 mg / ml for DSC analysis. Samples were scanned from 20-95°C at a scan rate of 90°C / h and no scans were repeated. Results are shown in Table 7.

[0392] IC compared to 309 used for lead optimization library generation 50 Up to 300-fold improvement in K and over 1000-fold improvement compared to the 309FGwt backbone was obtained for the best clones. Seven clones had K in the single-digit nM range. d had.

[0393] 3.3 CD40L-specific Tn3 scaffold 311 lead optimization Prior to performing the loop usage experiments (Figure 10A), initial efforts in lead optimization libraries focused on introducing diversity in the FG loop of 311, generating and screening the resulting phage display library. Screening was performed after four panning rounds against the biotinylated human MegaCD40L, and the majority of positive hits were found to contain an incidental mutation of residues K4 to E in the N-terminal constant region of Tn3 upstream of the BC loop. No clear consensus was detected among the FG loop sequences of the positive hits. Introduction of a single K4E mutation in 311 resulted in a 100-fold increase in potency (from approx. 4 μM to 36 nM) in the PBMC assay (see Figure 10C).

[0394] Loop swapping experiments indicated that the BC and DE loop sequences were required for binding to CD40L, so these loops were then targeted in the 311K4E scaffold for further affinity maturation. Two separate libraries were generated. One library targeted the BC loop with a strategy in which each residue had a 50% chance of being the wild-type 311 sequence and approximately 50% chance of being one of the other 11 NHT-encoded residues. The other library fully randomized the 6-residue DE loop.

[0395] For the BC loop library, oligonucleotides BC11-311Gly and BC11-311NHT (Table 8) were used in a PCR reaction with reverse primer KpnI amp rev v2 (Table 5) on a 311-derived template in which the BC loop codon had been replaced by a stop codon to generate a fragment containing the BC, DE and FG loops. Finally, a full-length Tn3 library fragment was obtained by amplification of a 1:1 mixture of these fragments with primers BC library amp K4E and KpnI amp rev v2.

[0396] A DE-loop library was generated as the 309FGwt DE-loop library described above, except that the 311 derived template was used in the PCR reaction and the BC library amp K4E primer was used in the final PCR amplification. [Table 8]

[0397] The full-length library fragment was digested with NcoI and KpnI and cloned into a phage display vector, and a phage library was generated as described in Example 1.

[0398] The two libraries were panned separately against biotinylated human MegaCD40L as described in Example 1, using 10 g protein in round 1, 5 g in round 2, and 5 g in round 3. After amplification of the phage output after round 3, single-stranded DNA was isolated using a Qiagen kit (Qiagen, Valencia, CA) and the two libraries were shuffled as described for the 309FGwt library. The shuffled libraries were panned against biotinylated human MegaCD40L as described above for the 309FGwt shuffled library for a total of five rounds, using 100 nM, 20 nM, 4 nM, 1 nM and 1 nM target for rounds 1 to 5.

[0399] The output was pool cloned into a soluble secretion vector as described above and five 96-well plates were screened for CD40L binding using the soluble protein screening assay described above. Positive hits were identified relative to the signal obtained for the 311K4E backbone variant. The 18 top scoring unique clones were designated 311K4E_1, 311K4E_2, 311K4E_3, 311K4E_4, 311K4E_5, 311K4E_7, 311K4E_8, 311K4E_9, 311K4E_10, 311K4E_11, 311K4E_12, 311K4E_13, 311K4E_14, 311K4E_15, 311K4E_16, 311K4E_19, 311K4E_20 and 311K4E_21 (sequences shown in Figures 12A and 12B) and assayed for off-rate ranking as crude unpurified proteins. Off-rate estimation of the unpurified Tn3 scaffold was performed on a ProteOn XPR36 Protein Interaction Array System (Bio-Rad, Hercules, CA) in a biosensor assay with CD40L immobilized on a chip. Mega human CD40L was immobilized on a GLC chip (BioRad) and all variants were diluted to an estimated concentration of 80 nM and injected for 300 s at a flow rate of 30 μl / min with dissociation time set at 1200 s. PBS, 0.005% Tween 20, 3 mM EDTA, pH 7.4 was used as the running buffer. Off-rates were ranked by visual inspection of the sensorgrams. A subset of four variants, 311K4E_3, 311K4E_11, 311K4E_12 and 311K4E_15, that showed the slowest off-rates were purified and analyzed using a 311K4E_20 antibody. d Values ​​ranging from 1.1 to 6.4 nM were measured (Table 9). [Table 9]

[0400] As shown in FIG. 10D, the K d The decrease in (18 nM to 1 nM) corresponds to a 12-fold increase in potency in the PBMC assay relative to the 311K4E scaffold.

[0401] Taken together, lead optimization studies of the initial hits 309 and 311 from the naive library yielded single-digit nM binders of CD40L.

[0402] Similar optimization studies were performed on the murine-specific M13 molecule (data not shown). The resulting optimized murine CD40L-specific molecule, designated M31, showed an approximately 20-fold increase in potency in the PBMC assay compared to the parent molecule (Figure 1A).

[0403] Example 4 Expression and purification of untagged CD40L-specific Tn3-HSA fusion The Tn3 constructs fused to HSA outlined in Figures 2A and 9A were expressed by transient transfection in mammalian 293F cell lines. The Tn3-HSA fusion expression constructs were generated based on an in-house generated mammalian expression vector. To increase product homogeneity, a mutant form of HSA in which the unpaired partially exposed cysteine ​​34 was mutated to serine (designated HSA C34S) (Zhao et al., 2009, Eur. J. Pharm. Biopharm. 72:405-11) was used.

[0404] The fusion protein can be purified in a single step by ion exchange chromatography (IEX). An example of elution of 309-309-HSA from a Q-HP column (GE HealthCare) with a salt gradient is shown in Figure 9B. In addition to the main peak, minor peaks eluting later were identified (constituting less than 10% of the total peak area). Mass spectrometry showed that these minor side peaks were enriched for O-glycosylated 309-309-HSA species. Fractions containing the main peak were pooled and used for subsequent activity assays.

[0405] For large-scale purification, the Tn3-HSA fusion from the culture supernatant was captured by affinity chromatography using an HSA affinity matrix, e.g., HiTrap Blue HP (GE HealthCare), prior to the IEX step. After washing, the HSA fusion protein could be eluted with an octenoic acid-containing buffer. The eluate was diluted 3-fold in phosphate buffer before loading onto a Q-HP column.

[0406] Analysis of the minor peaks revealed the presence of O-linked carbohydrate moieties, and it was proposed that the O-glycans were a heterogeneous mixture of carbohydrates derived from a previously reported O-xylosylated core structure (Wakabayashi et al., 1999, J. Biol. Chem. 274:5436-5442) shown below. [ka]

[0407] The major binding site was determined to be in the GGGGS linker between the Tn3 domains. Glycans were also found to be present to a lesser extent in the GGGGS linker found between Tn3 and HSA. Thus, the level of O-glycans was higher in the bivalent constructs compared to the monovalent constructs and in material produced in HEK cells compared to CHO cells. The levels also varied between different Tn3 constructs. Thus, the level of O-glycans can be reduced through careful host cell selection, for example, the use of CHO cells or other cells found to produce material with lower levels of O-glycans. Additionally, material containing O-glycans can be removed through purification methods to obtain a more homogenous product lacking O-glycans. Alternatively, the linker can be modified to remove the major O-glycan binding site, for example, by mutating a Ser residue to Gly. The linkers in some constructs were re-engineered to have one or more GGGGG linkers. No O-glycans of any type were detected in the material with the GGGGG linker and no differences in activity were identified (data not shown).

[0408] Example 5 Extending the serum half-life of a CD40L-specific Tn3 scaffold Fusion to serum albumin was utilized as a strategy to extend the serum half-life of the CD40L-specific Tn3 scaffold. Mouse PK assays were performed to measure the pharmacokinetic (PK) properties of murine CD40L-specific Tn3-MSA fusions. MSA fusions were chosen for testing of surrogate molecules to the corresponding HSA fusions because mouse FcRn binds to HSA much weaker than it does to MSA, resulting in reduced recycling from endosomes and consequently increased turnover (Andersen et al. J. Biol. Chem. 285, 4826-4836, 2010).

[0409] HEK293 cells were used to express mouse CD40L-specific tandem bivalent Tn3 scaffolds fused to MSA. High levels of expression were observed (Figure 3A). These constructs have (G 4 S) linker and three (G 4 The M13 and M31 scaffolds each had a linker between the N-linked glycosylation site and the S) repeat. Additionally, an N49Q mutation was introduced into each of the M13 and M31 scaffolds to remove a potential N-linked glycosylation site. This mutation did not affect the potency of these scaffolds (data not shown). Expression levels were estimated to be 200 mg / L 6 days after transfection. Purification was performed by IMAC via the C-terminal His tag. The yield of purified protein was estimated to be 125 mg per L of culture supernatant.

[0410] When MSA was fused to the bivalent M13 scaffold, an 8-fold decrease in potency was observed compared to the M13 dimer scaffold without MSA (Figure 3B). The bivalent scaffold containing affinity matured M31 fused to MSA was 140-fold more potent than the corresponding bivalent M13 scaffold fused to MSA, approximately 900-fold more potent than the monovalent M31MSA fusion, and had a potency comparable to that of the MR1 anti-murine CD40L monoclonal antibody (Figure 3C).

[0411] To determine the PK properties of the CD40L-specific Tn3-MSA fusion, mouse PK analysis was performed. Protein constructs were administered intravenously at 10 mg / kg into 5-7 week old female CD-1 mice. Each mouse was bled with 150 μl at various time points and serum concentrations of Tn3-HSA fusion were measured by ELISA assay. Briefly, Nunc MaxiSorp plates were coated with anti-FLAG M2 antibody (Agilent), blocked in 4% milk in PBS + 0.1% Tween (PBST) and incubated with murine MegaCD40L (Axxora). MegaCD40L was immobilized via its FLAG tag. Serum samples and protein standards were diluted in 4% milk PBST and added after washing the plates in PBST. After incubation, the plates were washed in PBST and the Tn3-HSA fusion construct was detected using rabbit anti-TN3 polyclonal antibody (Covance) and goat anti-rabbit HRP-conjugated antibody (Jackson ImmunoResearch) in a standard ELISA protocol. The concentration in serum samples was determined based on linear regression of a standard curve generated by assaying dilutions of the same Tn3-HSA fusion construct. The concentration was determined as the average for three different mice.

[0412] As seen in Figure 4A, M31-MSA and M13-M13-MSA had half-lives of 38 and 31 hours, respectively, while the M31-M31-HSA construct had a half-life of 12 hours. In comparison, the M13-M13 tandem construct by itself (not fused to MSA) exhibited a half-life of 30 minutes (not shown).

[0413] In contrast to the observations with the mouse scaffold, there was no significant decrease in potency when HSA was fused to the human CD40L-specific scaffold. Figure 9C shows that there was no significant decrease in potency by fusing the human CD40L-specific bivalent Tn3 scaffold containing two 309 monomers to HSA, as measured in the PMBC assay.

[0414] The PK properties of a human CD40L-specific 342-HSA monomer construct were compared to that of a 342-HSA variant containing two substitutions (L463N and K524L) to improve serum half-life in cynomolgus monkeys after a single intravenous injection. The protein construct was administered to male cynomolgus monkeys weighing 2-5 kg ​​at 10 mg / kg via slow bolus injection. 1 mL of blood / animal / time point was collected from the peripheral vein pre-dose, 5 and 30 min post-dose; 2, 12, 24, and 48 h post-dose; and on days 4, 8, 11, 15, 22, 29, 36, 43, and 57. Serum concentrations of the Tn3-HSA fusion were measured by ELISA assay. Briefly, Nunc MaxiSorp plates were coated with anti-FLAG M2 antibody (Agilent), blocked in 4% milk in PBS + 0.1% Tween (PBST), and incubated with human MegaCD40L (Axxora). MegaCD40L was immobilized via its FLAG tag. Serum samples and protein standards were diluted in 4% milk PBST and added after washing the plates in PBST. After incubation, the plates were washed in PBST and the Tn3-HSA fusion construct was detected using rabbit anti-TN3 polyclonal antibody (Covance) and goat anti-rabbit HRP-conjugated antibody (Jackson ImmunoResearch) in a standard ELISA protocol. Concentrations in serum samples were determined based on linear regression of a standard curve generated by assaying dilutions of the same Tn3-HSA fusion construct. Concentrations are plotted in Figure 4B. The half-life of the 342-HSA construct was approximately 7 days, while the 342-HSA L463N / K524L variant construct showed an increased half-life of 13-17 days during the initial linear phase (Figure 4B). After 30 days, serum concentrations of the 342-HSA L463N / K524L variant construct dropped sharply compared to the wild-type HSA construct. These observations may indicate some immunogenicity of this construct in monkeys.

[0415] Example 6 Characterization of the CD40L-specific Tn3 scaffold 6.1 Experimental Methods 6.1.1 PBMC Stimulation Assay: Blood was obtained from healthy donors according to MedImmune safety guidelines. PBMCs were isolated via CPT tubes (1500 g spin for 20 min) and 1×10 6 PBMCs (per condition) were stimulated with recombinant human MegaCD40L (Axxora) or human CD40L-expressing Jurkat cells (D1.1, ATCC). The percentage of CD19+ / CD86+ cells was measured by FACS 24 hours after stimulation. This assay was used to test and rank a panel of leading Tn3 scaffolds emerging from prioritization based on biochemical criteria. This assay can also be performed using a murine CD40L-expressing cell line (D10.G4) or murine MegaCD40L (Axxora ALX522120) instead of human cell or recombinant protein stimulation, since the murine ligand cross-reacts with the human receptor.

[0416] 6.1.2 Murine CD40R / NFκB Assay: NFκB reporter NIH3T3 cells (Panomics NFκB reporter system and in-house mCD40R transfection) were stimulated with murine MegaCD40L (Axxora, Cat. No. ALX522120) recombinant protein or CD40L overexpressing D10.G4 cells (ATCC) with or without Tn3 scaffold for 24 hours. Bright-Glow (Promega E2610) was added according to the manufacturer's instructions. The readout was luminescence (700) via NFκB reporter activation performed on an EnVision system (Perkin Elmer).

[0417] 6.1.3 Human CD40R / NFκB Assay: Reporter HEK293 cells (Panomics and in-house) were stimulated with MegaCD40L (Axxora ALX522110) recombinant protein or CD40L overexpressing D1.1 Jurkat subclone cells (ATCC) with or without Tn3 scaffold for 24 hours. Bright-Glow (Promega E2610) was added according to the manufacturer's instructions. Readout was luminescence (700) via NFκB reporter activation performed on an EnVision system (Perkin Elmer).

[0418] 6.1.4 Dual cell assay: Primary T / B cells were isolated from different donors. Anti-CD3 stimulated mitomycin C treated human CD4+ T cells (1×10 5 ) and purified human B cells (5 × 10 4 The readouts were as follows: day 2: activation markers (FACS), day 5: B cell proliferation (ATP metabolites, Cell-Titer Glo, Invitrogen), day 7: plasma cell differentiation (FACS), day 7: Ig production (ELISA, R&D Systems).

[0419] 6.1.5 Platelet aggregation assay: Adenosine diphosphate (ADP) was from Chrono-Log (Havertown, PA, USA). All other products were at least reagent grade. Blood samples were collected from healthy subjects in 12.9 mM sodium citrate and centrifuged at 150×g for 15 min to obtain PRP (platelet rich plasma). After separation of PRP, the tubes were centrifuged again at 1,200×g for 15 min to obtain PPP (platelet poor plasma). Platelets were washed using the method described by Mustard et al. (Br. J. Haematol. 22:193-204, 1972) and CaCl 2 2 mM MgCl 2Platelets were resuspended in Tyrode's solution, pH 7.35, containing 1 mM, 0.1% dextrose, 0.35% bovine serum albumin, and 0.05 U / mL apyrase. Platelet aggregation was examined using a light transmission aggregometer (Chrono-Log 700-4DR, Chrono-Log Corporation, Havertown, PA, USA) and recorded for 10 min after stimulation of platelets with the indicated platelet agonists as described. Tn3 scaffolds were preincubated with soluble CD40L (sCD40L) to form immune complexes before addition.

[0420] 6.1.6 Immunization assay: Sheep red blood cells (SRBCs) were purchased from Colorado Serum (Denver, CO) and diluted 10-fold in HBSS media immediately prior to use. Mice were immunized with 0.2 ml of diluted SRBCs on day 0. Primary germinal center (GC) responses in challenged mice were assayed 14 days post-immunization via FACS (GC B cells, non-GC B cells, and all T cell subsets). Tn3 scaffolds and controls were administered in escalating 24-hour increments as indicated on days 9-13.

[0421] 6.1.7 KLH-Specific T-Cell Dependent Antibody Response (TDAR) Assay: Cynomolgus monkeys (Macaca fascicularis) from China (Covance Research Products, Alice TX) weighing 3.1-4.6 kg were dosed intravenously (saphenous or cephalic vein) once weekly with the indicated doses (0.5, 5, 40 mg / kg) of inhibitors (342-monomeric-Tn3-HSA and 342-342 bivalent-Tn3-HSA or control / vehicle). KLH (Lot No. MD158678A, Supplier Pierce Biotechnologies, Rockford, Illinois) was diluted with an appropriate volume of sterile water for injection (Supplier Midwest Veterinary Medicine, Rockford, Illinois) and diluted with 0.1 ml of 0.0 ... The vials were reconstituted under sterile conditions using a 50% KLH solution (Provided by Sigma-Aldrich Supply, Norristown, Pennsylvania). The vials were vortex mixed and then pooled together in a sterile vial. One mL of KLH solution (10 mg / mL) was administered subcutaneously on the back of each animal, left of the midline at two time points (days 1 and 29), within 1 hour of the end of test or control article administration. Blood samples for further analysis were obtained from all animals at the following time points: pre-study, days 4, 6, 8, 11, 15, 22, 25, 32, 34, 36, 39, 43, 46, 50 and 57. Samples collected on days 8, 15 and 22 Blood samples were taken prior to dosing. Assessment of LH-specific IgM and IgG antibody titers was performed on days 8, 11, and 15. KLH-specific IgM and IgG antibody titers on day 15 are shown in Figures 5G and 5H, respectively. The cut-point titration method utilized an ELISA format to detect anti-KLH antibodies in monkey sera. Samples were incubated with immobilized KLH on ELISA plates. After incubation, plates were washed and bound antibodies were detected with goat anti-monkey IgG-HRP or IgM-HRP, followed by visualization with tetramethylbenzidine (TMB).

[0422] For all experiments utilizing animals, currently acceptable practices of good animal husbandry were followed, e.g., Guide for the Care and Use of Laboratory Animals; National Academy Press, 2011. Huntingdon Life Sciences, East Millstone, New Jersey, is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Animals were monitored by technical staff for any conditions requiring possible veterinary care and treated as necessary.

[0423] 6.2 The CD40L-specific Tn3 scaffold functionally neutralizes the CD40L:CD40 interaction.

[0424] CD40L-expressing T cells engage CD40-expressing B cells, leading to activation of the NFκB signaling pathway (Zangani, 2009). Therefore, an NFκB-luciferase reporter cell system was used to determine whether anti-CD40L-Tn3 molecules could inhibit signaling downstream of CD40 engagement. HEK293 cells expressing human CD40L and a reporter were transfected with either human or murine MegaCD40L for EC 90 (effective concentration resulting in 90% inhibition; ie, 1.5 μg / ml for human MegaCD40L and 3 μg / ml for murine MegaCD40L).

[0425] The human-specific 342 molecule inhibited human CD40L-induced NFκB activity with an IC of 1.5 nM. 50 The murine-specific M31 molecule inhibited murine CD40L-induced NFκB activity with IC 50 = 1.6 nM (Figure 1B). Positive control anti-CD40L monoclonal antibodies 5c8 (anti-human CD40L) and MR1 (anti-murine CD40L) both performed approximately 10-fold better than the monomeric Tn3 scaffold, with IC50 was 0.200 nM + / - SD (the lowest threshold of the assay), which could be attributed, in part, to the bivalent nature of the monoclonal antibodies, which contributed to the avidity of their respective interactions with CD40L.

[0426] 6.3 Dimeric CD40L-specific Tn3 scaffolds show improved binding.

[0427] The experimental data show that the binding of the CD40L-specific Tn3 bivalent scaffold was improved compared to that of the CD40L-specific Tn3 monomeric scaffold. The binding of the CD40L-specific Tn3 bivalent scaffold to CD40L improved the effect on targets in vitro by about 3 logs compared to that of the CD40L-specific Tn3 monomeric scaffold, in some cases, as shown in Figures 2C and 2D (murine) and Figures 8A and 8B (human).

[0428] FIG. 2C shows competitive inhibition of murine CD40L binding to murine CD40 receptor immobilized on a biosensor chip by murine CD40L-specific monovalent (M13) or bivalent tandem scaffolds. M13 monomers were attached by peptide linkers of varying length containing one (1GS), three (3GS), five (5GS) or seven (7GS) "GGGGS" repeats. IC of M13-1GS-M13 scaffolds 50 The IC of the monomeric M13 scaffold was 29 nM. 50 The IC of the bivalent M13 scaffold using a longer linker was 71 nM. 50 was significantly lower (5–6 nM).

[0429] Figure 2D shows the inhibitory effect of murine CD40L-specific monovalent (M13) or bivalent tandem scaffolds on murine CD40L-induced CD86 expression on B cells. The bivalent scaffolds were approximately 3 logs more potent than the monovalent scaffolds.

[0430] Figures 8A and 8B show that the human CD40L-specific Tn3 scaffolds 309 and 311 shown improved potency of the bivalent tandem format. The bivalent 311 scaffold (Figure 8A) and the bivalent 309 scaffold (Figure 8B) showed approximately 7-fold and 500-1000-fold improvement, respectively, in inhibiting human CD40L-induced expression on CD19-positive human PBMCs stimulated by Jurkat D1.1 cells. The bivalent 309 scaffold was comparable in potency to Biogen's 5c8 anti-human CD40L monoclonal antibody.

[0431] Solubility, stability and ease of purification were unaffected by the addition of peptide linkers of varying lengths containing one (1GS), three (3GS), five (5GS) or seven (7GS) "GGGGS" repeats (see Figure 2B).

[0432] 6.4 CD40L-specific Tn3 scaffold binding and function In addition to the biochemical binding described above, it was important to confirm that these novel Tn3 scaffolds could bind to endogenous CD40L expressed on primary T cells after activation. T cells were isolated from multiple donors and activated as described above. After 24 hours, CD40L expression was upregulated as determined by staining with 5c8 (human-specific) and MR1 (murine-specific) monoclonal antibodies (data not shown). CD40L-specific Tn3 scaffold molecules could detect CD40L expression at levels comparable to monoclonal antibodies, confirming that these molecules could bind to native proteins.

[0433] One of the functional consequences of CD40L:CD40 interaction is the upregulation of costimulatory molecules on B cells (Yellin et al., J. Exp. Med. 6:1857-1864, 1995). CD40L-directed Tn3 molecules were tested for their blocking ability. Cell lines that endogenously express human or murine CD40L (D1.1 Jurkat subclone or D10.G4, respectively) were used to stimulate peripheral blood mononuclear cells (PBMCs). Upon stimulation, B cell activation was assessed by measuring the percentage of CD86 upregulation by CD19+ B cells via flow cytometry. In this assay, positive control monoclonal antibodies increased the CD19+ percentage of cells with CD86 expression with IC of 0.170 nM (5c8) and 0.230 nM (MR1). 50 Human-specific optimized Tn3,342 inhibited CD86 upregulation with IC 50 Value = 0.700 nM (n = 5 donors) (see Figure 10B and Table 7).

[0434] Murine-specific optimized Tn3M31 has an IC of 1.5 nM 50 These similar results were observed when Mega-CD40L recombinant protein was used to stimulate PBMCs. The experimental data demonstrated that both molecules, whether murine or human specific, were able to inhibit not only the main signaling pathway (NFκB) in the cells, but also one of its most important functional roles: TB cell interaction. This inhibitory effect may attenuate the contribution of CD40L in many autoimmune diseases and pathologies.

[0435] 6.5 Anti-CD40L Tn3 inhibits B cell proliferation and plasma cell differentiation after T / B coculture.

[0436] The interaction of CD40L on T cells with CD40-expressing B cells is a fundamental aspect of T cell help that facilitates the development of adaptive immune responses (Banchereau, 1994; Oxenius, 1996, van Kooten & Banchereau, 1997). To model this, anti-hCD40L Tn3-HSA fusions of 340, 342 and 342-342 dimers were evaluated in primary co-cultures of T and B cells, where anti-CD3 stimulated mitomycin C-treated human CD4+ T cells were cultured with purified human B cells. The ability of B cells to proliferate at day 4, differentiate into plasma cells (PC) by day 7 and switch the antibody class they produced was measured (PC and antibody data not shown) (Figure 15) (Ettinger, 2007). The CD40L-specific Tn3 scaffold 342-342-HSA could reduce T cell-induced proliferation by at least 50% compared to the proliferation of B cells in the absence of scaffold or in the presence of a non-specific control scaffold. Proliferation is one of the precursor signals of plasma cell differentiation upon CD40L:CD40 ligation. Inhibition of plasma cell differentiation and antibody class switching (data not shown) was also observed.

[0437] 6.6 In vivo disruption of the CD40:CD40L axis The central role of CD40L:CD40R interactions in T-dependent immune responses has been well characterized (Noelle, 1992; Renshaw, 1994, Wykes, 2003). We assessed the effect of these novel molecules in a T-dependent immunization model by immunizing mice (intravenously) with sheep red blood cells (SRBC) on day 0 using the murine CD40L-specific Tn3 scaffold M31 (M31-MSA and M31-M31-MSA).

[0438] Mice were injected intraperitoneally daily with the indicated doses of inhibitors on days 9–13, and splenic and lymph node GC B cells were quantified on day 14. 1 / 2Daily dosing was required given the dose (Figure 4). It is well established from previous findings that CD40L controls humoral responses, e.g., the generation of germinal centers in anatomical sites such as the spleen and lymph nodes (Jacob, 1991). Here, disruption of the contribution of the CD40L:CD40 axis to their formation, as indicated by the percentage of GC B cells, was observed in a dose-dependent manner for M31-MSA versus naive or our non-specific control D1-MSA.

[0439] M31-MSA, even at 10 mg / kg, eliminated a proportion of GC B cells (Figure 5B) similar to the MR1 monoclonal antibody (Figure 5A). Other subpopulations of cells, such as specific T cell populations, appeared normal, confirming that the observations were not due to T cell depletion (Figures 5C, 5D, and 5E). Furthermore, results from anti-SRBC Ig ELISA data mirrored those of the germinal center B cell data (Figure 5F). Taken together, these data demonstrated that the murine-specific Tn3 scaffold M31-MSA could resolve responses driven via CD40 signaling.

[0440] Similarly, the effect of these novel molecules was evaluated in a KLH-specific T cell-dependent antibody response (TDAR) model in cynomolgus monkeys using human CD40L-specific Tn3 scaffold 342 (342-HSA and 342-342-HSA). Here, disruption of the CD40L:CD40 axis results in dose-dependent suppression of antibody production against the KLH antigen. As shown in Figures 5G and 5H, the 342-bivalent construct suppressed IgM and IgG antibody levels at 0.5 mg / kg (mpk), with near-complete suppression observed at 5 mg / kg. The 342-monomer construct also suppressed IgM and IgG levels, but at higher concentrations, near-complete suppression was observed at 40 mg / kg. These data indicated that both human-specific Tn3 scaffold constructs 342-HSA and 342-342-HSA could resolve responses driven via CD40 signaling.

[0441] 6.7 The human CD40L-specific Tn3 scaffold does not induce platelet aggregation.

[0442] A human clinical trial using an anti-CD40L monoclonal antibody was halted when thromboembolic events occurred in several patients (Davidson et al. Arth Rheu, 43:S271). Subsequent preclinical analysis suggested that this was an on-target class effect of the anti-CD40L monoclonal antibody. It was therefore important to test the human CD40L-specific Tn3 scaffold in a platelet aggregation assay.

[0443] Proaggregation-promoting effects were observed in citrated platelet-rich plasma (PRP), washed platelets, and whole blood when a ratio of three molecules of physiological CD40L to one molecule of anti-CD40L monoclonal antibody was used (Figure 16A). These effects were mediated by monoclonal antibody Fc domain-dependent interactions after CD40L binding (data not shown). In the absence of Fc domain fusions, no aggregation was observed. No aggregation was observed in multiple donors for either the human CD40L-specific Tn3 scaffold as a dimer or as an HSA fusion protein (Figures 16B and 16C).

[0444] Adverse side effects observed in clinical trials were observed by creating soluble CD40L / anti-CD40L monoclonal antibody immune complexes in the presence of platelets (Figure 16A and 5C8 trace on Figure 16C). Another example of this can be seen in the histology of transgenic human FcγRIIa murine studies (Francis et al., 2010). Upon administration of soluble CD40L / monoclonal antibody immune complexes, numerous thrombi were identified in the lung tissue within minutes of administration. However, normal tissue structures were present in the lungs consistent with control samples when overlapped with anti-CD40L Tn3 scaffolds (data not shown).

[0445] Example 7 Fibronectin type III domains engineered to bind CD40L: Cloning, expression, purification, crystallization, and preliminary X-ray diffraction analysis of two complexes. Recombinant human soluble CD40L was co-crystallized with two CD40L-specific Tn3 monomer scaffolds, 309 and 311K4E-12, both isolated from a phage display library as CD40L binders. The crystals diffracted to 3.1 and 2.9 Å, respectively. Additionally, recombinant human soluble CD40L was co-crystallized with optimized Tn3 monomer 342 alone and both the 342 and 311K4E_12 monomers. Crystals for these structures diffracted to 2.8 and 1.9 Å, respectively. The corresponding crystal structures aid in understanding the interaction of the Tn3 scaffold with CD40L and can be used to design higher affinity CD40L binders and tandem constructs that bind multiple epitopes.

[0446] 7.1 Expression and purification of Tn3 molecules and human soluble CD40L To produce untagged Tn3 molecules for crystallization, proteins were expressed in E. coli using an in-house IPTG-inducible vector designed to secrete recombinantly expressed proteins into the periplasmic space. This vector contains a Ptac promoter, an OppA signal peptide mutant L25 / M (MTNITKRSLVAAGVLAALMAGNVAMA) (SEQ ID NO: 210), a C-terminal 8xHis tag in addition to a thrombin cleavage site. Tn3 sequences were subcloned between the signal peptide and the thrombin cleavage site.

[0447] The expressed secreted His-tagged protein was purified using Ni-NTA resin according to the manufacturer's instructions (Qiagen, Valencia, California, USA), then cleaved with thrombin, followed by another Ni-NTA affinity purification to remove uncleaved intact protein and cleaved His-tagged fragments. This purification step was followed by an ion-exchange step using a HiTrap Q column (GE Healthcare, Piscataway, New Jersey, USA) run on an Aekta Purifier (GE Healthcare, Piscataway, New Jersey, USA). The purified untagged Tn3 protein shows a purity and homogeneity of more than 95% based on SDS-PAGE and SEC results.

[0448] The human soluble CD40L (113-261, UNIPROT:P29965) gene was synthesized by GeneArt with an N-terminal 6xHis tag and cloned into an in-house mammalian expression vector under the control of the cytomegalovirus major immediate early (hCMVie) promoter (Boshart et al., Cell 41:521-530, 1985). The CD40L gene was cloned in frame with the CD33 signal peptide. The EBNA and OriP genes in the vector were used to increase protein expression. The CD40L gene also incorporated an SV40 polyA sequence to allow proper processing of its mRNA 3' end. The construct was transiently transfected into 293F suspension cells (human embryonic kidney cells [HEK] grown in 293Freestyle medium using 293Fectin, Invitrogen, Carlsbad, California, USA). Cells were grown using standard protocols and medium was harvested after 4 and 8 days. Soluble CD40L protein was then purified using Ni-NTA resin, followed by an ion exchange step using a Hi-Trap SP FF column (GE Healthcare, Piscataway, New Jersey, USA) and dialysis against 50 mM Tris pH 7.5, 50 mM NaCl.

[0449] To prepare the complex, Tn3 molecules, either 309 or 311K4E_12 or 342, were mixed with CD40L in a 1.1:1 ratio, concentrated to approximately 10 mg / ml using a Vivaspin concentrator (30,000 Da cutoff; GE Healthcare, Piscataway, New Jersey, USA) and subjected to size exclusion chromatography (SEC) using a Superdex200 10 / 300GL column (GE Healthcare, Piscataway, New Jersey, USA) pre-equilibrated with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.02% NaN3 (Figure 19, panel A). After the separation step, the complex was concentrated to 18 mg / ml and subjected to crystallization. The 342-311K4E_12-CD40L complex was prepared essentially as described above using a 1.1:1.1:1 ratio of the three components.

[0450] 7.2 Crystallization Screening and Optimization Sitting drop crystallization experiments were set up in 96-well Intelli plates (Art Robbins Instruments, Sunnyvale, California, USA) using a Phoenix crystallization robot (Art Robbins Instruments, Sunnyvale, California, USA) by mixing 300 nL volumes of well solution and protein complex solution in the droplet compartment and equilibrating it against 50 μL of well solution. Commercial crystallization screens from Hampton Research (Aliso Viejo, California, USA), Emerald BioSystems (Bainbridge Island, Washington, USA) and Molecular Dimensions (Apopka, Florida, USA) were used.

[0451] Crystallization of the 309-CD40L, 342-CD40L and 342-311K4E_12-CD40L complexes each required an optimization step that included an additional screening using Additive Screen HT (Hampton Research, Aliso Viejo, California, USA). In the optimization step, well solutions of a 96-well plate were filled with 80% of the successful solutions from the first screening and 20% of the respective additive. Droplets were formed from 300 nL of protein solution and 300 nL of new well solution after thorough mixing of the latter. Diffractive crystals were directly collected from the 96-well plate. For frozen storage, the crystals were transferred into three successive solutions of mother liquor with increasing glycerol concentrations.

[0452] Diffraction-quality 311-CD40L crystals were grown in the first screen from solutions that did not require the addition of cryogens.

[0453] 7.3 X-ray diffraction and data collection X-ray diffraction patterns for the 309-CD40L complex were collected from single crystals in a Beamline 5.0.3 at the Advanced Light Source at Lawrence Berkeley National Laboratory (University of California, Berkeley) equipped with an ADSC Q315R CCD X-Ray detector (Area Detector Systems Corporation, Poway, California, USA). 360 consecutive images with an oscillation range of 0.5° were collected at a crystal-to-detector distance of 300 mm and an exposure time of 0.8 s.

[0454] X-ray diffraction...

Claims

1. A Tn3 scaffold comprising a CD40L-specific monomeric subunit, the monomeric subunit comprising seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, which specifically binds to CD40L.

2. The Tn3 scaffold of claim 1 , comprising a single CD40L-specific monomeric subunit.

3. The Tn3 scaffold of claim 1 , comprising two CD40L-specific monomeric subunits linked in tandem.

4. The Tn3 scaffold of claim 3 , wherein the two CD40L-specific monomeric subunits are directly linked.

5. The Tn3 scaffold of claim 3 , wherein the two CD40L-specific monomeric subunits are linked by a linker.

6. The Tn3 scaffold of claim 5 , wherein the linker comprises a peptide linker.

7. The Tn3 scaffold of claim 6 , wherein the peptide linker is a flexible peptide linker.

8. The peptide linker is ｍ X) ｎ The sequence (a) X is serine (S), alanine (A), glycine (G), Leu (L), isoleucine (I), or valine (V); (b) m and n are integers; (c) m is 1, 2, 3 or 4; (d) n is 1, 2, 3, 4, 5, 6, or 7.

8. The Tn3 scaffold of claim 7, comprising:

9. 9. The Tn3 scaffold of claim 8, wherein the peptide linker comprises SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:142 or SEQ ID NO:

143.

10. The Tn3 scaffold of claim 3 , wherein binding of the scaffold to CD40L is improved compared to that of a Tn3 scaffold comprising a single CD40L-specific monomeric subunit.

11. The Tn3 scaffold of claim 3 , wherein binding of the scaffold to CD40L improves the effect on the target compared to that of a Tn3 scaffold comprising a single CD40L-specific monomeric subunit.

12. The Tn3 scaffold of claim 10, wherein the improved binding to CD40L is improved binding affinity, improved binding avidity, or both.

13. The Tn3 scaffold of claim 10, wherein the binding affinity and protein stability for CD40L is improved compared to those of a Tn3 scaffold comprising a single CD40L-specific monomeric subunit.

14. The Tn3 scaffold of claim 10, wherein the binding avidity and protein stability for CD40L is improved compared to those of a Tn3 scaffold comprising a single CD40L-specific monomeric subunit.

15. The Tn3 scaffold of any one of claims 1 to 9, wherein at least one CD40L-specific monomeric subunit is attached to a linker or to a heterologous moiety.

16. 16. The Tn3 scaffold of claim 15, wherein a linker or heterologous moiety is conjugated to the N-terminus or C-terminus of the scaffold.

17. 17. The Tn3 scaffold of claim 15 or 16, wherein the linker comprises a peptide linker.

18. 18. The Tn3 scaffold of claim 17, wherein the peptide linker is a flexible peptide linker.

19. The peptide linker is ｍ X) ｎ The sequence (a) X is serine (S), alanine (A), glycine (G), leucine (L), isoleucine (I), or valine (V); (b) m and n are integers; (c) m is 1, 2, 3 or 4; (d) n is 1, 2, 3, 4, 5, 6, or 7.

19. The Tn3 scaffold of claim 17 or 18, comprising:

20. 20. The Tn3 of claim 19, wherein the peptide linker comprises SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:142, or SEQ ID NO:

143.

21. The Tn3 scaffold of claim 15 , wherein the linker comprises a functional moiety.

22. 22. The Tn3 scaffold of claim 21 , wherein the functional moiety is an immunoglobulin or a fragment thereof.

23. 23. The Tn3 scaffold of claim 22, wherein the immunoglobulin or fragment thereof comprises an Fc domain.

24. The Tn3 scaffold of claim 23, wherein the Fc domain is incapable of inducing at least one FcγR-mediated effector function.

25. 25. The Tn3 scaffold of claim 24, wherein said at least one FcγR-mediated effector function is ADCC.

26. The Tn3 scaffold of claim 15 , wherein at least one CD40L-specific monomeric subunit is linked to a heterologous moiety.

27. 27. The Tn3 scaffold of claim 15 or 26, wherein the heterologous moiety comprises a composition selected from the group consisting of a protein, a peptide, a protein domain, a linker, a drug, a toxin, a cytotoxic agent, an imaging agent, a radionuclide, a radioactive compound, an organic polymer, an inorganic polymer, polyethylene glycol (PEG), biotin, albumin, human serum albumin (HSA), an HSA FcRn binding moiety, an antibody, a domain of an antibody, an antibody fragment, a single chain antibody, a domain antibody, an albumin binding domain, an enzyme, a ligand, a receptor, a binding peptide, a non-FnIII scaffold, an epitope tag, a recombinant polypeptide polymer, a cytokine, and a combination of two or more of the moieties.

28. 28. The Tn3 scaffold of claim 27, wherein at least one CD40L-specific monomer subunit is conjugated to PEG.

29. 28. The Tn3 scaffold of claim 27, wherein at least one CD40L-specific monomeric subunit is conjugated to albumin.

30. 30. The Tn3 scaffold of claim 29, wherein the albumin is human serum albumin (HSA).

31. 31. The Tn3 scaffold of claim 30, wherein the HSA is a variant HSA.

32. 32. The Tn3 scaffold of claim 31 , wherein the amino acid sequence of the variant HSA is SEQ ID NO:

133.

33. 32. The Tn3 scaffold of claim 31 , wherein the variant HSA has at least one improved property compared to native HSA or a native HSA fragment.

34. 34. The Tn3 scaffold of claim 33, wherein the improved property is an altered plasma half-life compared to the plasma half-life of native HSA or a native HSA fragment.

35. The Tn3 scaffold of claim 34, wherein the altered plasma half-life is a longer plasma half-life compared to the plasma half-life of native HSA or a fragment of native HSA.

36. The Tn3 scaffold of claim 34, wherein the altered plasma half-life is a shorter plasma half-life compared to the plasma half-life of native HSA or a fragment of native HSA.

37. 37. The Tn3 scaffold of any one of claims 31 or 33-36, wherein the HSA variant comprises at least one amino acid substitution in HSA domain III.

38. 38. The Tn3 scaffold of any one of claims 31 or 33-37, wherein the HSA variant comprises the sequence of full length mature HSA (SEQ ID NO: 133 or 138) or a fragment thereof, except for at least one amino acid substitution numbered relative to its position in full length mature HSA at a position selected from the group consisting of: 407, 415, 463, 500, 506, 508, 509, 511, 512, 515, 516, 521, 523, 524, 526, 535, 550, 557, 573, 574, and 580; wherein the at least one amino acid substitution does not include a substitution of lysine (K) to glutamic acid (E) at position 573, and has a plasma half-life greater than the plasma half-life of a Tn3 scaffold that is not conjugated to the HSA variant.

39. The Tn3 scaffold of claim 38, wherein the at least one amino acid substitution, numbered relative to its position in full-length mature HSA, is at a position selected from the group consisting of 463, 508, 523, and 524, and has a plasma half-life greater than the plasma half-life of a Tn3 scaffold not conjugated to the HSA variant.

40. The HSA variant comprises the sequence of full-length mature HSA (SEQ ID NO: 133 or 138), or a fragment thereof, with the proviso that: (a) substitution of leucine (L) with asparagine (N) or tyrosine (Y) at position 407; (b) substitution of valine (V) with threonine (T) at position 415; (c) substitution of leucine (L) with asparagine (N) at position 463; (d) substitution of lysine (K) with arginine (R) at position 500; (e) substitution of threonine (T) with tyrosine (Y) at position 506; (f) substitution of threonine (T) with arginine (R) at position 508; (g) substitution of phenylalanine (F) at position 509 with methionine (M) or tryptophan (W); (h) substitution of alanine (A) with phenylalanine (F) at position 511; (i) substitution of aspartic acid (D) with tyrosine (Y) at position 512; (j) substitution of threonine (T) with glutamine (Q) at position 515; (k) substitution of leucine (L) with threonine (T) or tryptophan (W) at position 516; (l) substitution of arginine (R) with tryptophan (W) at position 521; (m) substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (n) substitution of lysine (K) with leucine (L) at position 524; (o) substitution of glutamine (Q) with methionine (M) at position 526; (p) substitution of histidine (H) with proline (P) at position 535; (q) substitution of aspartic acid (D) with glutamic acid (E) at position 550; (r) substitution of lysine (K) with glycine (G) at position 557; (s) substitution of lysine (K) at position 573 with phenylalanine (F), histidine (H), proline (P), tryptophan (W), or tyrosine (Y); (t) substitution of lysine (K) with asparagine (N) at position 574; (u) substitution of glutamine (Q) with lysine (K) at position 580; and (v) a combination of two or more of the above substitutions. Except for at least one amino acid substitution numbered relative to its position in full-length mature HSA selected from the group consisting of:

39. The Tn3 scaffold of any one of claims 31 or 33-38, having a plasma half-life greater than the plasma half-life of a Tn3 scaffold that is not conjugated to said HSA variant.

41. The HSA variant comprises the sequence of full-length mature HSA (SEQ ID NO: 133 or 138), or a fragment thereof, with the proviso that: (a) substitution of leucine (L) with asparagine (N) at position 463; (b) substitution of threonine (T) with arginine (R) at position 508; (c) substitution of isoleucine (I) at position 523 with aspartic acid (D), glutamic acid (E), glycine (G), lysine (K), or arginine (R); (d) substitution of lysine (K) with leucine (L) at position 524; and (e) a combination of two or more of the above substitutions. Except for at least one amino acid substitution numbered relative to its position in full-length mature HSA selected from the group consisting of:

41. The Tn3 scaffold of claim 40, having a plasma half-life greater than the plasma half-life of a Tn3 scaffold that is not conjugated to said HSA variant.

42. A Tn3 scaffold according to any one of claims 3 to 14, comprising at least two identical CD40L-specific monomeric subunits.

43. A Tn3 scaffold according to any one of claims 3 to 15, comprising at least two different CD40L-specific monomeric subunits.

44. 44. The Tn3 scaffold of any one of claims 1 to 43, which is a CD40 receptor agonist.

45. 45. The Tn3 scaffold of any one of claims 1 to 44, which is a CD40 receptor antagonist.

46. A Tn3 scaffold according to any one of claims 3 to 14, wherein at least two CD40L-specific monomeric subunits specifically bind to the same CD40L epitope.

47. The Tn3 scaffold of any one of claims 3 to 14, wherein at least two CD40L-specific monomeric subunits specifically bind to different CD40L epitopes.

48. 48. The Tn3 scaffold of claim 47, wherein the different CD40L epitopes are non-overlapping epitopes.

49. 48. The Tn3 scaffold of claim 47, wherein the different CD40L epitopes are overlapping epitopes.

50. 50. A Tn3 scaffold according to any one of claims 1 to 49, which binds to at least two CD40L molecules.

51. 51. The Tn3 scaffold of any one of claims 1 to 50, wherein a single CD40L-specific monomeric subunit binds to at least two CD40L molecules.

52. 2. The Tn3 scaffold of claim 1, wherein the beta chain of at least one CD40L-specific monomeric subunit has at least 90% sequence identity with the beta chain of SEQ ID NO:

3.

53. 2. The Tn3 scaffold of claim 1, wherein the Abeta chain comprises SEQ ID NO: 11 except for at least one mutation.

54. 2. The Tn3 scaffold of claim 1, wherein the B beta chain comprises SEQ ID NO: 12 except for at least one mutation.

55. 2. The Tn3 scaffold of claim 1, wherein the C beta chain comprises SEQ ID NO: 13 or 14 except for at least one mutation, and wherein neither the cysteine ​​of SEQ ID NO: 13 nor the cysteine ​​of SEQ ID NO: 14 has been substituted.

56. 2. The Tn3 scaffold of claim 1, wherein the D beta strand comprises SEQ ID NO: 15, except for at least one mutation.

57. 2. The Tn3 scaffold of claim 1, wherein the E beta chain comprises SEQ ID NO: 16 except for at least one mutation.

58. 2. The Tn3 scaffold of claim 1, wherein the F beta chain comprises SEQ ID NO: 17 except for at least one mutation, and wherein the cysteine ​​of SEQ ID NO: 17 is not substituted.

59. 2. The Tn3 scaffold of claim 1, wherein the G beta chain comprises SEQ ID NO: 18 except for at least one mutation.

60. The CD40L-specific monomeric subunit has the amino acid sequence: IEV(X ＡＢ ) ｎ ALITW(X ＢＣ ) ｎ CELX １ YGI(X ＣＤ ) ｎ TTIDL(X ＤＥ ) ｎ YSI(X ＥＦ ) ｎ YEVSLIC(X ＦＧ ) ｎ KETFTT (In the formula, (a) X ＡＢ , X ＢＣ , X ＣＤ , X ＤＥ , X ＥＦ , and X ＦＧ represent amino acid residues present in the sequences of the AB, BC, CD, DE, EF, and FG loops, respectively; (b) X １ represents the amino acid residue A or T; (c) the length of the loop, n, is an integer from 2 to 26.

60. The Tn3 scaffold of any one of claims 1 to 59, comprising:

61. 61. The Tn3 scaffold of claim 60, wherein the sequence of the AB loop comprises SEQ ID NO:4 or SEQ ID NO:136, the sequence of the CD loop comprises SEQ ID NO:6, and the sequence of the EF loop comprises SEQ ID NO:8 or SEQ ID NO:

137.

62. 61. The Tn3 scaffold of claim 60, wherein the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87, 88, 89, 90, 91, 92.

63. 61. The Tn3 scaffold of claim 60, wherein the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 94, 95, 96, 97, 98, and 169.

64. 61. The Tn3 scaffold of claim 60, wherein the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 99, 139, and 170.

65. 61. The Tn3 scaffold of claim 60, wherein the sequence of the BC loop comprises a sequence selected from the group consisting of SEQ ID NOs: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, and 174.

66. 61. The Tn3 scaffold of claim 60, wherein the sequence of the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs: 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, and 175.

67. 61. The Tn3 scaffold of claim 60, wherein the sequence of the FG loop comprises a sequence selected from the group consisting of SEQ ID NOs: 129, 130, and 177.

68. (a) the sequence of the BC loop comprises SEQ ID NO:83, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (b) the sequence of the BC loop comprises SEQ ID NO:83, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:99; (c) the sequence of the BC loop comprises SEQ ID NO:84, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (d) the sequence of the BC loop comprises SEQ ID NO:85, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (e) the sequence of the BC loop comprises SEQ ID NO:86, the sequence of the DE loop comprises SEQ ID NO:96, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (f) the sequence of the BC loop comprises SEQ ID NO:87, the sequence of the DE loop comprises SEQ ID NO:97, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (g) the sequence of the BC loop comprises SEQ ID NO:88, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (h) the sequence of the BC loop comprises SEQ ID NO:89, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (i) the sequence of the BC loop comprises SEQ ID NO:90, the sequence of the DE loop comprises SEQ ID NO:94, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (j) the sequence of the BC loop comprises SEQ ID NO:91, the sequence of the DE loop comprises SEQ ID NO:95, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; (k) the sequence of the BC loop comprises SEQ ID NO:92, the sequence of the DE loop comprises SEQ ID NO:98, and the sequence of the FG loop comprises SEQ ID NO:9 or 139; or (l) the sequence of the BC loop comprises SEQ ID NO: 93, the sequence of the DE loop comprises SEQ ID NO: 94, and the sequence of the FG loop comprises SEQ ID NO: 9 or 139; 61. The Tn3 scaffold of claim 60.

69. (a) the sequence of the BC loop comprises SEQ ID NO:100, the sequence of the DE loop comprises SEQ ID NO:118, and the sequence of the FG loop comprises SEQ ID NO:129; (b) the sequence of the BC loop comprises SEQ ID NO:101, the sequence of the DE loop comprises SEQ ID NO:119, and the sequence of the FG loop comprises SEQ ID NO:129; (c) the sequence of the BC loop comprises SEQ ID NO:102, the sequence of the DE loop comprises SEQ ID NO:120, and the sequence of the FG loop comprises SEQ ID NO:129; (d) the sequence of the BC loop comprises SEQ ID NO:103, the sequence of the DE loop comprises SEQ ID NO:121, and the sequence of the FG loop comprises SEQ ID NO:129; (e) the sequence of the BC loop comprises SEQ ID NO:104, the sequence of the DE loop comprises SEQ ID NO:122, and the sequence of the FG loop comprises SEQ ID NO:129; (f) the sequence of the BC loop comprises SEQ ID NO:105, the sequence of the DE loop comprises SEQ ID NO:121, and the sequence of the FG loop comprises SEQ ID NO:129; (g) the sequence of the BC loop comprises SEQ ID NO:106, the sequence of the DE loop comprises SEQ ID NO:123, and the sequence of the FG loop comprises SEQ ID NO:129; (h) the sequence of the BC loop comprises SEQ ID NO: 107, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129; (i) the sequence of the BC loop comprises SEQ ID NO:108, the sequence of the DE loop comprises SEQ ID NO:118, and the sequence of the FG loop comprises SEQ ID NO:129; (j) the sequence of the BC loop comprises SEQ ID NO: 109, the sequence of the DE loop comprises SEQ ID NO: 123, and the sequence of the FG loop comprises SEQ ID NO: 129; (k) the sequence of the BC loop comprises SEQ ID NO:110, the sequence of the DE loop comprises SEQ ID NO:121, and the sequence of the FG loop comprises SEQ ID NO:129; (l) the sequence of the BC loop comprises SEQ ID NO:111, the sequence of the DE loop comprises SEQ ID NO:123, and the sequence of the FG loop comprises SEQ ID NO:130; (m) the sequence of the BC loop comprises SEQ ID NO:108, the sequence of the DE loop comprises SEQ ID NO:121, and the sequence of the FG loop comprises SEQ ID NO:129; (n) the sequence of the BC loop comprises SEQ ID NO:112, the sequence of the DE loop comprises SEQ ID NO:124, and the sequence of the FG loop comprises SEQ ID NO:129; (o) the sequence of the BC loop comprises SEQ ID NO:113, the sequence of the DE loop comprises SEQ ID NO:125, and the sequence of the FG loop comprises SEQ ID NO:129; (p) the sequence of the BC loop comprises SEQ ID NO:114, the sequence of the DE loop comprises SEQ ID NO:118, and the sequence of the FG loop comprises SEQ ID NO:129; (q) the sequence of the BC loop comprises SEQ ID NO:115, the sequence of the DE loop comprises SEQ ID NO:126, and the sequence of the FG loop comprises SEQ ID NO:129; (r) the sequence of the BC loop comprises SEQ ID NO:116, the sequence of the DE loop comprises SEQ ID NO:127, and the sequence of the FG loop comprises SEQ ID NO:129; or (s) the sequence of the BC loop comprises SEQ ID NO: 117, the sequence of the DE loop comprises SEQ ID NO: 128, and the sequence of the FG loop comprises SEQ ID NO: 129; 61. The Tn3 scaffold of claim 60.

70. 70. The Tn3 scaffold of claim 69, wherein the AB loop comprises SEQ ID NO:

136.

71. 69. The Tn3 scaffold of claim 68, wherein the CD40L-specific monomer subunit comprises a sequence selected from the group consisting of SEQ ID NOs: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 146.

72. The CD40L-specific monomeric subunit has the amino acid sequence: IEVKDVTDTTTALITWX １ D.X. ２ X ３ X ４ X ５ X ６ X ７ X ８ CELTYGIKDVPGDRTTIDLWX ９ HX １０ A.X. １１ YSIGNLKPDTEYEVSLICRX １２ GDMSSNPAKETFTT (SEQ ID NO: 167) (In the formula, (a) X １ represents the amino acid residue serine (S) or leucine (L); (b) X ２ represents the amino acid residue aspartic acid (D) or glutamic acid (E); (c) X ３ represents the amino acid residue histidine (H), isoleucine (I), valine (V), phenylalanine (F) or tryptophan (W); (d) X ４ represents the amino acid residue alanine (A), glycine (G), glutamic acid (E) or aspartic acid (D); (e) X ５ represents the amino acid residue glutamic acid (E), leucine (L), glutamine (Q), serine (S), aspartic acid (D) or asparagine (N); (f) X ６ represents the amino acid residues phenylalanine (F) or tyrosine (Y); (g) X ７ represents the amino acid residue isoleucine (I), valine (V), histidine (H), glutamic acid (E) or aspartic acid (D); (h) X ８ represents the amino acid residue glycine (G), tryptophan (W) or valine (V); (i) X ９ represents the amino acid residue tryptophan (W), phenylalanine (F) or tyrosine (Y); (j) X １０ represents the amino acid residue serine (S), glutamine (Q), methionine (M) or histidine (H); (k) X １１ represents the amino acid residue tryptophan (W) or histidine (H); (l) X １２ represents the amino acid residue arginine (R) or serine (S) 61. The Tn3 scaffold of claim 60, comprising:

73. 70. The Tn3 scaffold of claim 69, wherein the CD40L-specific monomer subunit comprises a sequence selected from the group consisting of SEQ ID NOs: 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, and 82.

74. The CD40L-specific monomeric subunit has the amino acid sequence: IEVX １ DVTDTTALITWX ２ X ３ RSX ４ X ５ X ６ X ７ X ８ X ９ X １０ CELX １１ YGIKDVPGDRTTID LX １２ X １３ X １４ X １５ YVHYSIGNLKPDTX １６ YEVSLICLTTDGTYX １７ NPAKETFTT (SEQ ID NO: 171) (In the formula, (a) X １ represents the amino acid residue lysine (K) or glutamic acid (E); (b) X ２ represents the amino acid residue threonine (T) or isoleucine (I); (c) X ３ represents the amino acid residue asparagine (N) or alanine (A); (d) X ４ represents the amino acid residue serine (S), leucine (L), alanine (A), phenylalanine (F) or tyrosine (Y); (e) X ５ represents the amino acid residue tyrosine (Y), alanine (A), glycine (G), valine (V), isoleucine (I) or serine (S); (f) X ６ represents the amino acid residue tyrosine (Y), serine (S), alanine (A) or histidine (H); (g) X ７ represents the amino acid residue asparagine (N), aspartic acid (D), histidine (H) or tyrosine (Y); (h) X ８ represents the amino acid residue leucine (L), phenylalanine (F), histidine (H) or tyrosine (Y); (i) X ９ represents the amino acid residue histidine (H), proline (P), serine (S), leucine (L) or aspartic acid (D); (j) X １０ represents the amino acid residue glycine (G), phenylalanine (F), histidine (H) or tyrosine (Y); (k) X １１ represents the amino acid residue alanine (A) or threonine (T); (l) X １２ represents the amino acid residue serine (S), asparagine (N), glutamic acid (E), asparagine (R) or aspartic acid (D); (m) X １３ represents the amino acid residue serine (S), glutamine (Q), threonine (T), asparagine (N) or alanine (A); (n) X １４ represents the amino acid residues proline (P), valine (V), isoleucine (I) or alanine (A) or no amino acid; (o) X １５ represents the amino acid residue isoleucine (I) or no amino acid; (p) X １６ represents the amino acid residue glutamic acid (E) or lysine (K); (q) X １７ represents the amino acid residue serine (S) or asparagine (N) 61. The Tn3 scaffold of claim 60, comprising:

75. A Tn3 scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 205, 206, 207 and 208.

76. A Tn3 scaffold consisting of a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 205, 206, 207 and 208.

77. A Tn3 scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 201, 202, 203, and 204.

78. A Tn3 scaffold consisting of a sequence selected from the group consisting of SEQ ID NOs: 201, 202, 203, and 204.

79. 79. The Tn3 scaffold of any one of claims 1 to 78, wherein the CD40L is human CD40L.

80. 80. The Tn3 scaffold of claim 79, wherein the CD40L is membrane-bound CD40L (SEQ ID NO: 1), soluble CD40L (SEQ ID NO: 2), or a fragment thereof.

81. 81. A Tn3 scaffold according to any preceding claim, which binds to CD40L and prevents binding of CD40L to CD40.

82. 82. A Tn3 scaffold according to any one of claims 1 to 81 which binds to CD40L and disrupts CD40-mediated signalling.

83. 83. A method of altering the activity of a CD40L-expressing cell comprising contacting the cell with a Tn3 scaffold according to any one of claims 1 to 82, wherein the Tn3 scaffold binds to CD40L and prevents binding of CD40L to CD40.

84. 83. A method of altering a CD40-mediated signaling response comprising contacting a CD40L-expressing cell with a Tn3 scaffold according to any one of claims 1 to 82, wherein the Tn3 scaffold binds to CD40L and disrupts CD40-mediated signaling.

85. 85. The method of claim 84, wherein the CD40-mediated signaling response is a T-dependent immune response.

86. Affinity (K) of about 1 μM or less, or about 500 nM or less, or about 100 nM or less, or about 50 nM or less, or about 25 nM or less, or about 10 nM or less, or about 5 nM or less, or about 2 nM or less ｄ 83. The Tn3 scaffold of any one of claims 1 to 82, which binds to CD40L at the C-terminal end of the Tn3 scaffold.

87. 87. The Tn3 scaffold of any one of claims 1 to 82 and 86, wherein the CD40L-specific monomeric subunit specifically binds to a CD40L epitope comprising amino acids located at positions 142 to 155, 200 to 230, or 247 to 251 of SEQ ID NO:

2.

88. 80. The Tn3 scaffold of any one of claims 1-61, 65-67, 69, 70, 73, 74, 77, and 78, wherein the CD40L-specific monomer subunit interacts with CD40L amino acids E142, Y146, M148, N151, L155, R200, R203, and E230.

89. 80. The Tn3 scaffold of any one of claims 1-64, 68, 71, 72, 75 and 76, wherein the CD40L-specific monomer subunit interacts with CD40L amino acids R203, I204, V247, H249, and T251.

90. 80. The Tn3 scaffold of any one of claims 1-64, 68, 71, 72, 75 and 76, wherein the CD40L-specific monomeric subunit interacts with CD40L amino acids S245, V247, H249, and T251.

91. 89. The Tn3 scaffold of claim 88, wherein CD40L amino acids E142, Y146, M148, N151, L155 are located in a first CD40L molecule and amino acids R200, R203, and E230 are located in a second CD40L molecule.

92. 90. The Tn3 scaffold of claim 89, wherein CD40L amino acids R203 and I204 are located in a first CD40L molecule and CD40L amino acids V247, H249, and T251 are located in a second CD40L molecule.

93. 93. An isolated nucleic acid molecule encoding a Tn3 scaffold according to any one of claims 1 to 82 and 86 to 92.

94. 94. An expression vector comprising the nucleic acid of claim 93.

95. A host cell comprising the vector of claim 94.

96. 96. A method of producing a Tn3 scaffold comprising culturing a host cell of claim 95 under conditions in which the Tn3 scaffold encoded by the nucleic acid molecule is expressed.

97. 93. A composition comprising the Tn3 scaffold of any one of claims 1-82 and 86-92 and a pharma- ceutically acceptable excipient.

98. 97. A method for preventing, treating, ameliorating, or managing an autoimmune disease in a patient in need thereof comprising administering an effective amount of the composition of claim 96.

99. 94. A method of reducing the frequency and amount of corticosteroids administered to a patient having an autoimmune disease comprising administering to the patient a therapeutically effective amount of the composition of claim 93.

100. The autoimmune diseases include alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal glands, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, Sjogren's syndrome, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasia (including Graves' disease), corneal and other tissue transplants, as well as chronic inflammation, sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis (e.g. psoriatic arthritis), anaphylactic shock, organ ischemia, reperfusion injury, spinal cord injury and allograft rejection. Autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, 100. The method of any one of claims 98 or 99, wherein the therapeutic agent is selected from the group consisting of myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff man syndrome, systemic lupus erythematosus, lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis such as dermatitis herpetiformis vasculitis, vitiligo and Wegener's granulomatosis.

101. 100. The method of any one of claims 98 or 99, wherein the autoimmune disease is systemic lupus erythematosus (SLE).

102. 100. The method of any one of claims 98 or 99, further comprising an additional therapy, wherein said therapy is immunotherapy, biotherapy, chemotherapy, radiation therapy, or small molecule drug therapy.

103. A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:20 in complex with soluble CD40L (SEQ ID NO:2), １ 2 １ 2 １ Protein crystals with orthorhombic space group and unit cell dimensions of a=85.69 Å, b=90.64 Å, c=95.56 Å, crystal lattice at + / - 0.1%.

104. 104. The protein crystal of claim 103, wherein the asymmetric unit of the crystal comprises a trimer of CD40L and three molecules of a Tn3 scaffold.

105. 104. The protein crystal of claim 103, which diffracts X-rays for the determination of structural coordinates to a resolution of 3.2 Å or less.

106. A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:68 in complex with soluble CD40L (SEQ ID NO:2), １ Protein crystals with a cubic space group of 3 and unit cell dimensions of a=b=c=97.62 Å, crystal lattice at + / - 0.1%.

107. 107. The protein crystal of claim 106, wherein the asymmetric unit of the crystal comprises one CD40L molecule and one Tn3 scaffold molecule.

108. 107. The protein crystal of claim 106, which diffracts X-rays for determining structural coordinates to a resolution of 2.7 Å or less.

109. A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO:28 or 146 in complex with soluble CD40L (SEQ ID NO:2), said protein crystal having a P321 space group and a crystal lattice with unit cell dimensions of a=95.53 Å, b=93.53 Å, c=66.69 Å, + / - 0.1%.

110. 110. The protein crystal of claim 109, wherein the asymmetric unit of the crystal comprises one CD40L molecule and one Tn3 scaffold molecule.

111. 110. The protein crystal of claim 109, which diffracts X-rays for determining structural coordinates to a resolution of 2.8 Å or less.

112. A protein crystal comprising two different Tn3 scaffolds consisting of SEQ ID NO:68 and SEQ ID NO:28 or 146 in complex with soluble CD40L (SEQ ID NO:2), １ Protein crystals with a cubic space group and unit cell dimensions of a=80.32 Å, b=143.48 Å, c=111.27 Å, β=98.22 Å, crystal lattice at + / - 0.1%.

113. 113. The protein crystal of claim 112, wherein the asymmetric unit of the crystal comprises two CD40L trimers and six respective Tn3 scaffold molecules.

114. 113. The protein crystal of claim 112, which diffracts X-rays for determining structural coordinates to a resolution of 1.9 Å or less.

115. 115. The protein crystal of any one of claims 103 to 114, which has been crystallized by sitting drop vapor diffusion.

116. (a) mixing a volume of a liquid comprising a Tn3 scaffold comprising a CD40L-specific monomeric subunit in complex with CD40L with a volume of a reservoir solution comprising a precipitant; and (b) incubating the mixture obtained in step (a) in a closed container under conditions suitable for crystallization until protein crystals are formed. A method for producing protein crystals comprising:

117. 117. The method of claim 116, wherein the protein crystals are produced by sitting drop vapor diffusion.

118. The method of claim 116, wherein the Tn3 scaffold comprises SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:68 or SEQ ID NO:

146.

119. (a) to convert the data into a graphical three-dimensional representation of the structure of a portion of a protein crystal of a Tn3 scaffold that includes a CD40L-specific monomeric subunit complexed with CD40L; and (b) for producing a display of said graphical three-dimensional representation; A machine-readable data storage medium comprising data storage material encoded with machine-readable instructions.

120. The machine-readable data storage medium of claim 119, wherein the Tn3 scaffold comprises SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:68 or SEQ ID NO:

146.

121. 120. The machine-readable data storage medium of claim 119, wherein the protein crystal is a crystal of claim 103, a crystal of claim 106, a crystal of claim 118, or any combination thereof.

Images